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1.?Introduction?
Cancer? is?the? leading?cause?of?death? in?economic?strong?countries?and?the?second?cause?of?
death? in? developing? countries? (Jemal? et? al.,? 2011).? According? to? the? World? Health?
Organisation? (WHO)? in? 2008,? over? 12? million? people? worldwide? were? estimated? to? be?
diagnosed? with? cancer? and,? according? to? the? American? Cancer? Society? in? 2010,? about?
1,529,560?new?cancer?cases?were?expected? to?be?diagnosed? in? the?USA? (Cancer? facts?and?
figures? 2010).? Due? to? the? constant? growth,? the? increasing? live? expectancy? of? the? world?
population,? and? the? adaptation? of? cancer?favouring? behaviours? as? e.g.? smoking,? physical?
inactivity? and? “westernised”? diets,? the? burden? of? global? cancer? is? expected? to? be?
continuously? increasing? (Jemal? et? al.,? 2011).? Thus,? the? research? aiming? at? the? causes? of?
human? cancer,? the? mechanisms? of? carcinogenesis? and? the? development? of? scientific?
strategies?for?cancer?therapy? is?of?considerable? interest? in?human?medicine.?During?the? last?
decades?a? large?number?of? in?vitro?and? in?vivo?models? for?many?human?cancer?types?were?
developed.?These?models?were?established? from?cell? lines?and/or?xenografts?derived? from?
human?primary?tumours?or?their?metastases,?transgenic?and?genetically?engineered?mouse?
models? and? from? non?human? mammalian? species? which? spontaneously? develop? cancer.?
Thereby,? therapeutic? approaches? in? veterinary? patients? have? been? attracted? considerable?
interest? during? the? last? decade? in? research? and? human? medicine? because? several?
malignancies?resemble?their?human?counterparts? in?many?ways.?Hereby,?the?results?gained?
in? basic?? and?medical? research? are? considered? beneficial? for? both? species,? the? veterinary?
patient?and?by?providing?data?as?“animal?model”?for?humans.?Thereby,?the?“model?function”?
of?higher?mammals?completes?the?already?used?rodent?model?animals?in?research.??
In? terms? of? cancer,? especially? the? dog? has? been? attracting? interest? in? research? as? the?
neoplasias? occuring? in? dogs? share? several? characteristics?with? their? human? counterparts,?
which?are?missing?in?the?currently?used?rodent?animal?models.?A?major?advantage?of?canine?
cancer?models? is? that? tumours? in?dogs?develop?naturally?and?spontaneously? in?contrast? to?
the? rodent? cancer?models? in?which? tumours?had? to?be? induced?by? carcinogenic?agents?or?
transplantations? into? immunocompromised?animals.?Thus,? it?appears? that? the?mechanisms?
involved? in? canine? tumour? development? and? progression? are? more? similar? to? those? in?
humans.?Dogs?share,?in?contrast?to?rodents,?~?650?Mb?of?ancestral?sequence?in?common?with?
humans?and?canine?DNA?and?protein?sequences?are?more?similar?to?humans?than?those?of?
Introduction? ? ?
? 10
mice?(Lindblad?Toh?et?al.,?2005;?Rowell?et?al.,?2011),?thus?many?aspects?of?human?biology?are?
presumably?more?relevant?in?dogs?than?they?are?in?mice?(Khanna?et?al.,?2006;?Rowell?et?al.,?
2011).? According? to? the? American? Pet? Products? Association? (APPA)? survey? 2005,? over? 73?
million?dogs? lived? in?approx.?40%?of?US?households? (Rowell?et?al.,?2011)?and?were?mostly?
considered? as? family? members? enjoying? very? good? health? care? allowing? a? detailed?
surveillance?of?cancer,?its?progression?and?therapy.?Moreover,?the?excellent?clinical?care?also?
allows? sampling?during? surgery?or? clinical?examination?of? i.a.?blood,?bone?marrow,?organ,?
and?tumour?biopsies?that?are?necessary?for?molecular?analyses?in?preclinical?cancer?research.?
Dogs?also? share? the? same?environmental? conditions?with?humans?and?are?exposed? to? the?
same?oncogenic?factors?as?their?owners.?The?natural?progression?of?tumours?in?most?canine?
cancers? is? faster? than? that? of? the? human? counterparts.? This? allows? an? easier? tumour?
observation?within?a?short? time?span? thereby?allowing?a? timely?assessment?of?new?cancer?
therapies? (Khanna? et? al.,? 2006;?Withrow? and?Vail,? 2007).? It? is?believed? that?dogs?develop?
cancer?twice?as?often?as?humans?and?that?the?tumours?share?similar?key?characteristics?with?
their? respective? human? counterpart? such? as? the? presentation,? histology,? biological?
behaviour,? tumour?genetics?and? the? response? to? conventional? therapies? (MacEwen,?1990;?
Khanna? et? al.,? 2006;?Withrow? and? Vail,? 2007).? Several? canine? cancer? types? are? currently?
hypothesised?to?be?appropriate?models?for?their?human?counterparts?as?e.g.?malignant?non?
Hodgkin’s? lymphoma,? mammary? carcinomas,? oral? melanomas,? and? lung? carcinomas?
(Patterson?et?al.,?1982;?Knapp?and?Waters,?1997;?Withrow?and?Vail,?2007).?Taken?together,?
due?to?the?similarities?of?canine?and?human?cancer?development,?progression?and?biology,?
the?dog? is?considered? to? represent?a?valuable?model? for?human?neoplastic?diseases.?Thus,?
the?analyses?of?the?molecular?characteristics?of?canine?cancer?associated?genes?and?proteins?
and? the? elucidation? of? the? mechanisms? involved? in? disease? progression? is? of? major?
importance?for?the?establishment?of?clinical?therapies?for?the?dog?and,?due?to?its?similarities?
to? human? diseases,? also? for? the? establishment? of? preclinical? approaches? for? human?
neoplasias.??
At? the? beginning? of? this? thesis,? the? canine? genome? was? already? sequenced? but? not?
annotated,? leaving?the?genetic?structure?of?canine?genes?widely?unknown.?Thus,?the?aim?of?
the?work?presented?herein?was?the?characterisation?of?cancer?associated?genes?and?proteins?
in?canine?neoplastic?diseases.?Herein,?the?genomic?structure?and?the?expression?patterns?of?
the? canine? receptor? for? advanced? glycation? end?products? (RAGE)? were? characterised.?
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Further,? expression? analyses? of?members? of? the?High?Mobility?Group? (HMG)? family?were?
performed?in?several?canine?neoplasias?and?the?thesis?presented?herein?is?divided?intro?three?
topics.?
Firstly,? the? characterisation?of? the? canine?RAGE?and? its?naturally?occurring? splice?variants.?
Further,?as?deregulations?of?RAGE? and? its? ligand?high?mobility?group?protein?B1? (HMGB1)?
were?associated?with? tumour?progression?and?metastasis,? the?expression?patterns?of?both?
genes?were?analysed?in?two?different?types?of?canine?neoplasias?including?canine?malignant?
lymphoma?and?canine?disseminated?histiocytic?sarcoma?(DHS).??
Secondly,? further? family?members?of? the?HMG? family? including?HMGA1?and?HMGA2?were?
analysed?in?canine?lymphoma.??
Thirdly,?an?in?vivo?model?of?canine?prostate?cancer?was?established.??
?
RAGE?is?a?member?of?the?immunoglobulin?superfamily?of?cell?surface?molecules?encoded?on?
human? chromosome? 6p21.3?which,? depending? on? its? surrounding,? interacts?with? various?
ligands?and? is?thus?considered?as?a?multiligand?receptor?(Neeper?et?al.,?1992;?Sugaya?et?al.,?
1994;?Vissing?et?al.,?1994).?The?human?RAGE?gene?consists?of?eleven?exons?and?ten? introns?
encoding?a?404?amino?acid?(aa)?long?RAGE?protein.?Structurally?the?protein?is?subdivided?into?
an?extracellular?domain? (ED)? ?which? itself?contains? the? ligand?binding?V?domain?and? two?C?
domains? (C,?C´)?–? followed?by? a?hydrophobic? ??helix? transmembrane?domain? (TM),? and? a?
short? cytosolic? domain? (CD)?which? is? essential? for? RAGE? signalling? (Schmidt? et? al.,? 2001).?
RAGE? ligands? include? advanced? glycation? end?products? (AGE),? HMGB1? (also? known? as?
amphoterin),?proteins?of?the?S100/calgranulin?family,?amyloid?beta?and?Mac?1?(Neeper?et?al.,?
1992;?Hori?et?al.,?1995;?Yan?et?al.,?1996;?Hofmann?et?al.,?1999;?Chavakis?et?al.,?2003).?RAGE?
plays? a? critical? role? in? the? innate? immune? response? being?mediated? by? its? ligands?which?
represent?a?wide?range?of?environmental?stressors?(Schmidt?et?al.,?2001).?Moreover,?RAGE?is?
expressed?in?a?number?of?cells?that?are?involved?in?immune/inflammatory?responses,?such?as?
monocytes/macrophages,?granulocytes,?endothelial?cells,?vascular?smooth?muscle?cells,?and?
adipocytes? (Goldin? et? al.,? 2006).? The? ligand?receptor? complex? regulates? cell? signalling?
pathways?which? influence? cell? growth? and? proliferation? due? to? activation? of? for? example?
p21(ras),? erk1/2? (p44/p42),?mitogen? activated? protein? (MAP)? kinases,? p38,? SAP/JNK?MAP?
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kinases,? rho?GTPases,?phosphoinositol?3?kinase,?nuclear? factor?kappa?B? (NF??B),?and?cyclic?
adenosine?monophosphate?(cAMP)?response?element?binding?protein?(CREB)?(Neeper?et?al.,?
1992;? Yan? et? al.,? 1994;? Lander? et? al.,? 1997;? Deora? et? al.,? 1998;? Hofmann? et? al.,? 1999;?
Huttunen?et?al.,?1999;?Kislinger?et?al.,?1999;?Huang?et?al.,?2001;?Huttunen?et?al.,?2002b).? In?
terms? of? inflammatory?related? pathophysiological? states,? RAGE? levels? were? described? to?
increase?and?to?be?associated?with?various?diseases? including?diabetic?atherosclerosis?(Park?
et?al.,?1998;?Cipollone?et?al.,?2003),?impaired?wound?healing?(Goova?et?al.,?2001),?Alzheimer’s?
disease? (Yan? et? al.,? 1996;? Lue? et? al.,? 2001;? Lue? et? al.,? 2005),? immune? and? inflammatory?
disorders?(Hofmann?et?al.,?1999;?Schmidt?et?al.,?2001;?Hofmann?et?al.,?2002;?Chavakis?et?al.,?
2004),?and?various?cancers?(Taguchi?et?al.,?2000;?Huttunen?et?al.,?2002a;?Bartling?et?al.,?2005;?
Bhawal? et? al.,? 2005;? Ishiguro? et? al.,? 2005).? Besides? the? native? full?length? RAGE? protein,?
several? naturally? occurring? isoforms? of? RAGE? were? detected? in? humans.? These? are?
characterised? by? N?terminally? or? C?terminally? truncated? proteins? including? hRAGEsec?
(Malherbe? et? al.,? 1999),? sRAGE1,? sRAGE2? (also? named? endogenous? secretory? RAGE?
(esRAGE)),?and?sRAGE3?(Schlueter?et?al.,?2003),?N?truncated?and?Secretory?(Yonekura?et?al.,?
2003),??8?RAGE? (Park?et?al.,?2004),?Rage?,?NtRAGE??and?sRAGE?? (Ding?and?Keller,?2005b),?
and? RAGE_v4?RAGE_v13? (Hudson? et? al.,? 2008).? The? latter? author? introduced? a? consistent?
nomenclature? for? the?RAGE? splicing?variants?according? to? the?Human?Gene?Nomenclature?
Committee?(HGNC)?(Hudson?et?al.,?2008).?Thereby?the?variants?were?renamed?into?RAGE_v1?
to?RAGE_v19?and?within?this?thesis,? I?will?refer?to?this?uniform?nomenclature.?The?variants?
were?discussed?to?function?as?a?mechanism?for?receptor?regulation?by?acting?as?competitive?
inhibitors?of?the?receptor,?either?by? ligand?binding,?or?displacing?the?full?length?receptor? in?
the?membrane? (Ding?and?Keller,?2005a;?Geroldi?et?al.,?2005).?Deregulation?of? the?naturally?
occurring? protein? isoforms? was? supposed? to? have? significant? effect? on? RAGE? mediated?
diseases.?Thereby?soluble?forms?of?RAGE?which?were?found?to?circulate?in?plasma?and?tissues?
and? to? act? as? competitive? inhibitors? of? RAGE? signalling,? represent? the? isoforms? mostly?
focused?on.?Two?mechanisms?were? reported? for? the?generation?of? soluble?RAGE? variants.?
Firstly,?RAGE_v1? (formerly? known? as? esRAGE)? is? generated? through? alternative? splicing? of?
RAGE? pre?mRNA? (Santilli? et? al.,? 2009)? and? secondly,? soluble? variants? are? also? generated?
through? shedding? of? the?membrane?associated?wild? type? full?length? RAGE? receptor.? This?
mechanism?is?mediated?by?several?proteases?including?a?disintegrin?and?metalloprotease?10?
????????????? ? ?
? ??
??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ??????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
????????????????????????? ?????????????????????????????????????????????????????????????????
????????????????????? ???????? ?????????????????????????????????????????????????? ??? ?????????
???????? ??????? ????? ?????????? ???? ????????? ????????? ??? ????? ?????? ???????? ??? ????? ???????
????????????????? ??????????????????? ??????? ??? ????????????? ??????????? ????????? ??? ????????
???????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????? ?????? ?????????????????????????????? ??????????????????????
????? ??????? ?????? ????? ???????? ?????????? ??? ????? ??????? ????? ???????? ???????????? ????????
???????????????? ?????? ???????? ???? ????????? ??????? ?????????? ??? ????? ?????? ????? ??? ?????
??????? ????? ??? ????? ??????? ?????? ??? ????? ??????? ?????????????? ???????? ??? ???? ?????????
???????????? ???????? ????????? ????? ???? ?????? ??? ???????????????? ?????????? ??? ?????
??????? ????? ????????? ??? ???????? ????? ?????????????? ??? ??????????? ???????????? ??? ????????
???????????????????????????????????????????????????????????????????????????????????????????????
??? ?????? ??? ??????? ???? ???????????? ???? ??????????? ???????? ???? ????? ?????????? ???
?????????? ??????????????????????????????????????????????????? ????????????? ????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????? ??????????????????????
????? ??????????? ?????????????? ???? ??????????? ????????? ?????????? ??? ???? ??????????? ?????
??????????? ???????? ????? ??????? ?????? ?? ???????? ??? ????? ???????????? ???????? ??? ????? ??????
?????????????????????????????? ???????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
???????????? ???????? ??? ????? ??????? ????????? ??? ?????? ??????????? ??????????? ???????????
????????????????????????????????????????????????????????????????????????????????????????
???????????? ???? ????????? ???????? ????? ??????? ?????????? ??? ????? ???????? ??????????????
?????????????? ??? ????? ???? ???? ??????? ?????? ???? ????? ????? ??? ? ???????? ????? ??? ???????
??????? ????????????? ??? ???? ?????????? ??? ????? ???????? ???? ????????????? ????? ???? ????????
???????????????????????????????????????????????????????????????????????????????????????????
???? ???????? ????????? ??? ??? ?????????????? ??? ?? ????????????? ???? ??????? ???????????? ???
?????????????? ??????????? ?????? ??? ????????? ??? ???? ??????? ??????????? ???????? ???? ????
Introduction? ? ?
? 14
design?of?gene?specific?real?time?PCR?assays,?which?were?not?commercially?available?at?the?
time?of?the?performed?work.?
Generally,?HMGB1?is?described?to?feature?different?functions?depending?on?its?localisation.?In?
the?nucleus,?it?acts?as?a?DNA?binding?nuclear?protein,?while?in?the?extracellular?environment?
it?acts?as?a?proinflammatory?cytokine?and?as?a?dose?dependent?mediator?of?angiogenic?and?
neo?vascularising?processes?(Schlueter?et?al.,?2005;?van?Beijnum?et?al.,?2006;?van?Beijnum?et?
al.,? 2008).? During? progression? of? solid? and? haematopoietic? tumours,? hypoxia? occurs? and?
necrotic? regions? develop? due? to? high? cell? proliferation.? The? growing? tumour? secretes?
proangiogenic? factors? such? as? vascular? endothelial? growth? factor? (VEGF),? tumour?necrosis?
factor? alpha? (TNF??)? and? interleukin? 8? (IL? 8)? in? order? to? activate? cellular? angiogenic?
mechanisms?to?assure?sufficient?supply?of?the?growing?tumour?mass?with?oxygen?(Moehler?
et?al.,?2001;?van?Beijnum?et?al.,?2008).? In?response?to?angiogenic?and? inflammatory?signals,?
HMGB1? is?actively?secreted?by?macrophages?or?passively?released?by?necrotic?cells? into?the?
extracellular?environment?and?binds?to?RAGE?and?the?toll?like?receptors?(TLR)?TLR?2?and?TLR?
4?(van?Beijnum?et?al.,?2008).?Activation?of?these?receptors?results?in?activation?of?intracellular?
factors? including? NF??B,? which? itself? induces? the? up?regulation? of? leukocyte? adhesion?
molecules? and? the? production? of? proinflammatory? cytokines? and? angiogenic? factors? like?
VEGF,? thereby?promoting? inflammation? (van?Beijnum?et?al.,?2008).?Moreover,? the? induced?
intracellular? activation? of? NF??B? leads? to? a? positive? feedback? loop? in? RAGE? expression?
through?a?NF??B?binding?site?within?the?RAGE?promoter (Li?and?Schmidt,?1997;?van?Beijnum?
et? al.,? 2008).? High? RAGE? expression? in? turn? enhances? RAGE? mediated? cellular? effects?
characterised?by?sustained?inflammation?and?angiogenesis?leading?to?progression?of?various?
pathophysiological? processes? as? described? in? diabetic? atherosclerosis,? impaired? wound?
healing,?Alzheimer’s?disease,? immune? and? inflammatory?disorders,? and? in? various? cancers?
(Yan?et?al.,?1996;?Park?et?al.,?1998;?Hofmann?et?al.,?1999;?Taguchi?et?al.,?2000;?Goova?et?al.,?
2001;? Lue? et? al.,? 2001;? Schmidt? and? Stern,? 2001;?Hofmann? et? al.,? 2002;?Huttunen? et? al.,?
2002a;?Cipollone?et?al.,?2003;?Chavakis?et?al.,?2004;?Bartling?et?al.,?2005;?Bhawal?et?al.,?2005;?
Ishiguro?et?al.,?2005;?Lue?et?al.,?2005;?van?Beijnum?et?al.,?2008).?Regarding?haematopoietic?
malignancies,? increased? angiogenesis? measured? by? high? HMGB1? and? VEGF? levels? was?
reported? in?human?non?Hodgkin’s? lymphoma?and? the? levels?of?circulating?VEGF?have?been?
shown?to?correlate?with?the?survival?and?the?event?free?survival?(Ribatti?et?al.,?1996;?Salven?
et?al.,?1997;?Bertolini?et?al.,?1999;?Salven?et?al.,?2000;?Molica?et?al.,?2002;?Meyer?et?al.,?2008).?
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In? this? context,? high? VEGF? levels? and? HMGB1? serum? levels? were? reported? in? canine?
lymphoma? indicating? similar? mechanisms? and? involvement? of? pro?angiogenic? factors? in?
canine? lymphoma? progression? to? those? apparent? in? human? non?Hodgkin’s? lymphoma?
(Wolfesberger?et?al.,?2007;?Meyer?et?al.,?2010;?Zizzo?et?al.,?2010).?Consequently,?due?to?the?
reported?role?of?HMGB1?and?RAGE? in?mediation?of?angiogenesis?and?neo?vascularisation? in?
solid?and?haematopoietic?tumours,?a?deregulation?of?both?genes?may?also?play?an?important?
role?in?canine?lymphoma?progression.?Thus,?the?expression?level?of?both?genes?was?analysed?
in? canine? lymphoma? tumour? samples.?As? canine? lymphoma?acts?as?appropriate?model? for?
human?non?Hodgkin’s?lymphoma,?elucidation?of?mechanisms?involved?in?disease?progression?
will?be?of?significant?value?for?the?dog?as?patient?and?as?a?model?for?human?non?Hodgkin’s?
lymphoma.??
In? response? to? microbial? and? inflammatory? stimuli,? dendritic? cells? (DC)? actively? secrete?
HMGB1? in?order?to?stimulate?the? immune?response?(Dumitriu?et?al.,?2005a;?Dumitriu?et?al.,?
2005b).? Generally,? DCs? and? macrophages,? which? are? also? summarised? as? “histiocytes”,?
represent? leukocytes?which?are?playing?an? important? role? in? the? immune?system?by?either?
phagocytosis?of?debris?and?pathogens?or?by?presenting?of?antigens?to?naive?T?cells?(Fulmer?
and?Mauldin,?2007;?Withrow?and?Vail,?2007).?Thereby,?DCs?stay? in?tissues?without?dividing?
actively?and? remain? in?an? immature?status?until?activation?by?an?antigen.?Upon?activation,?
DCs?secrete?HMGB1?which? itself?binds?to? its?receptor?RAGE?which? is? located?on?the?DC?cell?
membrane.? Within? the? DC,? the? RAGE/HMGB1? mediated? signal? cascade? activates? MAP?
kinases? and? NF??B? leading? to? the? remodelling? of? the? DC? actin?sceleton,? enabling? the?
migration?of? the?DC? towards? lymph?nodes.? Furthermore,?RAGE/HMGB1? induced? signalling?
up?regulates?the?expression?of?receptors?such?as?C?C?chemokine?receptor?type?7?(CCR7)?and?
C?X?C? chemokine? receptor? type? 4? (CXCR4)? allowing? a? chemotactic? migration? of? the? DC?
towards? the? lymph? nodes? secreting? the? respective? ligands.? After?migration? to? secondary?
lymphoid?organs,?secreted?HMGB1? is?required?for?clonal?expansion,?survival?and?functional?
polarisation?of?naive?T?cells?(Dumitriu?et?al.,?2005c;?Bianchi?and?Manfredi,?2007;?Dumitriu?et?
al.,?2007;?Palumbo?et?al.,?2007;?Yang?et?al.,?2007;?Chen?et?al.,?2008;?Manfredi?et?al.,?2008),?
and? stimulates? canine? T?cell? proliferation? (Altmann? et? al.,? 2008).? Summarising,? the?
HMGB1/RAGE?complex?represents?a?checkpoint? in?DC?maturation,?migration?and? following?
immune? responses? and? the? deregulation? of? the? expression? of? HMGB1? and? RAGE? as?well?
could? have? an? effect? on? dendritic? cell? biology.? In? histiocytic? neoplasias? such? as? human?
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Langerhans? cell? histiocytosis? (LCH),? dendritic? Langerhans? cells? (LCs)?were? described? to? be?
arrested? in? an? immature,? partially? activated? stage? and? to? show? a? different? proliferation?
pattern?than?“normal”?dendritic?LCs?leading?to?an?accumulation?in?the?affected?tissues?and?to?
disease?progression?(Laman?et?al.,?2003).?Canine?histiocytic?neoplasias? like?DHS???a?rare?and?
very?aggressive?histiocytic?neoplasm?affecting?multiple?sites?simultaneously? ??share?several?
similarities?with?the?dendritic?cell?sarcomas?described?in?humans?(Affolter?and?Moore,?2002).?
Consequently,? similar?mechanisms? leading? to?disease?progression? could? also? take?place? in?
dogs?and?thus,?the?expression?pattern?of?HMGB1?and?RAGE?in?canine?DHS?were?analysed.?
In? the? second? part? of? this? thesis,? further? members? of? the? HMG? family? were? analysed?
including?HMGA1?and?HMGA2.?The?high?mobility?group?protein?A?(HMGA)?family?consists?of?
two?members? HMGA1? and? HMGA2,?which? encode? four? proteins,?with? the? HMGA1? gene?
encoding? three? proteins? including? HMGA1a,? HMGA1b,? HMGA1c? which? develop? through?
alternative? splicing.? HMGA? proteins? are? small? chromatin? associated? non?histone? proteins?
that? act? as? architectural? transcription? factors.? They? regulate? the? expression? of? different?
target? genes? by? changing? the? conformation? of? DNA? by? binding? to? AT?rich? regions,? thus?
enabling? binding? of? various? transcriptions? factors? (Bustin? and? Reeves,? 1996).? The?
transcriptional? actions? of? HMG? proteins? influence? various? important? biological? cellular?
processes? like? cell? growth,? proliferation,? differentiation,? and? death.? The? expression? of?
HMGA1? and? HMGA2? is? very? high? during? embryogenesis? while? their? expression? in? adult?
tissues?is?strongly?reduced?to?very?low?levels,?which?are?barely?detectable?(Cleynen?and?Van?
de?Ven,?2008).?The?human?HMGA1?and?HMGA2?genes?are? located?on?chromosomes?6p21?
and? 12q14?15? and? chromosomal? aberrations? in? these? regions? lead? to? an? up?regulation? of?
HMGA?expression,?which?was?described?in?benign?mesenchymal?tumours?including?lipomas,?
uterine? leiomyomas,?pulmonary?chondroid?hamartomas,?and?endometrial?polyps? (Williams?
et?al.,?1997;?Kazmierczak?et?al.,?1998;?Tallini?et?al.,?2000).?This? transcriptional?activation? is?
probably? an? early? event? in? benign? mensenchymal? tumour? development.? In? malignant?
epithelial? tumours,?HMGA? expression? seems? to? be? a? late? event?which? is? associated?with?
aggressiveness?of?the?tumours.?Thus,?the?re?expression?of?HMGA?genes?on?a?high? level?was?
described? in?many? human? cancers? including? breast,? colorectum,? lung,? pancreas,? prostate,?
thyroid,? sarcomas,? oral? squamous? cell? carcinomas? (OSCC),? and? non?small? cell? lung? cancer?
(NSCLC)?(Cleynen?and?Van?de?Ven,?2008)?and?was?associated?with?progression?and?aggressive?
behaviour?of?the?tumours.?Thereby,?the?correlation?between?HMGA?expression?and?tumour?
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aggressiveness? has? led? to? the? conclusion? that? HMGA? expression? represents? a? powerful?
prognostic?molecular?marker?(Rogalla?et?al.?1997,?1998,?Reeves?2000).?
Regarding? the? canine? counterparts? of? the? human? HMGA? genes? and? proteins,? the? canine?
HMGA1?was?already?characterised?by?our?group?and?in?terms?of?expression?profile?in?canine?
neoplasias,? a? HMGA2? over?expression? was? found? in? canine? prostate? carcinoma? (Murua?
Escobar?et?al.,?2004;?Murua?Escobar?et?al.,?2005;?Winkler?et?al.,?2007b;?Beuing?et?al.,?2008).?
During? this?work,? the?expression?pattern?of?HMGA1?and?HMGA2?genes?was?comparatively?
analysed?in?canine?lymphoma.?
Within? the? last?part?of? this? thesis,? the?establishment?of?a?canine? in?vivo?model?of?prostate?
cancer? is?described.? In?humans,?prostate? cancer? is? the? second?most? frequently?diagnosed?
cancer?and?the?sixth?leading?cause?of?cancer?deaths?in?males?worldwide?(Ferlay?et?al.,?2008;?
Jemal?et?al.,?2011).?During?the?last?decades,?a?large?number?of?in?vitro?and?in?vivo?models?for?
human?prostate?cancer?were?established?whereby?the?human?cell? lines?DU?145,?LNCaP?and?
PC?3?are?the?most?prevalent?(Sobel?and?Sadar,?2005b;?Sobel?and?Sadar,?2005a;?Pienta?et?al.,?
2008).?The?number?of?animal?models?which?derived? from?spontaneous?developed?prostate?
carcinoma? is? rather? smaller,? and? the? dog? is? the? only? larger? mammalian? that? develops?
prostate? cancer? spontaneously.?Unlike? the? situation? in?men,? canine? prostate? cancer? is? an?
uncommon?neoplasm?with?a?prevalence?of?approximately?0.2?%?to?0.6?%?based?on?necropsy?
studies? (Withrow? and? Vail,? 2007).? Regarding? the? clinical? presentation? and? pathogenesis,?
canine?prostate?cancer?shares?many?similarities?with?the?human?counterpart.?Analogous?to?
men?high?grade?prostatic? intraepithelial?neoplasia? (PIN)?was?described,?which? is? the?most?
likely?precursor?of?most?human?prostate?cancers?(Waters?and?Bostwick,?1997;?Waters?et?al.,?
1998).?Furthermore,?the?metastatic?pattern?and?increased?incidence?with?age?reflect?further?
similarities?with?human?prostate?cancer?(Bell?et?al.,?1991;?Waters?et?al.,?1998;?Cornell?et?al.,?
2000).?In?humans,?established?markers?such?as?prostate?specific?antigen?(PSA)?and?prostate?
specific?membrane?antigen? (PMSA)?are?widely?used? for?early?diagnosis?of?prostate?cancer.?
Unlike?the?situation? in?men,?prognostic?tools?which?allow?early?detection?of?the?disease?are?
missing? in?dogs?and? the? therapy? in?most?cases? remains?palliative? (Bell?et?al.,?1995)?with?a?
poor?prognosis?due? to? the?high?malignancy?of? the? tumours? (Fan?and?Lorimier,?2007;?Leroy?
and?Northrup,?2009).?Identification?of?markers?for?canine?prostate?carcinoma?would?thus?be?
of? considerable? interest? for? the? development? of? therapeutic? approaches? in? dogs.? In? this?
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neoplasias? offered? the? possibility? to? design? therapeutical? strategies? targeting? HMGA?
expression?in?neoplasias?that?over?express?HMGA?genes.?Thereby,?these?studies?provide?data?
for?the?dog?as?veterinary?patient?and?as?“model”?for?the?human?neoplastic?counterparts?due?
to?their?reported?similarities?in?cancer?genetics.?
?
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2.?Materials?and?Methods?
2.1.?Tissues?
Canine? tissue? samples?were? provided? by? the? Small?Animal?Clinic,?University? of?Veterinary?
Medicine?Hannover,?Germany.?The?samples?were? immediately?frozen? in? liquid?nitrogen?and?
stored?at??80°C.?
?
2.2.?Cell?lines??
2.2.1?Generation?of?canine?cell?lines?
Cell? lines? were? generated? from? freshly? isolated? tissues.? After?mincing? of? the? tissue,? the?
sample? was? treated? with? 0.26%? collagenase.? The? dissociated? cells? were? pelleted? and?
transferred? into?a?sterile?cell?culture? flask? (PAA?Laboratories?GmbH,?Coelbe,?Germany)?and?
cultivated?with?5?ml? culture?medium? (Medium?199? (Invitrogen,?Karlsruhe,?Germany),?10%?
fetal?calf?serum?(PAA),?200?U/ml?penicillin?and?200?ng/ml?streptomycin?(Biochrom?AG,?Berlin,?
Germany))?in?5%?CO2/95%?air?at?37°C.?Well?grown?cells?were?trypsinised?with?TrypLE?Express?
(Invitrogen)?and?transferred?to?new?sterile?culture?flasks?for?further?cultivation.?
?
2.2.2.?Cell?proliferation?assay?
Cell? proliferation?was? evaluated? using? a? Cell? proliferation? enzyme?linked? immunosorbent?
assay? (ELISA),?bromodeoxyuridin? (BrdU)? (colorimetric)? kit? according? to? the?manufacturer’s?
protocol?(Roche?Diagnostics,?Mannheim,?Germany).?Measurements?and?data?analyses?were?
performed?with?Synergy?2?multi?mode?microplate?reader?and?the?Gen5™?software?(BioTek,?
Bad?Friedrichshall,?Germany).?
?
2.2.3.?Cell?vitality?assay?
Cell?vitality?was?evaluated?using?sterile?0.5%?Trypane?blue?solution?(Sigma?Aldrich,?Munich,?
Germany).?After? incubation? for?10?min?with?500?μl?0.5%Trypane?blue?solution?the?cultured?
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cells? were? trypsinised,? and? the? cell? number? of? dead? blue? cells? and? vital? unstained? cells?
determined.??
2.2.4.?In?vitro?labelling?of?CT1258?cells?with?MnCl2?
Cultured?cells?were? incubated?with?5?ml?culture?medium?containing?0.035?M?MnCl2? (Appli?
Chem,?Darmstadt,?Germany)? for? 1.5? h? at? 37°C? and? 5%? CO2.?After? incubation,? the? culture?
medium?was?discarded?and?the?labelled?cells?further?cultivated?in?culture?medium?over?night?
at?37°C?and?5%?CO2.??
?
2.2.5.?In?vitro?labelling?of?CT1258?cells?with?SPIOs?
The? labelling? was? performed? with? Endorem®? suspension? (Guerbet? S.A.,? Roissy,? France)?
according? to? a? concentration? of? 130? pg? ironoxide? nanoparticles/per? cell.? The? cells? were?
labelled?over?night?at?37°C?and?5%?CO2.??
?
2.2.6.?In?vivo?inoculation?of?labelled?CT1258?cells?
Aliquots?of?trypsinised?labelled?cells?were?transferred?into?1.5?ml?reaction?tubes?(Eppendorf,?
Hamburg,?Germany)?and?pelleted?for?10?min?at?1,000?rpm.?The?cell?pellet?was?washed?twice?
with?sterile?PBS.?Cell?pellets?were?resuspended?in?200?μl?sterile?PBS?and?aspirated?into?Insulin?
Syringes? (BD?Micro?Fine,?Heidelberg,?Germany)? and? subsequently? injected? subcutaneously?
into?the?respective?NOD?scid?mice.?
?
2.3?RNA?isolation?from?tissue?samples?and?cell?lines?
Tissue? samples?were?homogenised?using? stainless?steel?beads? and? a?Qiagen?TissueLyser? II?
homogeniser?(Qiagen,?Hilden,?Germany)?according?to?the?manufacturer’s?protocol.?Cultured?
cells? were? homogenised? using? QIAshredder? spin? columns? (Qiagen)? according? to? the?
manufacturer’s?protocol.?RNA?was? isolated?using?RNeasy?Mini?Kit?(Qiagen)?according?to?the?
manufacturer’s?protocol.?Additional?on?column?DNase?digestion?was?performed?with?RNase?
Free?DNase?set?(Qiagen).??
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2.4.?cDNA?synthesis?
cDNA? synthesis? was? performed? using? the? QuantiTect? Reverse? Transcription? Kit? (Qiagen)?
following?to?the?manufacturer’s?protocol.??
?
2.5.?Rapid?amplification?of?cDNA?Ends?(RACE)?PCR?
3´RACE?PCR?was?performed?using?the?adapter?primer?AP2? (AAGGATCCGTCGACATC(17)T),?5?
μg? total? RNA? and? reverse? transcriptase? SuperScript? II? (Invitrogen)? according? to? the?
manufacturer’s? protocol.? 5´RACE? PCR?was? performed? using? the? 5´RACE? System? for? Rapid?
Amplifications?of?cDNA?Ends?(Invitrogen)?according?to?the?manufacturer’s?protocol?and?gene?
specific?lower?primers.??
?
2.6.?Polymerase?Chain?Reaction?(PCR)??
2.6.1?Classical?PCR??
PCR?reactions?were?performed?with?gene?specific?upper?and?lower?primers?and?GoTaq?DNA?
polymerase?(Promega,?Mannheim,?Germany)?according?to?the?manufacturer’s?protocol.?PCR?
conditions?varied?and?were?adapted?accordingly?to?the?annealing?temperatures?of?the?primer?
pair? used? and? the? amplicon? length? of? the? targeted? PCR? product.? PCR? reactions? were?
performed?using?the?Thermoblock?T?Gradient? (Biometra?GmbH,?Goettingen,?Germany)?and?
the?Thermoblock?Mastercycler?Gradient?(Eppendorf).??
?
2.6.2.?Relative?real?time?PCR?
Real?time?PCR?amplifications?were?performed?with? the?Applied?Biosystems?7300? real?time?
PCR?system?(Applied?Biosystems,?Darmstadt,?Germany)?and?with?the?Eppendorf?Mastercycler?
ep?realplex?PCR?system?(Eppendorf).?
In? total,? 250? ng? RNA?were? used? as? template? for? cDNA? synthesis? and? 2? μl? of? each? cDNA?
according?to?25?ng?RNA?were?used?as?template?in?a?total?volume?of?25?μl?using?the?Universal?
PCR? Mastermix? and? TaqMan? Gene? Expression? Assays? for? the? respective? gene? (Applied?
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Biosystems).? In?case?of?self?designed?real?time?PCR?assays?600?nM?of?each?primer,?200?nM?
probe? and? the? universal? PCR?Mastermix? (Applied? Biosystems)?were? used.? PCR? conditions?
were?as?follows:?2?min?at?50°C,?10?min?at?95°C,?45?cycles?with?15?s?at?95°C?and?1?min?at?60°C.??
All?samples?were?measured?in?triplicate?and?for?each?run,?a?negative?control?of?the?real?time?
PCR? assay?was? included.? Additionally? the? negative? control? and? non?reverse? transcriptase?
control?of?the?cDNA?synthesis?were?included.??
Before?performing?expression?analyses,?efficiency?analyses?of? the? respective? real?time?PCR?
assays?were?performed.?Therefore,?2?μg?of?RNA?were?reverse?transcribed?and?serially?diluted?
1:1.?The? resulting? concentrations? corresponded? to?200,?100,?50,?25,?12.5,?6.25,?3.125?and?
1.56?ng?of?RNA.??
?
2.6.3.?Absolute?real?time?PCR?
Real?time?PCR?amplifications?were?performed?with? the?Applied?Biosystems?7300? real?time?
PCR?system?(Applied?Biosystems).?2?μl?of?each?cDNA?were?amplified?in?a?total?volume?of?25?
μl? using? universal? PCR?Mastermix? and? 600? nM? of? each? primer,? 200? nM? probe? and? the?
universal? PCR?Mastermix? (Applied? Biosystems).? PCR? conditions?were? as? follows:? 2?min? at?
50°C,? 10?min? at? 95°C,? 45? cycles?with? 15? s? at? 95°C? and? 1?min? at? 60°C.? All? samples?were?
measured?in?triplicate?and?for?each?run?non?template?control?and?non?reverse?transcriptase?
control?reaction?were?included.?Absolute?transcript?levels?of?the?target?gene?were?calculated?
using?an?amplicon?specific?standard?curve?and?were? indicated?as?copy?number/250?ng?total?
RNA.??
?
2.7.?Cloning?and?sequencing?of?PCR?products?
PCR?products?were?eluted?using?the?QIAEX?II?Gel?Extraction?Kit?or?QIAquick?Gel?Extraction?Kit?
(Qiagen)? according? to? the?manufacturer’s?protocols.? The? ligation?was?performed?with? the?
pGem?T?Easy? vector? system? (Promega)? according? to? the? manufacturer’s? protocol.? After?
ligation,? the?vectors?were? transfected? into? thermocompetent?Escherichia?coli? (E.coli)?DH5??
(Invitrogen)? following? the?protocol?by? Inoue?et?al.? (Inoue?et?al.,?1990).? Isolation?of?plasmid?
DNA? was? performed? with? the? QIAprep? Spin? Miniprep? Kit? (Qiagen)? according? to? the?
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manufacturer’s?protocol.?The?nucleotide?sequence?of?the?isolated?plasmid?DNA?was?verified?
by?sequencing?(Eurofins?MWG?Operon,?Ebersberg,?Germany).??
?
2.8.?Northern?Blot?
RNA?was? transferred? onto? a?Hybond?N+? positive? nylon?membrane? (Amersham? Pharmacia?
Biotech,?Freiburg,?Germany)?by?capillary?blot.?The?probe?was?labelled?with?50?μCi(?32P)dCTP?
(Roche?Diagnostics)? according? to? the?manufacturer’s?protocol? and? the? labelled?probe?was?
purified? using? Sephadex? G?50? Nick? Columns? (Amersham? Pharmacia? Biotech,? Freiburg,?
Germany).?Prehybridisation?was?performed?for?30?min?at?68°C?and?hybridisation?overnight?at?
68°C? using? the? PERFECTHYB? PLUS? solution? (Sigma?Aldrich,? Munich,? Germany).? The?
membrane?was?washed?once?for?5?min?at?room?temperature?with?2xSCC/0.1%?SDS?and?twice?
for?20?min?at?68°C?with?0.5xSSC/0.1%?SDS.?Signals?were?visualised?using?a?STORM? imager?
(Molecular?Dynamics,?Sunnyvale,?USA).?
?
2.9.?Fluorescence?in?situ?hybridisation?(FISH)?
Chromosomes?were?stained?using?an?adapted?GTG?banding?method?and?the?G?bands?were?
identified? according? to? Reimann? et? al.? (Reimann? et? al.,? 1996).? After? recording? of? the?
metaphases,?the?slides?were?destained?in?70%?ethanol?for?15?min,?and?incubated?over?night?
at?60°C?after?air?drying.?FISH?was?performed?using?the?protocol?of?Fischer?et?al.?(Fischer?et?
al.,?1996)?with?some?modifications.?The?probe?was?labelled?using?the?Dig?Nick?Translation?Kit?
(Roche? Diagnostics)? according? to? the? manufacturer’s? instructions.? Chromosomes? were?
counterstained?with?propidiumiodide.?
?
2.10.?Agar?phantom?construction?for?in?vitro?MRI?scans??
Hand?warm?1%?agar? (Invitrogen)?solution?was? filled?half?full? into?an?empty?pipette? tip?box?
(Greiner? Bio?One,? Frickenhausen,? Germany)? and? a? 96? well? PCR? plate? (Eppendorf)? was?
embedded?onto?the?agar?solution.?After?polymerisation?of?the?agar?gel,?sample?wells?were?
formed.?Cell?aliquots?were?centrifuged?for?10?min?at?1,000?rpm?and?the?pellets?were?mixed?
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with?30?μl?hand?warm?4%?gelatine?solution?and?the?gelatine?cell?solution?was?pipetted? into?
the?wells?of?the?polymerised?agar?block.?Air?bubbles?were?removed?with?a?pipette?tip?and?the?
block?was?cooled?down?for?10?min?at?4°C.?Finally,?the?block?was?covered?with?1?%?hand?warm?
agar?solution?and?air?bubbles?were?removed?with?a?pipette?tip.?The?block?was?stored?at?4?°C?
until?the?agar?gel?polymerised?and?the?plastic?box?was?removed?prior?to?the?MRI?scans.?
?
2.11.?In?vitro?and?in?vivo?MRI?scan?parameters?
In? vitro? scans? of? the? agar? block?were? performed?with? a? clinical? 1? T?MRI? system? (Siemens?
Magnetom?Expert,?Erlangen,?Germany)?and?data?were?analysed?with?dicomPACS?version?5.2?
(OEHM?and?Rehbein,?Rostock,?Germany).?Scanning?parameters?were?as?follows:?T1?weighted?
MRI:?pulse?repetition?time?(TR)?=?330?ms,?echo?time?(TE)?=?12?ms,?flip?angle?(FA)?=?90°,?slice?
thickness?(ST)?=?3?mm.?T2*?weighted?MRI?scanning?parameters?were:?TR?=?800?ms,?TE?=?26?
ms,?FA?=?20°,?ST?=?2?mm.??
In? vivo?MR? Imaging? was? performed? on? a? 7T? Bruker? Pharmascan? 70/16? (Bruker? Biospin,?
Ettlingen,? Germany)? equipped? with? a? 6? cm? Volume? Resonator? under? Paravision? 5.0.?
Anaesthesia? of? the? NOD?Scid? mice? was? maintained? during? the? MRI? scans? with? a?
concentration? of? 1?? 2?%? isoflurane? and? the? body? temperature?was? held? at? approximately?
37°C?using?a?temperature?control?unit?(Small?Animal?Instruments,?Stony?Brook,?NY,?USA).?The?
scan?parameters?were?as?follows:?Fast?Spin?Echo?(FSE)?T1:?TR?=?1300?ms,?TE?=?9.5?ms,?ST?=?1?
mm;? FSE? T2:? TR? =? 2500? ms,? TE=? 36? ms,? FA? =? 180°;? Rapid? Acquisition? with? Relaxation?
Enhancement?(RARE)?T1:?TR?=?1300?ms,?TE?=?9?ms,?ST?=?1?mm;?Turbo?RARE?T2:?TR?=?2500?ms,?
TE?=?(eff)?36?ms,?FA?=?180°,?ST?=?1?mm;?T2*:?Multi?Gradient?Echo?(MGE)?TR?=?2000?ms,?TE?=?9?
ms,?FA=?30°,?ST=?1?mm.??
?
2.12.?Software?
2.12.1.?Analysis?of?sequence?data?
Sequence?data?was?analysed?using?DNASTAR?Lasergene?software?(DNAStar,?Madison,?USA).?
?
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2.12.2.?Statistical?analysis?of?relative?real?time?PCR?
Statistical? analysis? of? relative? real?time? PCR? results? applying? the? hypothesis? test? was?
performed?with? Relative? Expression? Software? Tool? (REST)? 2008? programme,? version? 2.0.7?
(Pfaffl?et?al.,?2002).?REST?determined?a?significant?expression?difference?of?the?target?gene?
between? samples? and? controls? taking? into? account? reaction? efficiencies? and? using?
randomisation?techniques.?
?
2.12.3.?MRI?data?analysis?
Analysis? of? the? MRI? image? data? was? performed? with? the? ITK?SNAP? 2.1.4?rc1? software?
(Yushkevich? et? al.,? 2006).? The? analyses? of? tumour? sizes? were? performed? by? manual?
segmentation?in?three?orthogonal?planes?at?once.??
?
?
?
?
?
?
?
?
?
?
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3.?Results?
?
3.1.?? Characterisation? of? the? canine? RAGE? gene,? protein? and? its? naturally?
occurring?splicing?variants??
The?following?section?describes?the?molecular?characterisation?of?the?canine?RAGE?gene?and?
protein.? RAGE? is? a?member? of? the? immunoglobulin? superfamily? of? cell? surface?molecules?
playing? key? roles? in? pathophysiological? processes? such? as? tumourigenesis? and?metastasis.?
RAGE?was?characterised?as?a?multiligand?receptor? interacting?with? i.a.?HMGB1?(also?known?
as? amphoterin).? The? RAGE/HMGB1? complex? significantly? influences? inflammation? and?
metastasis?by?effecting? invasiveness,?growth,?and?motility?of? tumour?cells,?and? the? in?vitro?
and? in?vivo?blocking?of? this?complex?resulted? in?drastic?suppression?of? tumour?cell?growth.?
The? characterisation? of? the? canine? RAGE/HMGB1? complex? is? thus? required? for? future?
establishment?of? therapeutical?approaches?based?on?blocking?of? this? complex.?The? canine?
HMGB1? gene? and?protein?were? already? characterised?by?our? group.? Thus,? the? aim?of? the?
present?study?was?the?characterisation?of?the?canine?RAGE?gene?and?protein.?
?
I.?“Cloning?and?characterization?of?the?canine?receptor?for?advanced?glycation?end?
products”?
Murua?Escobar?et?al.,?Gene,?2006?
The? chromosomal? localisation? of? the? canine?RAGE? gene?was? determined? on? chromosome?
CFA12.? The? genomic? structure? consisted? of? eleven? exons? and? ten? introns.? The? analysed?
genomic? size? was? 2835? bp.? The? total? homology? to? the? human? counterpart? was? 63.4? %?
whereas? the? identities? to? the? respective? exons? varied? between? 73.9%? and? 86.7%.? The?
homology? between? the? introns? ranged? between? 43.4%? and? 71? %.? The? complete? cDNA?
structure?spanned?1384?bp?and?consisted?of?an?18?bp?long?5´UTR,?a?1215?bp?long?CDS?and?a?
151?bp? long?3´UTR.?The? identity?to?the?human?counterpart?regarding?the?whole?cDNA?was?
80.9%?and?within?the?5´UTR,?the?CDS?and?the?3´UTR?the?homologies?ranged?from?100?%?to?
82.9?%?and?70.8?%?respectively.?The?total?protein?was?404?aa?long?and?the?homology?to?the?
Results? ? ?
? 30
whole? human? RAGE? protein? was? 77.6? %.? The? protein? consisted? of? three? domains:?
extracellular?domain?(ED)?containing?the?ligand?binding?V?domain?and?the?C?and?C´?domains,?
the?transmembrane?domain?(TM)?and?the?acidic?carboxy?terminal?cytosolic?domain?(CD).?The?
identities?of?the?respective?human?counterparts?were?78.2?%,?85.7?%,?78.9?%,?72.7?%?(ED,?V?
domain,?TM,?CD).?The?screening?of?six?different?dog?breeds?showed?a?nucleotide?transition?in?
a? Bernese? mountain? dog? leading? to? an? aa? change? within? the? protein.? Expression? level?
analysed? via? Northern? blot? showed? a? strong? 1.4? kb? signal? in? lung? tissue? while? in? the?
remaining?non?neoplastic? tissues? (liver,? kidney,?heart,? testis,?muscle,?pancreas,? spleen)?no?
strong?RAGE?signals?could?be?detected.??
?
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Abstract
Metastasis is one of the major problems when dealing with malignant neoplasias. Accordingly, the finding of molecular targets, which can be
addressed to reduce tumour metastasising, will have significant impact on the development of new therapeutic approaches. Recently, the receptor
for advanced glycation end products (RAGE)–high mobility group B1 (HMGB1) protein complex has been shown to have significant influence
on invasiveness, growth and motility of tumour cells, which are essential characteristics required for metastatic behaviour. A set of in vitro and in
vivo approaches showed that blocking of this complex resulted in drastic suppression of tumour cell growth.
Due to the similarities of human and canine cancer the dog has joined the common rodent animal model for therapeutic and preclinical studies.
However, complete characterisation of the protein complex is a precondition to a therapeutic approach based on the blocking of the RAGE–
HMGB1 complex to spontaneously occurring tumours in dogs. We recently characterised the canine HMGB1 gene and protein completely. Here
we present the complete characterisation of the canine RAGE gene including its 1384 bp mRNA, the 1215 bp protein coding sequence, the 2835
bp genomic structure, chromosomal localisation, gene expression pattern, and its 404 amino acid protein. Furthermore we compared the CDS of
six different canine breeds and screened them for single nucleotide polymorphisms.
© 2005 Elsevier B.V. All rights reserved.
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deoxycytidine 5′-triphosphate; DNA, deoxy-ribonucleic acid; DNase, deoxyribonuclease; EC, extracellular; FISH, fluorescence in situ hybridisation; G, guanosine;
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1. Introduction
The canine genome offers a wide field for genetic studies on
various areas as e.g. phenotypic diversity, heredity and diseases
including cancer. In terms of cancer, the canine model shows
several advantages. First of all, the dog enjoys after the human
the second best medical care of all species allowing a detailed
surveillance of the cancer, progression, and therapy. The cancers
seen in dogs are spontaneously developing as opposed to rodents
with tumours being experimentally induced by carcinogen or
transplanted to immunocompromised animals. Also, the canine
cancers are more akin to human cancers than rodent tumours in
terms of patient size and cell kinetics allowing better comparison
of medical examinations as e.g. ultrasonography. It is generally
believed that dogs develop cancer twice as frequently as
humans, and it has been shown that the presentation, histology
and biology of several canine cancers are similar to those in
humans (Withrow and MacEwen, 1989, 2001; MacEwen,
1990). Most canine cancers progress more rapidly than their
human counterparts permitting a better surveillance of the
tumour state (Withrow andMacEwen, 2001). Additionally, dogs
show similar characteristics of physiology and metabolism for
most organ systems and drugs, which allows better comparabil-
ity of modalities e.g. surgery, radiation, chemotherapy (Withrow
and MacEwen, 2001), and new therapeutic approaches aimed at
cancer treatment. At least a dozen distinct canine cancers are
hypothesized to be appropriate models for their human counter-
parts (Patterson et al., 1982; Withrow and MacEwen, 1989;
MacEwen, 1990; Knapp and Waters, 1997), among those
osteosarcoma, breast carcinoma, oral melanomas, lung carcino-
mas and malignant non-Hodgkin's lymphomas (MacEwen,
1990).
Lately, the RAGE–HMGB1 protein complex has attracted
significant interest in terms of metastasic behaviour of tumours.
The receptor itself is a multiligand member of the immunoglob-
ulin superfamily, which was shown to bind nonenzymatically
glycated adducts, i.e. advanced glycation end products (AGE). It
has been described to be involved in a variety of pathophysi-
ological processes, e.g. immune/inflammatory disorders (Hof-
mann et al., 1999, 2002), Alzheimer's disease (Yan et al., 1997;
Lue et al., 2001), abnormalities associated with diabetes, e.g.
arteriosclerosis (Park et al., 1998) or impaired wound healing
(Goova et al., 2001), and tumourigenesis (Taguchi et al., 2000;
Huttunen et al., 2002). In terms of tumours and metastasis, the
interaction with the extracellular ligand amphoterin, synony-
mously called HMGB1, was shown to have significant influence
(Taguchi et al., 2000; Huttunen et al., 2002) by activating key
cell signalling pathways such as MAP kinases and NF-κB
(Taguchi et al., 2000). Taguchi et al. (2000) were able to show
that blocking of this complex by using a soluble variant of the
receptor lacking the cytosolic and transmembrane domains
strongly inhibited the metastatic behaviour of glioma cells in
terms of invasive growth, motility and migration. To establish a
therapeutic approach based on blocking of the RAGE–HMGB1
protein complex in canine tumours as preclinical approach for
human neoplasias, the knowledge of the canine protein complex
is precondition. Previously we characterised the canine HMGB1
gene and its protein (Murua Escobar et al., 2003). Here we
present the complete characterisation of the canine RAGE gene
including its mRNA, the genomic structure, chromosomal
localisation, gene expression pattern, and its protein. Further-
more we compared the protein coding sequences (CDS) of six
different canine breeds and screened them for single nucleotide
polymorphisms (SNPs).
The complete characterisation of the canine RAGE–
HMGB1 protein complex will serve as base for future clinical
studies aimed at the development of blocking strategies to
inhibit metastatic behaviour of canine and human tumours.
2. Methods and materials
2.1. Tissues
The tissues used in this study were provided by the Small
Animal Clinic, University of Veterinary Medicine, Hannover,
Germany. The breeds represented were Bernese Mountain Dog,
Border Collie, Dachshund, Golden Retriever, Rottweiler, and
Siberian Husky. From each breed up to three samples of lung
tissue were taken and used for analyses.
2.2. Bacterial artificial chromosome (BAC) screening and
fluorescence in situ hybridisation FISH
A canine genomic RAGE DNA probe was used for
hybridisation of canine RPCI 81 BAC/PAC filter (BACPAC
RESOURCES/Children's Hospital Oakland Research Institute,
Oakland, USA). The 261 bp probe was generated by PCR with
the primer set 480up and canisRlo623 (5′ AGGGACTCT-
TAGCTGGCACT 3′/5′ GAAGGTGGGGTGGGGAGCTC 3′)
on genomic DNA prepared from a blood sample of a healthy
dog. The obtained PCR product was separated on a 1.5%
agarose gel, recovered with QIAEX II (QIAGEN, Hilden,
Germany), cloned in pGEM–T-Easy vector system (Promega,
Madison, USA) and sequenced for verification. The probe
labelling was performed by random primed labelling (Roche
Diagnostics, Mannheim, Germany) as described in the
manufacturer's protocol with 250 ng probe and 250 μCi
(α32P)dCTP (GE Healthcare, Freiburg, Germany). Purification
of the labelled probe was done using Sephadex G-50 Nick
Columns (Amersham Pharmacia Biotech, Freiburg, Germany)
and the probe was stored at −20 °C before use.
The filters were placed in a minimum volume of Church
Buffer (0.15 mM bovine serum albumin (BSA), 1 mM EDTA,
0.5 M NaHPO4, 7% SDS) and transferred into hybridisation
bottles. The filters were prehybridised at 65 °C for 1 h in 25 ml
Church Buffer. Hybridisation was performed at 65 °C overnight
(16–18 h) in the same solution. All further steps were performed
according to manufacturer's protocol. Signals were visualised
using a STORM imager (Molecular Dynamics, Sunnyvale,
USA).
Metaphase preparations were obtained from blood samples
of different dogs. The samples were stimulated with phytohe-
magglutinin (PHA) and cultured for 96 h at 37 °C. After
incubation for 2 h with colcemide (0.1 μg/ml), the lymphocytes
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were harvested and slides were prepared according to routine
procedures. Prior to FISH, chromosomes were stained using an
adapted GTG-banding method. Chromosomal G-bands were
identified according to Reimann et al. (1996). After recording
the metaphases, the slides were destained in 70% ethanol for 15
min, air-dried and incubated at 60 °C overnight.
FISH was performed using the protocol of Fischer et al.
(1996) with some modifications. BAC DNA was digoxigenin
labelled (Dig-Nick-Translation-Kit, Roche Diagnostics, Man-
nheim, Germany). The hybridisation mixture contained 200 ng
probe, 43.2 μg salmon sperm DNA, 800 ng sonicated dog DNA,
1× SSC, 1× SSPE, 50% formamide and 10% dextransulfate. The
chromosomes were counterstained with propidiumiodide.
2.3. Genomic characterisation
For genomic characterization the canine RAGE gene was
amplified by PCR using the screened BAC RP81339J10
(BACPAC RESOURCES/Children's Hospital Oakland Re-
search Institute, Oakland, USA). A 1298 bp fragment spanning
exon 1 to exon 6 was generated by the primer pair canisRup1/
canisRlo623 (5′ ATGGCAGCAGGGGCGGCAGC 3′/5′
GAAGGTGGGGTGGGGAGCTC 3′) and an additional 1403
bp fragment spanning exon 6 to exon 11 was generated with pair
cEx6up/3046lo (5′ CTCCCCACCCCACCTTCTCC 3′/5′
TCATGGCCCTGCTGCACCGCTCT 3′) including the respec-
tive introns. The obtained PCR products were separated on an
1.5% agarose gel, recovered with QIAEX II (QIAGEN,
Hilden, Germany), cloned in pGEM–T-Easy vector system
(Promega, Madison, USA) and sequenced for verification. The
final genomic canine RAGE contig and the identity alignments
were created with Lasergene software (DNAStar, Madison,
USA) using various sequences from the NCBI database
(GenBank accession nos.: D28769, AB036432, NM_001136,
BC020669, M91211) and the following described cDNA (see
Section 2.4).
2.4. cDNA characterisation
Total RNAwas isolated from 50 mg canine lung tissue using
TRIZOL LS (Invitrogen, Karlsruhe, Germany) following the
manufacturer's protocol. To avoid genomic DNA contamination
a DNase digest of each sample was performed using RNase-
Free DNase Set (Qiagen, Hilden, Germany). cDNA was
synthesised using 3′-RACE adaptor primer AP2 (AAG-
GATCCGTCGACATC(17)T), 5 μg total RNA, and SuperScript
II (Invitrogen, Karlsruhe, Germany) reverse transcriptase
according to the manufacturer's instructions. The PCRs for the
molecular cloning of the cDNA were done using the primer
pairs canisRup1/canisRlo623 (5′ ATGGCAGCAGGGGCGG-
CAGC 3′/5′ GAAGGTGGGGTGGGGAGCTC 3′), 480up/
RAGElo1236 (5′ AGGGACTCTTAGCTGGCACT 3′/5′
TGTCTGTGGGCCCCTCAAGG 3′) and gene-specific primers
cEx6up/cEx11up (5′ CTCCCCACCCCACCTTCTCC 3′/5′
GAATCAGTCAGAGGAGCCCGAGG 3′). 3′RACE PCR
was done using the adaptor primer AP2 specified above. The
primers were derived from human cDNA sequences (GenBank
accession no. M91211). 5′RACE was performed using the
primers 5′RACE Abridged Anchor Primer (5′ GGCCAC-
GCGTCGACTAGTACGGGIIGGGIIGGGII 3′), Universal
Amplification Primer (5′ CTACTACTACTAGGCCACG-
CGTCGACTAGTAC 3′), and the gene-specific primers
RAGElo1236 and canisRlo623 determined as above according
to the 5′RACE System for Rapid Amplifications of cDNA Ends
by Invitrogen. The PCR products were separated on a 1.5%
agarose gel, recovered with QIAEX II (QIAGEN, Hilden,
Germany), cloned in pGEM–T-Easy vector system (Promega,
Madison, USA) and sequenced. The cDNA contig and the
identity alignments were created with Lasergene software
(DNAStar, Madison, USA) and various sequences from the
NCBI database (GenBank accession nos.: D28769, AB036432,
NM_001136, BC020669, M91211).
2.5. CDS comparison between breeds
The CDSs were characterised for all breeds as described
previously in Section 2.2. The contigs and the identity
alignments were created using several sequences from the
NCBI database (GenBank accession nos.: D28769 AB036432,
NM_001136, BC020669, M91211). In case of single-nucle-
otide exchanges, the samples were sequenced again in both
forward and reverse direction. Exchanges causing no amino
acid (aa) substitution were not taken into account for further
analyses. For all samples with aa substitutions, the initial PCR
was repeated and the exchange verified by sequencing the
product in both forward and reverse direction.
2.6. Protein sequences
The canine RAGE protein sequence was derived from the
ORF (open reading frames) of the characterised cDNA
sequence described previously in Section 2.4. The protein
homology alignments were created with four sequences from
the NCBI database (GenBank accession nos.: BAA89369,
NP_776407, AAA42027, AAH61182).
2.7. Northern Blot and RT–PCR
Total RNA was isolated from canine liver, kidney, heart,
testis, lung, muscle, pancreas and spleen tissue using RNeasy
midi system (QIAGEN, Hilden, Germany). For Northern Blot
hybridisation 30 μg of total RNA from each tissue sample was
separated on a 1.2% denaturing agarose gel containing 0.65%
formaldehyde. RNAwas transferred onto Hybond–N+ positive
nylon membrane (Amersham Pharmacia Biotech, Freiburg,
Germany) by capillary blot.
A 624 bp cDNA fragment derived from the canine RAGE
sequence (exon 1/exon 5) served as a molecular probe for
hybridisation. The probe was generated by PCR with the primer
set canisRup1 and canisRlo623 (5′ ATGGCAGCAGGGG-
CGGCAGC 3′/5′ GAAGGTGGGGTGGGGAGCTC 3′) using
the cloned cDNA described in Section 2.2. Probe labelling was
performed by random primed labelling (Amersham Pharmacia
Biotech, Freiburg, Germany) as described in the manufacturer's
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protocol with 50 μCi (α32P)dCTP (Amersham Pharmacia
Biotech, Freiburg, Germany). Purification of the labelled
probe was performed using Sephadex G-50 Nick Columns
(Amersham Pharmacia Biotech, Freiburg, Germany) and the
probe was stored at −20 °C before use.
Prehybridisation was carried out for 30 min and hybridisa-
tion overnight at 68 °C using the PERFECTHYB PLUS hybri-
disation solution (Sigma-Aldrich, Saint Louis, MO, USA). The
membrane was washed for 5 min at room temperature in 2×
SSC/0.1% SDS, and twice for 20 min at 68 °C in 0.5× SSC/
0.1% SDS. Signals were visualised using a STORM phosphor-
imager (Molecular Dynamics, Sunnyvale, USA).
RT–PCR was performed using all isolated tissue cDNAs
with primer pair cEx6up/3046lo (5′ CTCCCCACCCCACCT-
TCTCC 3′/5′ TCATGGCCCTGCTGCACCGCTCT 3′).
3. Results and discussion
The RAGE–HMGB1 protein complex has lately attracted
significant interest of researchers working on cancer and other
diseases. Several publications demonstrate the involvement of
the RAGE receptor in a variety of pathophysiological processes,
e.g. immune/inflammatory disorders (Hofmann et al., 1999,
2002), Alzheimer disease (Yan et al., 1997; Lue et al., 2001),
abnormalities associated with diabetes, e.g. arteriosclerosis
(Park et al., 1998) and impaired wound healing (Goova et al.,
2001). It has been shown that the specific RAGE-related
diseases are caused by binding of different specific ligands to
the receptor (for reviews, see Schmidt et al., 2001; Huttunen and
Rauvala, 2004). In terms of tumourigenesis and metastasis, the
interaction with the extracellular ligand amphoterin, synony-
mously called HMGB1, was shown to have significant
influence by activating key cell signalling MAP kinase
pathways (Huttunen et al., 2002; Taguchi et al., 2000). A set
of in vivo and in vitro experiments showed that blocking of this
complex strongly inhibited the metastatic behaviour of cancer
cells in terms of invasive growth, motility and migration
(Taguchi et al., 2000). Furthermore, deregulation of the RAGE
gene expression level was associated with prostate cancer
(Simm et al., 2004), with malignant potential of colorectal
cancer (Sasahira et al., 2005) and non-small-cell lung cancer
(Bartling et al., 2005).
To establish a therapeutic approach based on blocking of the
RAGE–HMGB1 protein complex in canine tumours as a
preclinical approach for human neoplasias, the knowledge of
the canine protein complex is preconditioned.
3.1. Chromosomal localisation
A canine RAGE genomic DNA probe was generated and used
for screening of a canine BAC for localisation of the canine
RAGE gene locus by FISH. The verified BAC 339-J10 was used
for FISH experiments. Twelve well-spread metaphases were
Fig. 1. An example of a metaphase spread after FISH with signals on both
chromosomes 12 (A) and the same metaphase after GTG-banding (B).
Fig. 2. Structure of the canine RAGE gene on genomic, cDNA and protein level.
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examined for analyses, showing signals on both chromatides of
both chromosomes CFA 12 (Fig. 1). The chromosomal
localisation was done following the nomenclature established
by Reimann et al. (1996). Presented synteny studies (Yang et
al., 1999; Breen et al., 1999) showed that the canine CFA 12
shares homology to the human chromosome 6 where the
RAGE gene is located at HSA 6p21.32. As far as we know,
chromosomal aberrations affecting CFA 12 are not reported to
be significantly associated with canine neoplasias.
3.2. Genomic structure
The genomic structure of the canine RAGE gene consists of
eleven exons and ten introns. The complete canine gene spans
2835 bp. The exon/intron structure, size and the homologies to
their human counterparts were analysed and defined (Fig. 2 and
Table 1). The total identity to the corresponding human region
shows 63.4%. In detail, the identities of the exons vary between
73.9% and 86.7% to their human counterpart, while the introns
show identities between 43.4% and 71.0% (for details see Table
1). The genomic sequences were submitted to the NCBI
database (GenBank accession no. AY836509).
3.3. The canine RAGE cDNA transcript
The complete canine RAGE cDNA consist of eleven exons
spanning 1384 bp in total. The exon size varies between 27 bp
to 254 bp composing all together a 5′UTR of 18 bp, a CDS of
1215 bp, and a 3′UTR of 151 bp (Fig. 2 and Table 1). Identity
comparison to its human counterpart (GenBank accession no.
D28769) revealed a total identity of 80.9% on nucleotide level
varying in the exons from 73.9% (exon 11) to 86.7% (exon 2)
(for details see Table 1). In humans several naturally occurring
truncated RAGE transcripts have been described lacking the
cytosolic and transmembrane domains named soluble RAGE
variants (sRAGE) (Malherbe et al., 1999; Schlueter et al.,
2003). These aberrant transcripts act as naturally occurring
competitive inhibitors of the RAGE receptor taking effect on
receptor efficiency. Detailed analysis of the aberrant transcript
structure revealed the partial insertion of different genomic
RAGE intron DNA fragments leading to the observed aberrant
splicing products (Malherbe et al., 1999; Schlueter et al.,
2003). In dogs, we could not detect corresponding aberrant
splicing products using the experimental design developed
previously in our group by Schlueter et al. (2003). However,
the application of such soluble RAGE variants to block e.g. the
HMGB1 protein drastically suppressed the growth of tumour
cells in vitro and in vivo (for review see Huttunen et al., 2002).
Treatment of mice with sRAGE completely suppressed
diabetic atherosclerosis in a glycemia- and lipid-independent
manner (Park et al., 1998). The total canine RAGE cDNA
sequence was submitted to the NCBI database with GenBank
accession no. AY836152 completing our previous submission
of AY530943.
3.4. RAGE CDS comparison between different canine breeds
For six different canine breeds the protein coding
sequences were characterised by amplification of a fragment
spanning the CDS using the canine lung cDNA samples as
template. Nucleotide exchanges causing no amino acid
substitution were not taken into account in further analyses.
The comparison of these six protein-coding sequences
revealed one amino acid change. A Bernese Mountaindog
sample showed a nucleotide transition from C (CGG) to T
(TGG) at the first base of the CDS codon 364, leading to an
aa replacement from arginine (R) to tryptophane (W).
Possible PCR artefacts seem rather unlikely, since several
clones were sequenced for verification. Polymorphisms
causing mutations in the RAGE gene had been associated
with various inflammatory diseases and diabetic syndromes
such as rheumatoid arthritis, psoriasis, nephropathy, period-
ontitis, and microvascular diseases (Hudson et al., 1998,
2001; Kankova et al., 1999, 2001; Liu and Xiang, 1999;
Poirier et al., 2001; Hofmann et al., 2002; Schmidt, 2002;
Vasku et al., 2002). Considering the fact that canine breeds
show breed-specific predispositions for various cancers and
Table 1
Detailed analysis of the RAGE gene elements and the RAGE protein
Element Size in bp Identity to human counterpart
in % (D28769)
Total genomic gene 2835 63.4
Total cDNA 1384 80.9
5′UTR 18 100
CDS 1215 82.9
3′UTR 151 70.8
Detail exons/introns
Exon 1 58 78.0
Intron 1 170 67.5
Exon 2 107 86.7
Intron 2 131 71.0
Exon 3 193 85.8
Intron 3 159 53.8
Exon 4 65 85.5
Intron 4 119 57.0
Exon 5 88 86.6
Intron 5 98 71.1
Exon 6 183 86.7
Intron 6 94 47.3
Exon 7 125 80.2
Intron 7 199 57.6
Exon 8 139 85.0
Intron 8 268 51.8
Exon 9 27 79.2
Intron 9 106 62.3
Exon 10 127 84.3
Intron 10 125 62.3
Exon 11 254 73.9
Protein Size in aa Identity to human counterpart
in % (BAA89369)
Total protein 404 77.6
Total extracellular domain 318 78.2
Ig-type V domain 33 85.7
Transmebrane domain 19 78.9
Cytosolic tail 43 72.7
Identity comparison of the canine RAGE genomic elements, cDNA elements,
and protein to their human counterparts.
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other diseases, the detailed analyses of single breeds could be
of significant value to unravel the disease associated
mechanisms involved.
The CDS cDNA sequences of the six breeds were submitted
to the NCBI database with GenBank accession nos.
DQ125936, DQ125937, DQ125938, DQ125939, DQ125940,
and DQ125941.
3.5. The canine RAGE protein
The canine RAGE protein sequence was deduced from the
characterised cDNA sequence. The canine RAGE protein is a
404-amino-acid molecule with a calculated weight of 43 kDa
(Fig. 1 and Table 1). Identity comparison of the canine
molecule to its human counterpart (GenBank accession no.
BAA89369) showed a total of 77.6% identity to the human
protein including the described three extracellular (EC)
immunoglobulin (Ig) type domains V, C, C′, the hydrophobic
transmembrane domain (TM), and the highly charged
cytosolic tail including acidic carboxy-terminal domain
(CD) (Neeper et al., 1992). The total canine extracellular
domain shows 78.2%, the transmembrane domain 78.9%, and
the cytosolic tail 72.7% identity to their human counterparts,
respectively. The RAGE immunoglobulin type V domain was
identified as HMGB1 binding domain. The identity compar-
ison of this domain between dog and human showed 85.7%
with 10 amino acid exchanges (Fig. 3). Recently, the motive
of the human HMGB1 protein for binding the V domain of
RAGE receptor was identified to consist of aa 150–183
including the HMG-Box-B and part of carboxy-terminal
domain (Huttunen et al., 2002). We previously characterised
the canine HMGB1 protein and comparison of the functional
domains revealed that the canine amino acid sequence is
identical to the human counterpart (Murua Escobar et al.,
2003). Due to the high similarity of the canine and human
RAGE–HMGB1 protein complexes in their interacting
domains, therapeutic approaches applied in dogs could be
more suitable in terms of transferability for the development
of human therapies than approaches tested in other
organisms.
Comparison of the canine RAGE protein with the described
mouse (GenBank accession no. AAH61182), rat (GenBank
accession no. AAA42027) and bovine (GenBank accession no.
Fig. 3. Comparison of the canine, human, mouse, rat, and bovine RAGE proteins. The amino acid differences are shown as bold letters.
Fig. 4. Total RNA Northern blot showing 1.4 kb RAGE and 1.3 kb GAPDH
transcripts. Lanes: (1) canine testis, (2) canine heart, (3) canine lung, (4) canine
muscle, (5) canine kidney, (6) canine pancreas, (7) canine spleen, (8) canine
liver.
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NP_776407) molecules showed identities of 73.5%, 72.8% and
77.7%, respectively (Fig. 3).
The canine RAGE protein sequence was submitted to the
NCBI database with GenBank accession no. AAX38183.
3.6. Canine RAGE expression analysis
To elucidate the expression patterns of the canine RAGE
gene, a canine Northern blot was performed using RNA from
canine liver, kidney, heart, testis, lung, muscle, pancreas and
spleen tissue samples as well as RNA from different canine
cell lines and hybridised with a 32P-labelled canine RAGE
cDNA probe. Except for the lung tissue showing a clear
approx. 1.4 kb signal, none of the samples revealed a distinct
signal. After stripping and rehybridisation with a canine
GAPDH probe, all samples revealed signals corresponding to
approx. 1.3 kb demonstrating intact RNA (Fig. 4). For
verification, performed RT–PCR using the same RNA
revealed, additionally to a clear lung signal, very weak
signals in spleen and heart tissue (data not shown). These
results are in accordance to the gene expression pattern seen
in humans. However, as mentioned before, aberrant tran-
scripts like those found in humans could not be detected by
RT–PCR. Lately, deregulation of the RAGE gene had been
associated with various cancers and diseases e.g. up-
regulation of the gene has been shown to be associated
with prostate cancer development, human heart dysfunction,
and inhibition of liver regeneration (Simm et al., 2004;
Cataldegirmen et al., 2005; Ishiguro et al., 2005), while
down-regulation of the RAGE gene has been shown to
support non-small-cell lung carcinomas (Bartling et al.,
2005). Additionally, RAGE gene expression has been
associated with malignant potential of colorectal adenomas
(Sasahira et al., 2005). As far as we know, in canine
neoplasias, no RAGE expression analyses have been carried
out. Considering the mentioned characteristics of canine
neoplasias as model for human cancer, expression analyses
done in canine tumours could be of significant value to
further elucidate the role of RAGE in tumour and disease
development.
4. Conclusions
As reviewed lately by Khanna and Hunter (2005), the dog
is significantly helping to reveal characteristics of human
tumour biology especially of metastasis due to the described
similarities of the naturally occurring malignancies in both
species. Accordingly, the development of new therapeutic
approaches in animal model systems will be facilitated by
the ongoing characterisation of model species specific
molecular targets. Especially in points of transferability, the
newly gained knowledge will be of great value. Due to the
significant role of the RAGE–HMGB1 protein complex in
cancer metastasis and the described various other diseases,
the complete characterisation of the canine RAGE–HMGB1
protein complex will serve as basis for future clinical
studies.
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RAGE is a member of the immunoglobulin superfamily of cell surface molecules playing key roles in
pathophysiological processes, e.g. immune/inﬂammatory disorders, Alzheimer's disease, diabetic arterio-
sclerosis and tumourigenesis. In humans 19 naturally occurring RAGE splicing variants resulting in either N-
terminally or C-terminally truncated proteins were identiﬁed and are lately discussed as mechanisms for
receptor regulation. Accordingly, deregulation of sRAGE levels has been associated with several diseases e.g.
Alzheimer's disease, Type 1 diabetes, and rheumatoid arthritis. Administration of recombinant sRAGE to
animal models of cancer blocked tumour growth successfully. In spite of its obvious relationship to cancer
and metastasis data focusing sRAGE deregulation and tumours is rare. In this study we screened a set of
tumours, healthy tissues and various cancer cell lines for RAGE splicing variants and analysed their structure.
Additionally, we analysed the ratio of the mainly found transcript variants using quantitative Real-Time PCR.
In total we characterised 24 previously not described canine and 4 human RAGE splicing variants, analysed
their structure, classiﬁed their characteristics, and derived their respective protein forms. Interestingly, the
healthy and the neoplastic tissue samples showed in majority RAGE transcripts coding for the complete
receptor and transcripts showing insertions of intron 1.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The receptor for advanced glycation end products (RAGE) is a
member of the immunoglobulin superfamily of cell surface molecules
which binds nonenzymatically glycated adducts like advanced
glycation end products (AGE). Acting as a multiligand receptor it has
been described to interact with various ligands i.e. amphoterin also
known as HMGB1 (Hori et al., 1995), amyloid beta (Yan et al., 1996),
proteins of the S100/calgranulin family (Hofmann et al., 1999) and
Mac-1 (Chavakis et al., 2003). The ligand-receptor-complexes regulate
cell signalling pathways having inﬂuencing effect on cell growth and
proliferation, i.e. p21ras, erk1/2 (p44/p42) MAP kinases, p38, SAPK/
JNK Map kinases, rho GTPases, phosphoinostiol-3 kinase, NFkB, and
cAMP response element binding protein (CREB) (Neeper et al., 1992;
Yan et al., 1994; Lander et al., 1997; Deora et al., 1998; Hofmann et al.,
1999; Huttunen et al., 1999; Kislinger et al., 1999; Huang et al., 2001;
Huttunen et al., 2002b). In terms of pathophysiological processes
RAGE has been described to be involved in various diseases including
diabetic arteriosclerosis (Park et al., 1998; Cipollone et al., 2003),
impaired wound healing (Goova et al., 2001), Alzheimer's disease (Yan
et al., 1996; Lue et al., 2001, 2005), immune and inﬂammatory
disorders (Hofmann et al., 1999; Schmidt et al., 2001; Hofmann et al.,
2002; Chavakis et al., 2004) and various cancers (Taguchi et al., 2000;
Huttunen et al., 2002a; Bartling et al., 2005; Bhawal et al., 2005;
Ishiguro et al., 2005). In humans 19 naturally occurring RAGE splicing
variants resulting in either N-terminally or C-terminally truncated
proteins were identiﬁed and are currently discussed as mechanisms
for receptor regulation (hRAGEsec (Malherbe et al., 1999), sRAGE1,
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sRAGE2, sRAGE3 (Schlueter et al., 2003), N-truncated and Secretory
(Yonekura et al., 2003), Δ8-RAGE (Park et al., 2004), RageΔ, NtRAGEΔ
and sRAGEΔ (Ding and Keller, 2005b), RAGE_v4-RAGE_v13 (Hudson et
al., 2007). The function of these variants was unclear, but lately the
described truncated RAGE protein variants were supposed to act as
competitive inhibitors of the receptor either by ligand binding or
displacing the full-length receptor in the membrane (Ding and Keller,
2005a; Geroldi et al., 2005). Deregulations of the naturally occurring
protein isoforms are supposed to have signiﬁcant effect on RAGE
mediated diseases. Accordingly, deregulations of sRAGE levels have
been associated with several diseases e.g. Alzheimer's disease
(Emanuele et al., 2005), Type 1 diabetes (Challier et al., 2005; Forbes
et al., 2005; Katakami et al., 2005; Miura et al., 2007), Type 2 diabetes
(Nakamura et al., 2006; Tan et al., 2006; Yamagishi et al., 2006;
Humpert et al., 2007), atherosclerosis (Falcone et al., 2005; Koyama et
al., 2005), rheumatoid arthritis (Moser et al., 2005; Pullerits et al.,
2005), essential hypertension (Geroldi et al., 2005), and renal disease
(Kalousova et al., 2006). On the other hand Taguchi et al. (2000) were
able to show that blocking of the binding of the RAGE ligand HMGB1
to the receptor, by using RAGE variants lacking the cytosolic or
transmembrane domains, strongly inhibited the metastatic behaviour
of glioma cells in terms of invasive growth, motility andmigration. The
data clearly showed that the application of soluble RAGE variants
drastically suppressed the growth of tumour cells in vitro and in vivo
(for review see Huttunen and Rauvala, 2004). In spite of its obvious
relationship to cancer and metastasis data focusing soluble RAGE
deregulations or structural aberrations and tumours is currently rare.
Only recently Takeuchi et al. reported a correlation between esRAGE,
RAGE, and HMGB1 and staging of chondrosarcomas classifying
esRAGE expression as tumourmarker for malignancy (Takeuchi et
al., 2007).
As reviewed lately by Khanna and Hunter (2005) the dog is
signiﬁcantly helping to reveal characteristics of human tumour
biology especially of metastasis due to various similarities of the
malignancies seen in both species. Generally, in the case of cancer, in
dogs we ﬁnd naturally spontaneously developing neoplasias which
are more similar to human cancers than induced tumours used in
rodent model systems in terms of presentation, histology and biology
(Withrow and MacEwen, 1989, 2001; MacEwen, 1990). Additionally,
dogs show similar characteristics of physiology and metabolism for
most organ systems and drugs, which allows better comparability of
modalities e.g. surgery, radiation, chemotherapy (Withrow and
MacEwen, 2001), and new therapeutic approaches aimed at cancer
treatment.
In this study we screened a set of 14 different canine tumours,
healthy tissues and various canine and human cancer cell lines for
RAGE splicing variants and analysed their structures. Additionally,
we analysed the ratio of the mainly found transcript variants using
quantitative and relative Real-Time PCR.
2. Methods and materials
2.1. Tissues and cell lines
The analysed canine healthy (lung, ovar, pancreas, skin, spleen,
testis, thyroid) and tumour tissues (adenoma of pancreas, colon
cancer, ﬁbrosarcoma, histiocytoma, insulinoma, liver adenoma, malig-
nant histiocytosis, malignant lymphoma, mamma tumour, mastocy-
toma, melanoma, splenic hemangiosarcoma, testis tumour, thyroid
carcinoma, vaginal tumour) were provided by the Small Animal Clinic,
University of Veterinary Medicine, Hanover, Germany. The canine cell
lines CT1258 (prostate cancer), MTH53A (non neoplastic tissue of the
mammary gland), MTH52C (malignant small-cell carcinoma of the
mammary gland), and ZMTH3 (pleomorphic adenoma of the
mammary gland) and the human cell lines Hela (cervical cancer),
Li14 (lipoma), and MCF7 (breast cancer) which were used in this
study, were provided by the Centre for Human Genetics, University of
Bremen, Bremen, Germany.
2.2. RNA isolation and cDNA synthesis for transcript characterisation
The cultured cells were homogenized using QIAshredder spin
columns (Qiagen, Hilden, Germany) while the used tissue samples
were homogenized using the iron-beads QIAshredder homogenizer
method (Qiagen, Hilden, Germany). Following, total RNA was isolated
using the RNeasy Mini Kit according to the manufacturer's instruc-
tions (Qiagen, Hilden, Germany). To avoid genomic DNA contamina-
tions, on-column DNase digestion with the RNase-Free DNase set
(Qiagen, Hilden, Germany) was performed.
The respective total cDNA syntheses were performed using 5 μg
total RNA of each sample, the adaptor poly dT primer AP2: AAG GAT CCG
TCG ACA TC(17)T, and MMLV reverse transcriptase following the
manufacturer's protocol (Invitrogen, Karlsruhe, Germany). The
respective cDNA syntheses were performed several times during the
experiments.
2.3. PCR reactions
All performed PCR reactions were designed to amplify products
spanning from exon 1 to exon 11 of the canine or human RAGEmRNA,
respectively. The PCR reactions using the total poly dT primed cDNAs
of the canine cell lines and tissue samples were performed either with
the primer pair 1 (up 5′GAA GCC TGG GAA GGA ACG ATG3′/lo 5′GAG
AGC AAG GGG GAA GAA AAG3′) or pair 2 (up 5′CCT GGG TGC TGG TCC
TCA GT3′/lo 5′TCA TGG CCC TGC TGC ACC GC TCT3′). The reactions
using human templates were performed with the primer pair 5′CCT
GGG TGC TGG TCC TCA GT3′ as upper primer and the primer 5′TCA
AGG CCC TCC AGT ACT ACT TC3′ as lower primer for PCR reactions
amplifying RAGE transcripts in human cell lines (Hela, Li14, MCF7).
The PCR reactions were performed with a “touch down”
programme with the following conditions: initial denaturation at
95 °C for 5 min, followed by 10 cycles with 30 s denaturation at
95 °C, 1 min annealing by 70–60 °C with a decrease of 1 °C per cycle
and an elongation at 72 °C for 1 min. The following 30 cycles were
performed at 95 °C for 30 s, 60 °C for 1 min and 72 °C for 1 min,
respectively.
2.4. Characterisation of RAGE transcript variants
The respective ampliﬁed PCR products were separated electro-
phoretically in 1.5% agarose gels and recovered using the QIAquick Gel
Extraction Kit following the manufacturer's protocol (Qiagen, Hilden,
Germany). The isolated fragments were cloned into the pGem-T-Easy
vector system (Promega, Mannheim, Germany), transfected in
thermocompetent DH5α E. coli cells, and veriﬁed by sequencing
(MWG, Ebersberg, Germany). The received sequence data was
analysed using Lasergene software (DNAStar, Madison, USA).The
generated sequences were submitted to the NCBI database (GenBank
accession nos: EU428788, EU428789, EU428790, EU428791,
EU428792, EU428793, EU428794, EU428795, EU428796, EU428797,
EU428798, EU428799, EU428800, EU428801, EU428802, EU428803,
EU428804, EU428805, EU428806, EU428807, EU428808, EU428809,
EU428810, EU428811, EU428812, EU428813, EU428814, EU428815,
EU428816).The CDS and protein alignments were performed using
various sequences from NCBI database (GenBank accession nos.:
D28769, NM001048081; BAA89369, ABA18650).
2.5. Quantitative Real-time RT-PCR
2.5.1. RNA isolation and cDNA syntheses for qRT-PCR
Total RNAs from the homogenized cultured cells and tissue
samples were isolated using the RNeasy Plus Mini Kit (Qiagen, Hilden,
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Fig. 1. RAGE transcript variants. Characterisation of RAGE transcript variants in canine non neoplastic tissues: pancreas, spleen, testis and thyroid (cA–cE), canine cell lines: CT1258, MTH 53A, MTH 52C and ZMTH3 (cF–cN), canine tumours:
histiocytoma, malignant lymphoma, malignant melanoma, mastocytoma and thyroid carcinoma (cO–cX) and human cell lines: Hela, Li14 and MCF7 (hA–hF). The ampliﬁed PCR products range from the start codon in exon 1 till stop codon in
exon 11. The RT PCR was performed with a poly dT primer. The transcript variants show different structural modiﬁcations like insertions of introns and deletions of both whole exons and parts of exons.
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Germany). This isolation method does not require an additional on
column DNase digestion due to a direct removal of genomic DNA
(gDNA) by a gDNA eliminating spin column.
The respective cDNA syntheses were performed using 250 ng total
RNA of each sample, the gene speciﬁc lower primer 5′
TTCTGTCCGACCTGTGTTCAGCTT3′, and Quantiscript Reverse Tran-
scriptase following the manufacturer's protocol (Qiagen, Hilden,
Germany) with an integrated removal of genomic DNA contamination.
For absolute and relative quantiﬁcation of the RAGE transcript
levels RT-PCR ampliﬁcations were carried out using the Applied
Biosystems 7300 Real-Time PCR System (Applied Biosystems,
Darmstadt, Germany). 2 μl of each cDNA corresponding to 25 ng of
total RNA was ampliﬁed in a total volume of 25 μl using universal
PCR Mastermix (Applied Biosystems) with 600 nM of each primer
(forward primer 1: 5′GTCTGTGGGGAGCAGTAGTAGG3′, forward pri-
mer 2: 5′TACTCCTCCACCATTGTCCCATCT3′, reverse primer: 5′
TTCTGTCCGACCTGTGTTCAGCTT3′) and 200 nM ﬂuorogenic probe
(5′ 6-FAM-AAGCCGCTGGTGCTCAACTGTA-TAMRA 3′). PCR conditions
were as follows: 2 min at 50 °C and 10 min at 95 °C, followed by
45 cycles with 15 s at 95 °C and 1 min at 60 °C. All samples were
measured in triplicate and for each run non-template controls and
no reverse transcriptase reactions were included. Expression levels
of RAGE mRNA transcripts were calculated using an amplicon-
speciﬁc standard curve. For absolute quantiﬁcation the transcript
levels were normalised to total RNA concentration and expressed as
copy number/250 ng total RNA. For relative quantiﬁcation the
healthy full length RAGE transcript was chosen as endogenous
control. The calibrator sample was lung tissue to which all other
samples were compared to determine the ratio of the relative
expression level.
3. Results and discussion
3.1. Characterisation of RAGE transcript variants
In humans 19 naturally occurring RAGE splicing variants resulting
in either N-terminally or C-terminally truncated proteins were
identiﬁed and are just recently discussed as mechanisms for receptor
regulation (hRAGEsec, sRAGE1, sRAGE2, sRAGE3, N-truncated and
Secretory, Δ8-RAGE, RageΔ, NtRAGEΔ and sRAGEΔ, RAGE_v4 till
RAGE_v13). The described truncated RAGE protein variants are
discussed to act as competitive inhibitors of the receptor either by
ligand binding or displacing the full-length receptor in the membrane.
Deregulation of the naturally occurring protein isoforms is supposed
to have signiﬁcant effect on RAGE mediated diseases. Accordingly,
deregulation of sRAGE levels has been associatedwith several diseases
Table 1
Canine and human RAGE transcript variants
Name
(Fig. 1)
Structure insertion/deletion Acc. No. Putative protein (Fig. 2)/characteristic
Non neoplastic canine tissues
Pancreas cA Insertion: intron1, intron 8 EU428787 J/non sense protein
Spleen cB Insertion: intron1, intron 2, intron 8 EU428788 I/non sense protein
Testis cC Deletion: exon 8 EU428789 A/soluble isoform, ligand binding
Thyroid cD Insertion: intron 1, intron 2 EU428790 C/membrane bound, no ligand binding
cE Insertion: intron 2 EU428791 F/membrane bound, no ligand binding
Canine cell lines
CT1258 cF Insertion: intron1, intron 2/deletion: 16 bp exon 8 EU428802 K/non sense protein
cG Insertion: intron 1 EU428803 E/membrane bound, no ligand binding
cH Insertion: intron 1/deletion: exon 3, exon 6, exon 7, exon 8 EU428804 No putative protein
MTH 53A cI Insertion: intron 1, intron 2, intron 8 EU428805 I/non sense protein
cJ Insertion: intron 1, intron 8 EU428806 J/non sense protein
MTH 52C cK Insertion: intron 1/deletion: exon 8 EU428807 M/non sense protein
ZMTH3 cL Insertion: intron 1, intron 5 EU428808 D/membrane bound, no ligand binding
cM Insertion: intron 1 EU428809 E/membrane bound, no ligand binding
cN Insertion: intron 1, intron 2/deletion: exon 7, exon 8 EU428810 G/membrane bound, no ligand binding
Canine tumours
Histiocytoma cO Insertion: intron 1, intron 2, intron 8 EU428792 I/non sense protein
cP Insertion: intron 1 EU428793 E/membrane bound, no ligand binding
Malignant lymphoma cQ Insertion: intron 1 EU428795 E/membrane bound, no ligand binding
cR Insertion: intron 1/deletion: 16 bp exon 8 EU428794 L/non sense protein
cS Deletion: 16 bp exon 8 EU428796 B/soluble isoform, ligand binding
Malignant melanoma cT Insertion: intron 1, intron 10 EU428797 No putative protein
cU Insertion: intron 1/Deletion: exon 7, exon 8, exon 9 EU428798 H/membrane bound, no ligand binding
Mastocytoma cV Insertion: intron1, intron 5, intron 6, intron 8 EU428799 No putative protein
cW Insertion: intron 1 EU428800 E/membrane bound, no ligand binding
Thyroid carcinoma cX Insertion: intron1/deletion: 16 bp exon 8 EU428801 L/non sense protein
Human cell lines
Hela hA Deletion: 80 bp exon2, exon3, exon 4, exon 5, 120 bp exon6 EU428811 CC/membrane bound, no ligand binding
Li 14 hB Insertion: intron 1 EU428812 AA/membrane bound, no ligand binding
hC Insertion: intron 1/deletion: exon 9 EU428812 BB/membrane bound, no ligand binding
hD Insertion: intron 9/deletion: 72 bp exon 2, exon 3, exon 4, exon 5 EU428814 No putative protein
MCF 7 hE Insertion: intron 1/deletion: exon 9 EU428815 BB/membrane bound, no ligand binding
hF Insertion: intron 1, intron 9/deletion: 52 bp exon 8, 22 bp intron 9 EU428816 No putative protein
Detailed characterisation of the different respective RAGE transcript modiﬁcations and analyses of their derived protein isoforms.
Fig. 2. The canine RAGE CDS and protein structure. The different RAGE transcript variants characterised in canine non neoplastic tissues, cell lines, tumours and in human cell lines
code for different putative protein structures: canine soluble RAGE protein isoforms with the ability to bind RAGE ligands without subsequent signalling in the cell (A, B), canine
membrane bound RAGE isoformswithout the competence of binding RAGE ligands (C–H), canine non sense RAGE protein isoforms (I–M) and humanmembrane bound RAGE protein
isoforms (AA–CC).
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e.g. Alzheimer's disease, Type 1 diabetes, Type 2 diabetes, athero-
sclerosis, rheumatoid arthritis, essential hypertension, and renal
disease. On the other hand blocking of the binding of the RAGE ligand
HMGB1 to the receptor by using RAGE variants lacking the cytosolic or
transmembrane domains, strongly inhibited the metastatic behaviour
of glioma cells in terms of invasive growth, motility and migration
(Taguchi et al., 2000). A recent study based on immunohistologic
analyses reports a correlation of esRAGE and staging of chondrosar-
comas classifying RAGE expression as tumourmarker for malignancy
(Takeuchi et al., 2007).
In the herein screened canine 17 neoplastic and seven healthy
tissue samples as well as the four canine and 3 human cell lines we
found in total 24 canine and 6 human transcripts coding for 16
structural different canine and 5 different human forms. Fourteen of
these found canine and four human forms were previously not
described for any other species (Fig.1, Table 1). In detail the transcripts
detected in healthy tissues are characterised by various combinations
of insertions of intron 1, 2 and 8 and by an observed deletion of the
exon 8 (Figs.1cA–cE). In canine cell lines the following events could be
detected: various combinations of insertions of the introns 1, 2, 5, 8
and 10, a 16 bp partial deletion of exon 8, and complete deletions of
the exons 3, 6, 7 and 8 (Figs. 1cF–cN). The neoplastic samples showed
several insertions of introns 1, 2, 5, 6, 8 and 10, the partial 16 bp
deletion of exon 8, and ﬁnally deletions of exons 7, 8 and 9 (Figs. 1cO–
cX). The human cell lines showed insertion of intron 1, partial large
deletions of parts of the exons 2, 6, and 8, compete deletions of the
exons: 3, 4, 5, 8, and 9, and ﬁnally insertion of intron 9 with an
additional deletion of parts of intron 9 (Figs. 1hA–hF).
These different transcript variants can be roughly classiﬁed into
two groups. One group of splicing variants coding for full length RAGE
transcripts or soluble RAGE variants which code for protein forms
capable to bind extracellular ligands, and the other group showing
various insertions of introns and alternative splicing of exons leading
to mutated protein forms (Fig. 1,Fig. 2, Table 1). The recurrent
remarkable modiﬁcation in the latter group is the insertion of intron
1. This modiﬁcation is seen in transcripts found in healthy tissues as
well as in the cell lines and neoplastic samples. Depending on further
modiﬁcations of the seen transcripts respective protein isoforms
would result, missing the V — domain required for ligand binding or
result in nonsense proteins (Fig. 2). Previously Yonekura et al. found a
similar variant showing an insertion of intron 1 in a sample of human
endothelial cells and pericytes (Yonekura et al., 2003). However, this
reports the existence of these transcripts for the ﬁrst time in
neoplastic samples and cell lines.
3.2. Quantitative Real-Time PCR analyses
Following the assumption that the transcripts showing the intron 1
insertion are lost as competitive inhibitors we decided to quantify the
ratio between these variants and variants coding for proteins capable
to bind RAGE ligands in neoplastic canine samples providing naturally
occurring tumour material. The designed assay discriminates genomic
DNA detection, due to the position of the chosen primers (Fig. 3). The
comparative quantiﬁcation showed a diverse pattern (Table 2) in the
analysed samples. Generally, in all screened tissue samples and cell
lines, an expression of both forms could be detected varying from
1.38⁎103 (mastocytoma) to 6.53⁎108 (lung) transcripts for the normal
splicing variant and 1.3⁎103 (mastocytoma) to 1.88⁎106 (lung)
transcripts for the “intron 1” variant. In the screened healthy tissues
the variant coding for a functional complete or soluble RAGE variant is
signiﬁcantly higher expressed in lung, testis and thyroid tissue
showing in absolute numbers 6.53⁎108, 6.27⁎105 and 1.02⁎107
more “healthy” transcripts than their respective ”intron 1” variants.
The pattern seen in the 17 tumour tissue samples and cell lines is quite
different. The majority of samples showed a higher presence of the
“intron 1” variant with the exception of a mastocytoma, which shows
a similar level of both variants (1.3⁎103 “intron 1” to 1.38⁎103
“healthy”) and a testis tumour, which as only neoplastic sample
showed a higher expression “healthy” variant (Table 2). In absolute
numbers the “intron 1” variant outnumbers in the “healthy” variant 15
of the neoplastic samples with a range of 15 to 17 transcripts. The
screened four cell lines showed uniformly a higher level of the intron 1
variant varying from 5.38⁎104 to 9.17⁎104.
However, as lately discussed by Hudson et al. (2007), the wide
diversity of seen RAGE transcripts and the obvious relationship of
RAGE to several pathologic ﬁndings arise many new questions. The
Fig. 3.Designed Real Time assay for absolute quantiﬁcation of RAGE transcripts allowing
differentiation of “healthy” and “intron 1” RAGE splicing variants. For the absolute
quantiﬁcation of healthy RAGE transcript the designed upper primer binds at the border
of exon 1/exon 2, the probe anneals in exon 2 and the lower primer binds at the exon 2/
exon 3 border avoiding measurement of genomic contaminations. The assay for
measurement of the quantity of the intron 1 transcript variant consists of the same
probe and lower primer like the healthy transcript detection, and the upper primer
anneals in intron 1. Due to the upper and lower primer, transcripts which bear intron 1
but no genomic contaminations will be detected.
Table 2
Absolute Real Time quantiﬁcation transcript numbers of “healthy” and “intron 1” RAGE
transcript variants in canine healthy tissues, neoplastic samples and cell lines
Copy no./250 ng total RNA
Healthy transcript Intron 1 transcript
Non neoplastic canine tissues
Lung 6.53⁎108 1.88⁎106
Ovar 6.9⁎103 7.36⁎104
Pancreas 2.6⁎104 3.08⁎105
Skin 1.9⁎103 1.1⁎104
Spleen 7.1⁎103 8.26⁎104
Testis 6.27⁎105 5.6⁎104
Thyroid 1.02⁎107 1.9⁎105
Canine cell lines
CT1258 2.98⁎103 5.38⁎104
MTH 53A 4.68⁎103 6.77⁎104
MTH 52C 9.3⁎103 9.17⁎104
ZMTH3 6.83⁎103 8.8⁎104
Canine tumours
Adenoma of pancreas 4.26⁎103 5.5⁎104
Colon cancer 5.66⁎103 6.19⁎104
Fibrosarcoma 4.7⁎103 7.67⁎104
Histiocytoma 1.46⁎104 1.47⁎105
Insulinoma 1.7⁎104 2.6⁎105
Liver adenoma 3.9⁎103 2.9⁎104
Malignant histiocytosis 9.52⁎103 8.34⁎104
Malignant lymphoma 1.18⁎104 1.49⁎105
Malignant lymphoma 7.6⁎103 8.62⁎104
Malignant lymphoma 1.2⁎104 2.1⁎105
Mammatumour 1.5⁎104 5.29⁎104
Mastocytoma 1.38⁎103 1.3⁎103
Melanoma 4.77⁎103 4.14⁎104
Splenic hemangiosarcoma 2.17⁎104 1.07⁎105
Testis tumour 7.84⁎105 2.11⁎105
Thyroid carcinoma 5.16⁎104 1.53⁎105
Vaginal tumour 1.13⁎104 1.5⁎105
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growing understanding of its biology combined with the accessibility
of an adequate animal model – like the dog providing naturally
occurring neoplastic samples – will be of great value to elucidate the
pathologic events with RAGE involvement. The here newly described
24 canine and 4 human RAGE splicing variants as well as their
respective derived protein forms will further help to understand the
diversity of RAGE biology. The comparative quantitative Real-Time
PCR analyses of both major RAGE transcript classes represent a ﬁrst
approach to analyse, if deregulation/structural aberrations of RAGE
can be detected at RNA level and play a role in RAGE mediated
pathologic events. Anyway, further studies will be needed, to conﬁrm
at protein level the qPCR data. We tested the commercially availed
RAGE antibodies for detection of recombinant canine protein but got
unspeciﬁc results. This may be due to the fact that the identity of the
canine RAGE protein to its human is just 77.6% (Murua Escobar et al.,
2006).
However, studies done with human neoplasias using the herein
generated data as basis should be a promising approach to answer the
remaining questions.
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3.2.?? Expression? pattern? of? HMGB1? and? its? receptor? RAGE? in? canine?
neoplastic?disorders?
The? deregulation? of?HMGB1? and? RAGE? expression?was? reported? in?many? human? tumour?
types?and?was?associated?with?tumour?progression?and?aggressiveness.?Due?to?the?genomic?
characterisation?of?the?canine?HMGB1?and?RAGE?genes,?the?establishment?of?gene?specific?
real?time?PCR?assays?to?analyse?the?expression?patterns?of?both?genes? in?canine?neoplasias?
was?enabled.?Within?this?thesis,?expression?studies?of?HMGB1?and?RAGE?were?performed?in?
canine?neoplasias? including? canine? lymphoma? and?DHS.?Canine? lymphoma? is? a? commonly?
occurring? spontaneously?developing?haematopoietic?neoplasia? that?acts?as?an?appropriate?
model? for? human? non?Hodgkin´s? lymphoma.? Canine? DHS? is? a? histiocytic? neoplasm? of?
interstitial?DCs?which?shares?many?similarities?with?human?histiocytic?cell?related?neoplasias?
such?as?histiocytic?sarcomas?and?LCH.?
?
III.?“High?mobility?Group?B1?(HMGB1)?and?Receptor?for?Advanced?Glycation?End?products?
(RAGE)?Expression?in?Canine?Lymphoma”?
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Within? this? study,? the? HMGB1? and? RAGE? expression? levels? were? measured? via? relative?
quantitative? real?time? PCR? in? 22? canine? lymphoma? and? three? non? neoplastic? lymph? node?
samples.?As?endogenous?control,?the?canine?beta?glucuronidase?gene?(GUSB)?was?used.?The?
study?included?three?intestinal?lymphomas,?15?B?cell?lymphomas,?two?T?cell?lymphomas,?two?
multicentric? lymphomas?of?unknown?origin,?and? three?non?neoplastic? control? lymph?node?
samples.?HMGB1?expression?was?significantly?higher?in?the?intestinal?lymphoma?(p=0.03),?in?
the?B?cell? lymphoma? (p=0.001),?and? in? the?T?cell? lymphoma? (p=0.033)?samples? than? in? the?
non?neoplastic?tissue,?while?no?significant?difference?in?HMGB1?expression?could?be?detected?
in?the?two?lymphoma?samples?of?unknown?origin.?RAGE?expression?remained?stable?without?
statistical?significant?expression?deregulation?within?the?tumour?samples?when?compared?to?
the?non?neoplastic?control?samples.?
?
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Abstract. Background: Canine lymphoma is a commonly
occurring, spontaneously developing neoplasia similar to
human non-Hodgkin’s lymphoma and, thus, is used as a
valuable model for human malignancy. HMGB1 and RAGE
are strongly associated with tumour progression and
vascularisation. Consequently, deregulated RAGE and
HMGB1 may play an important role in the mechanisms
involved in lymphoma progression. Materials and Methods:
Expression patterns of HMGB1 and RAGE were analysed in
22 canine lymphoma and three canine non-neoplastic control
samples via real time PCR and canine beta-glucuronidase
gene (GUSB) as endogenous control. Results: HMGB1 was
up-regulated in the neoplastic samples, while RAGE
expression remained inconspicuous. Conclusion: This study
demonstrated similar mechanisms in lymphoma progression
in humans and dogs due to overexpression of HMGB1, which
was described in human lymphomas. RAGE remained stable
in terms of expression indicating that the extracellular
HMGB1-induced effects are regulated by HMGB1 itself. 
Human and canine tumours share many biological similarities
including tumour progression, metastatic pattern and histology.
Accordingly, these spontaneously occurring canine tumours
represent a valuable model for several human neoplasias and
may help to elucidate the biology of those neoplasias. Focusing
on haematopoietic tumours, canine lymphoma is a commonly
occurring neoplasia serving as an appropriate model for human
non-Hodgkin’s lymphoma. The frequency of canine lymphoma
cases among haematopoietic malignancies is approximately
83%, representing 7% to 24% of all canine neoplasms (1). The
response of this malignancy to chemotherapy protocols varies
substantially (2). Thus, the identification of factors involved in
the formation and progression of lymphomas are of significant
value for future development and evaluation of therapeutic
approaches, providing benefits for both species. 
During tumour progression, hypoxic and necrotic regions
develop as a result of fast cell proliferation. To assure a
sufficient supply of oxygen, solid and haematopoietic tumours
activate cellular angiogenic mechanisms by secretion of pro-
angiogenetic factors such as vascular endothelial growth factor
(VEGF), tumour necrosis factor alpha (TNF-α) and
interleukin-8 (IL-8) (3-5). In human haematopoietic
malignancies, increased angiogenesis, measured by high
vascular density levels, was observed in the lymph nodes of B-
cell non-Hodgkin’s lymphoma and B-cell chronic lymphocytic
leukaemia, as well as in bone marrow specimens from patients
with childhood acute lymphoid leukaemia, acute myeloid
leukaemia, chronic myelocytic leukaemia, myelodysplastic
syndromes and idiopathic myelofibrosis (6-12). VEGF plays an
important role in this process as a master regulator of the
angiogenic switch. Sustained angiogenesis leads to disease
progression described by tumour growth and metastasis. In
non-Hodgkin’s lymphoma, for example, circulating levels of
VEGF have been shown to correlate with overall survival and
event-free survival (13-15). 
The high-mobility group box protein 1 (HMGB1), also
known as amphoterin or HMG-1, was initially described as a
DNA-binding protein but seems to act as a proinflammatory
cytokine and as well as a dose-dependent mediator of
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angiogenic and neo-vascularising effects (16). In response to
angiogenic and inflammatory signals, HMGB1 is passively
released by necrotic cells or actively secreted by activated
macrophages. HMGB1 signalling itself is mediated via the
receptor for advanced glycation end-products (RAGE) and
toll-like receptors (TLR) such as TLR-2 and TLR-4.
Activation of these receptors results in activation of nuclear
factor kappa B (NFκB), among other factors, which itself
acts as a transcriptional enhancer for RAGE, pro-
inflammatory cytokines and the pro-angiogenic factor VEGF
(17). Due to the positive feedback loop caused by activation
of NFκB, a sustained inflammation or angiogenic reaction
contributes to disease progression and, in the case of tumour
development, to uncontrolled growth and metastasis (17). An
in vitro study by Sasahira et al. (18) showed that the
HMGB1/RAGE complex induces VEGF expression through
the activation of NFκB in two human oral squamous cell
carcinoma cell lines. The abrogation of the HMGB1-
mediated effect was observed by down-regulation of RAGE
expression via application of antisense S-oligodeoxynucleic
acid, resulting in a significantly lower VEGF secretion (18). 
In this context, a study by Wolfesberger et al. (19)
examined the expression pattern of VEGF in canine
lymphomas, demonstrating a high expression of VEGF in
60% of the analysed tumours. However, studies in human
neoplasias focusing on RAGE and HMGB1 expression levels
showed a significant up-regulation of RAGE and HMGB1 in
pancreatic cancer, prostate cancer and colon cancer (20). In
summary, the interaction of HMGB1, RAGE and VEGF is
strongly associated with vascularisation and plays a key role
in tumour progression. Consequently, deregulation of RAGE
and HMGB1 expression may play a key role in lymphoma
progression. To elucidate this, the present study analysed the
expression patterns of the previously characterized canine
HMGB1 and RAGE genes (21-23) in a set of canine
lymphomas and controls.
Materials and Methods
Tissue samples. Fine-needle aspirates of enlarged lymph nodes of
22 lymphoma-bearing dogs (19 multicentric and three intestinal
lymphomas) and three inconspicuous lymph nodes were examined.
The control lymph node samples were derived from dogs diagnosed
with diseases other than haematopoietic neoplasia and with
clinically unaltered peripheral lymph nodes. All diagnoses were
cytologically or histologically confirmed. Clinical staging was
performed according to the World Health Organization (WHO)
clinical staging system (24) and determination of the
immunophenotype of the 19 multicentric lymphomas was performed
by flow cytometry (25). Among the 19 multicentric lymphomas, 15
samples showed B-cell origin, two samples were of T-cell origin and
two samples could not be determined. The dogs represented 13
different breeds, namely Beagle, Dogo Argentino, German
Shepherd, Golden Retriever, Hovawart, Jack Russell Terrier,
Jagdterrier, Mixed-breed, Munsterlander, Pitbull, Rottweiler, Teckel
and West Highland. After collection, the samples were immediately
frozen in liquid nitrogen and stored at −80˚C until RNA isolation.
All samples were provided by the Small Animal Clinic, University
of Veterinary Medicine, Hannover, Germany.
RNA isolation and cDNA synthesis for transcript characterisation.
The tissue samples were homogenised using the iron-beads
QIAshredder homogeniser method (Qiagen, Hilden, Germany).
Following, total RNA was isolated using the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. To avoid
genomic DNA contaminations, on-column DNase digestion with the
RNase-Free DNase set (Qiagen) was performed. 
The respective cDNA syntheses were performed using 250 ng
total RNA of each sample and the QuantiTect Reverse Transcription
Kit (Qiagen) following the manufacturer’s protocol. 
Quantitative real-time RT-PCR. Relative real-time PCRs were
performed with the Applied Biosystems 7300 real-time PCR System
(Applied Biosystems, Darmstadt, Germany). The canine Glucuronidase
Beta transcript was chosen as endogenous control (26). Two μl of each
cDNA corresponding to 25 ng of total RNA was amplified in a total
volume of 25 μl using universal PCR Mastermix (Applied Biosystems)
with 600 nM of each primer and 200 nM fluorogenic probe. The
following PCR conditions were applied: 2 min at 50˚C and 10 min at
95˚C, followed by 45 cycles with 15 s at 95˚C and 1 min at 60˚C.
Primer and probe sequences were as follows: HMGB1 forward primer:
5’AAGTGAGAGCCAG ACGGG3’, HMGB1 reverse primer:
5’TCCTTTGCCCATGTTTAA TTATTTTC3’, HMGB1 probe: 5’ 6-
FAM-CTGGGCGACTCT GTGCCTCGCT-TAMRA3’, RAGE forward
primer: 5’GTCTGT GGGGAGCAGTAGTAGG3’, RAGE reverse
primer: 5’TTCTGTC CGACCTGTGTTCAGCTT3’, RAGE probe: 5’
6-FAM-AAGCCGCTGGTGCTCAACTGTA-TAMRA 3’, GUSB
forward primer: 5’TGGTGCTGAGGATTGGCA3’, GUSB reverse
primer: 5’CTGCCACATGGACCCCATTC3’, GUSB probe: 5’ 6-FAM-
CGCCCACTACTATGCCATCGTGTG-TAMRA 3’.
All samples were measured in triplicate and non-template
controls and non-reverse transcriptase control reactions were
included for each run.
A precedent absolute real-time PCR reaction was carried out with
all PCR assays using the same templates and dilution steps in order
to ensure the comparability between the PCR reactions showing
similar amplification efficiencies appropriate for relative
quantification PCRs.
For the analysis based on the ΔΔCT method, the sample within
the control group with the most stable CT values for target and
endogen control was defined as the calibrator for the analysis of
RAGE/GUSB as well as HMGB1/GUSB relative real-time PCR. 
Statistical analysis. Statistical analysis of the relative real-time PCR
results applying various hypothesis test was performed with the software
REST 2008, version 2.0.7 (27). REST determines whether there is a
significant difference between samples and controls taking into account
reaction efficiencies and using randomisation techniques. Regarding
clinical parameters, a Mann-Whitney-test was performed using SPSS
15.0 statistic software (SPSS Inc., Chicago, IL, USA). The HMGB1 and
RAGE expression levels were evaluated for statistical significance
regarding WHO substage (substage a vs. substage b), WHO stage
(clinical stage III and IV vs. V), and, additionally, for the comparison of
multicentric lymphomas vs. control dogs and intestinal lymphomas. A
p-value <0.05 was considered to be statistically significant. 
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Results 
Expression analyses of HMGB1 and RAGE in canine
lymphomas were performed using relative real-time PCR on
lymph node aspirates from 22 lymphoma-bearing dogs and
three dogs without haematopoietic neoplasias. Both real-time
reactions were analysed using the ΔΔCT method and the
results are shown in Figures 1 and 2. In both graphs, the same
samples were put in the same position to compare the tumour
samples directly for both candidate genes. The HMGB1
expression (Figure 1) quotient in the tumour samples varied
from 1.587 (sample seven) to 8.549 (sample three) relative to
the defined calibrator. The median expression levels were 1.33
for the control group (samples 1-3), 4.22 for the intestinal
lymphoma group (samples 4-6), 4.26 for the B-cell lymphoma
group (samples 7-21), 3.83 for the T-cell lymphoma group
(samples 22-23) and 2.13 for the unknown lymphoma group
(samples 24-25). In the case of RAGE (Figure 2), the relative
quotients varied from 0.36 (sample 10) to 18.282 (sample 3).
The median expression levels were 0.55 for the control group
(samples 1-3), 6.69 for the intestinal lymphoma group
(samples 4-6), 1.73 for the B-cell lymphoma group (samples
7-21), 0.56 for the T-cell lymphoma group (samples 22-23)
and 1.61 for the unknown lymphoma group (samples 24-25). 
Samples 6 (intestinal lymphoma), 15, 20 and 21 (B-cell
lymphoma) showed the highest RAGE expression levels and,
accordingly, in samples 6, 20 and 21 high HMGB1
expression levels were also detected. Samples 20 and 21 had
the highest HMGB1 expression within the group of B-cell
lymphomas and sample 6 showed the highest expression of
HMGB1 in the intestinal lymphoma group. Sample 15
showed an average HMGB1 expression level. 
Hypothesis tests of the relative real-time PCR results were
performed using the REST software. Analysis of expression of
control samples vs. all tumour samples showed a highly
significant up-regulation of HMGB1 (p=0.001), while RAGE
showed no significant expression value (p=0.155). The test was
also performed for all subgroups within the sample collective
(intestinal lymphoma, B-cell lymphoma, T-cell lymphoma and
unknown multicentric lymphoma). Comparison of the control
samples vs. intestinal lymphomas revealed a significant
difference for HMGB1 (p=0.03) but not for RAGE (p=0.096).
B-Cell lymphomas were significantly different to the control
samples for HMGB1 (p=0.001) but not different for RAGE
(p=0.07). Compared to the control samples, T-cell lymphomas
showed significant up-regulation of HMGB1 expression
(p=0.033) but no significant difference of RAGE expression
(p=0.792). The group of multicentric lymphoma samples,
which were unable to be determined by flow cytometry,
showed no statistically significant difference in the expression
of HMGB1 (p=0.135) nor RAGE (p=0.303) in comparison to
the control group. The results of the statistical analysis using
the REST programme are displayed in Table I. 
The Mann-Whitney test regarding the difference in the
expression levels between the multicentric lymphomas and the
control samples revealed significant differences for HMGB1
(p=0.003) but not for RAGE (p=0.078). The expression of
HMGB1 and RAGE also showed no significant differences
between multicentric and intestinal lymphomas (p=0.907 for
HMGB1 and p=0.702 for RAGE). WHO stage and substage of
the samples were not significantly associated with HMGB1 and
RAGE expression values (results not shown).
Discussion
Vascularisation under normal conditions is strongly
regulated by a delicate balance of pro- and anti-angiogenic
molecules. In the case of tumour progression, sustained
secretion of pro-angiogenic factors such as HMGB1, RAGE
and VEGF is triggered by tumour microenvironmental
hypoxic and necrotic areas leading to neo-vascularisation.
Regarding haematological malignancies, increased
vascularity was observed in B-cell non-Hodgkin’s
lymphoma (9) and high serum levels of VEGF were
associated with poor outcome (14). In this context, a study
targeting canine lymphomas showed high levels of VEGF in
the analysed tumour samples, indicating an involvement of
pro-angiogenic factors in lymphoma progression (19, 28).
Sterenczak et al: HMGB1 and RAGE in Canine Lymphoma
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Table I. Hypothesis tests of relative HMGB1/GUSB and RAGE/GUSB real-time PCR results in canine lymphoma using the REST software. A total
of 25 samples with 3 control and 22 tumour samples (3 intestinal lymphomas, 15 B-cell lymphomas, 2 T-cell lymphomas and 2 of unknown origin)
were analysed. A p-value <0.05 was considered statistically significant. 
Hypothesis test: Expression pattern of HMGB1 Expression pattern of RAGE 
Control group vs. tumour group compared to control group (p-value) compared to control group (p-value)
All tumour samples (n=22) Up-regulation (p=0.001) Not significantly different (p=0.155)
Intestinal lymphoma (n=3) Up-regulation (p=0.030) Not significantly different (p=0.096)
B-cell lymphoma (n=15) Up-regulation (p=0.001) Not significantly different (p=0.07)
T-cell lymphoma (n=2) Up-regulation (p=0.033) Not significantly different (p=0.792)
Unknown multicentric lymphoma (n=2) Not significantly different (p=0.135) Not significantly different (p=0.303)
ANTICANCER RESEARCH 30: 5043-5048 (2010)
5046
Figure 1. Relative HMGB1/GUSB expression in canine lymphoma. A total of 25 samples were analysed. The set of samples consisted of 3 control
and 22 tumour samples of the following subgroups: 3 intestinal lymphomas, 15 B-cell lymphomas, 2 T-cell lymphomas and 2 of unknown origin.
Green bars: lymph node control; orange bars: intestinal lymphoma; red bars: B-cell lymphoma; brown bars: T-cell lymphoma and grey bars:
lymphomas of unknown origin.
Figure 2. Relative RAGE/GUSB expression in canine lymphoma. A total of 25 samples were analysed. The set of samples consisted of 3 control and
22 tumour samples of the following subgroups: 3 intestinal lymphomas, 15 B-cell lymphomas, 2 T-cell lymphomas and 2 of unknown origin. Green
bars: lymph node control; orange bars: intestinal lymphoma; red bars: B-cell lymphoma; brown bars: T-cell lymphoma and grey bars: lymphomas
of unknown origin. 
These findings raise the question whether RAGE and
HMGB1 are also deregulated in lymphomas. For several
other neoplasias such as pancreatic, prostate and colon
cancer deregulation of the expression of HMGB1 and
RAGE has been described (20). 
Therefore, the present study examined the expression of
HMGB1 and RAGE in lymph node samples of canine
lymphomas in comparison to lymph nodes from dogs without
haematopoietic neoplasias. The tumour samples were
cytologically and histologically confirmed and flow cytometry
determined the immunophenotype of the multicentric
lymphomas. The present study showed a significant up-
regulation in HMGB1 expression in the analysed lymphoma
samples, while the detected RAGE expression did not change
significantly when compared to the control samples.
Furthermore, statistical analyses were performed not only with
all control and all tumour samples together as groups, but also
for the different subgroups of the sample collective. The
sample numbers of intestinal, T-cell and unknown lymphomas
were too small for an appropriate powerful statistical analysis
(n=3, 2 and 2, respectively) and, consequently, more samples
of both non-neoplastic and tumour types would be necessary
for further analyses. However, the results of the present study
indicated a trend of the expression pattern of HMGB1 and
RAGE in this lymphoma types. 
Meyer et al. (29) examined the expression of HMGB1 in
human non-Hodgkin lymphoma using real-time PCR and
showed high levels of HMGB1 expression, while RAGE
expression was not analysed. The HMGB1 overexpression
detected in the canine lymphoma samples strongly
emphasises that similar HMGB1-related mechanisms exist in
canine and human lymphoma progression. Furthermore, in
canine lymphomas, elevated HMGB1 serum levels were
detected and the prognostic value of initial and sequential
serum level was suggested (30). 
The RAGE expression data determined herein indicated that
the HMGB1-induced effects in all 22 analysed lymphoma
samples are regulated by the overexpression of HMGB1 itself,
while RAGE, as a receptor, remains stable in terms of
expression. Using tumour tissue microarray slides, a study by
Hsieh et al. (31), detected a borderline positive staining for
RAGE antibodies in lymphoma tumours, suggesting that only
certain cells or vessels on the tissue disc were stained positive,
thus, indicating low levels of RAGE in the tumour slides
analysed; however, that finding was not discussed further in
detail by the authors. Besides the present study, there have
been no significant data published concerning RAGE
expression in lymphomas. In summary, the data of the present
study showed significant deregulation of HMGB1 but not
RAGE in canine lymphoma, contradictory to the observations
in many solid tumours. However, the TLR receptors 2 and 4
also participate in the complex signalling pathways induced
by HMGB1 and, thus, should be considered with regard to
lymphoma development and progression. Accordingly, recent
studies concerning the expression of TLR receptors showed
associations of expression/overexpression of these receptors in
gastric carcinoma, colon cancer and breast cancer (32).
Additionally, gene polymorphisms in TLR-2 and -4 gene
sequences have been hypothesised as possible contributors to
follicular lymphoma and mucosa-associated lymphoid tissue
lymphoma (33). 
The analysed samples were of 13 different dog breeds and
some breeds show higher incidences in development of
malignant lymphomas; for example, the German Shepherd,
Beagle and Golden Retriever breeds (34). In the present study,
the two highest values for HMGB1 in B-cell lymphomas were
detected in a Beagle and a German Shepherd. 
In conclusion, pathways leading to vascularisation and
tumour progression are described by the complex interaction
of all involved factors including their interactions on DNA and
protein level. In the present study, it should be noted that an
up-regulated HMGB1 signalling was mediated not only by
RAGE, but also by TLR-2 and -4 and the extensive interactions
between all factors. Thus, elucidating whether the interaction
between HMGB1 and its respective receptors plays a key role
in the mechanisms involved in lymphoma development and
progression will be of significant value for the development of
therapeutic approaches for the dog as patient and as a model
system for human non-Hodgkin’s lymphoma. 
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IV.?“Quantitative?PCR?and?Immunohistochemical?Analyses?of?HMGB1?and?RAGE?
Expression?in?Canine?Disseminated?Histiocytic?Sarcoma?(Malignant?Histiocytosis)”?
Sterenczak?et?al.,?Anticancer?Research,?2011?
Within? this? study,? the? HMGB1? and? RAGE? expression? levels? were? measured? via? relative?
quantitative?real?time?PCR?and? immunohistochemistry.?As?endogenous?controls,?the?canine?
GUSB? and? hypoxanthine?guanine? phosphoribosyltransferase? (HPRT)? genes?were? used.? The?
study?included?neoplastic?and?non?neoplastic?tissue?samples?deriving?from?lymph?node,?liver,?
lung?and?spleen?tissues?of?DHS?affected?dogs?and?dogs?which?were?euthanised?due?to?DHS?
unrelated? disorders.? HMGB1? and? RAGE? gene? expression? was?measured? in? a? total? of? 20?
neoplastic?and?eight?non?neoplastic?control?samples?and? the? immunohistochemical?studies?
of? HMGB1? and? RAGE? proteins? were? performed? in? 13? neoplastic? and? 20? non? neoplastic?
control?sections.?HMGB1?was?shown?to?be?significantly?down?regulated?in?the?lung?(p=?0.00)?
when?using?GUSB?as?endogenous? control?and?within? the? lymph?node? (p=0.00)?and? spleen?
(p=0.00)?samples?when?using?HPRT?and?compared?to?the?respective?non?neoplastic?control?
samples.?RAGE?was?significantly?down?regulated? in?the?DHS? lung?samples?compared?to?the?
non?neoplastic? lung?sample?when?using?both?endogenous?control?genes.?The? intensities?of?
the? immunohistochemical? stainings? confirmed? the? results? obtained? by? real?time? PCR.?
HMGB1?immunoreactivity?was?restricted?to?the?cytoplasm?in?neoplastic?sections?and?nuclear?
within? the? non? neoplastic? sections.? RAGE? immunoreactivity? was? cytoplasmic? within? the?
analysed?non?neoplastic?and?neoplastic?sections.?
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Abstract. Background: Disorders of histiocytic origin
affecting humans and dogs share various similarities. Canine
disseminated histiocytic sarcoma (DHS) (formerly known as
malignant histiocytosis) is an aggressive neoplasm of
interstitial dendritic cells (DCs). The receptor for glycation
end products (RAGE) and the high mobility group box1
protein (HMGB1) have been shown to be required for the
maturation and migration of DCs. Thus, deregulation of the
expression of these genes could have a major effect on the
progression of histiocytic disorders. Materials and Methods:
Neoplastic canine DHS samples and non-neoplastic control
samples were analysed immunohistochemically and via real-
time PCR. Results: Significant down-regulation of RAGE in
the lung tumour samples and down-regulation of HMGB1 in
the lung, lymph node and spleen tumour samples were
detected compared to their non-neoplastic counterparts.
Conclusion: RAGE and HMGB1 expression down-regulation
in canine DHS points to a role in the progression of
histiocytic disorders.
Several well-documented neoplasias of histiocytic origin ranging
from localized, reactive and benign lesions to systemic
syndromes with rapid clinical progression leading to death, show
similar biological behaviour in both humans and dogs (1, 2). 
The term “histiocyte” including macrophages and dendritic
cells (DCs) represents a subset of leukocytes which are able
to migrate into tissues. These cells play an important role in
the immune system by presenting antigens to naive T-cells
(dendritic cells) and by phagocytosing cellular debris and
pathogens (macrophages) (1, 2). Disseminated histiocytic
sarcoma (DHS) is a rare and very aggressive histiocytic
neoplasm of interstitial DCs and usually occurs in multiple
sites, mainly the lymph nodes, lungs, spleen and liver (1-4).
Bernese mountain dogs show a high breed-specific
predisposition for DHS (approximately 25% affected, mean
age of onset 6.5 years) but the mode of inheritance is still not
well understood and multigenic involvement is suggested (5-
7). The progression of the disease is very rapid and prognosis
is poor with a median survival time of 128 days and a one year
survival rate of 0%-30% (2). Human malignant histiocytic-cell
related proliferations including histiocytic sarcomas and
Langerhans cell histiocytosis (LCH) also show very aggressive
progression resulting in the death of most patients with
widespread disease involving e.g. lymph nodes, intestine, liver,
spleen, lung and bone marrow (2, 8) showing either
macrophage or dendritic origin (8, 9). 
High mobility group box 1 (HMGB1) (amphoterin or
HMG-1) acts in the nucleus as a DNA-binding nuclear
protein, while in the extracellular environment as a
proinflammatory cytokine and also as a dose-dependent
mediator of angiogenic and neo-vascularising processes (10).
HMGB1 expression varies in different tissues and can be
either developmentally regulated or respond to signals from
the environment (11). HMGB1 induced signalling is mediated
via receptor for advanced glycation end products (RAGE) and
toll-like receptors (TLR) (12). RAGE expression is high
during embryonic development while in adult tissues RAGE
expression is widespread but relatively low except in the lung,
where the expression levels remain high throughout life.
RAGE expression increases in inflammatory-related
pathological states (13-17). DCs are able to secrete HMGB1
in response to inflammatory stimuli for proliferation, survival
and polarization of naive CD4+ T cells (18) and for canine T-
cell proliferation (19). The maturation and migration of DCs
into lymphoid organs was described to depend on HMGB1
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and its receptor RAGE due to HMGB1-RAGE induced
cellular pathways (20-22). Taken together, the RAGE-
HMGB1 complex thus represents a checkpoint in DC
maturation, migration and immune response. The
deregulation of the expression of HMGB1 and RAGE could
thus have an effect on dendritic cell biology. In histiocytic
disorders such as LCH, dendritic Langerhans cells (LCs) are
described to be arrested in an immature, partially activated
stage and show a different proliferation pattern than “normal”
dendritic LCs leading to an accumulation in the affected
tissues and disease progression (23). In canine DHS the
pivotal role of HMGB1-RAGE on DCs could thus play an
important role in the progression and severity of disease.
Since canine RAGE and HMGB1 genes correspond closely to
their human counterparts (14, 24, 25) characterisation of the
biology of canine neoplastic histiocytic disorders could
benefit both dogs and human patients. 
Materials and Methods
Canine tissue samples. HMGB1 and RAGE gene expression was
assesses by real-time PCR in 20 DHS tumour samples obtained
during clinical examination (7 liver, 3 lung, 2 lymph node and 8
spleen) from 15 dogs (4 female and 11 male; 1 Australian Shepherd
and 14 Bernese mountain dogs) aged between four and nine years.
Eight non-neoplastic surgically removed control samples (3 liver, 1
lung, 2 lymph node and 2 spleen tissues) from six dogs (1 female and
5 male; 2 Bernese mountain dog, 2 German Shepherd, 1 Mixed breed
and 1 Newfoundland) were also assessed. These dogs were aged
between six and eleven years and euthanized due to DHS unrelated
diseases (anal fissure, ascites, interstitial pneumonia, lung sarcoma,
mastocytoma and peritonitis). The non-neoplastic samples were
collected from clinically unaltered lung, liver, lymph node and spleen
tissues. After collection, the samples were immediately frozen in
liquid nitrogen and stored at –80˚C until RNA isolation. 
The immunohistochemical study of the HMGB1 and RAGE
proteins included 13 neoplastic DHS samples (5 liver, 2 lung, 3 lymph
node and 3 spleen) from six dogs (1 female and 5 male; 1 Australian
Shepherd and 5 Bernese mountain dog). The tumour samples from five
of these dogs were also analyzed in the gene expression study. As non-
neoplastic control an additional 20 samples (5 liver, 5 lung, 5 lymph
node and 5 spleen) from five dogs (4 female and 1 male; 1 Labrador
retriever, 2 Mixed breed, 1 Rottweiler and 1 Schnauzer) were included.
These dogs were euthanized due to DHS unrelated diseases (arthritis,
epilepsy, kidney dysplasia, meningoencephalitis and tibial fracture).
After collection the samples were fixed in 10% neutral buffered
formalin and embedded in paraffin. All the DHS diagnoses were
cytologically and histologically confirmed accordingly to the WHO
nomenclature. All the samples were provided by the Small Animal
Clinic, University of Veterinary Medicine, Hannover, Germany.
RNA isolation and cDNA synthesis for transcript characterization.
The tissue samples were homogenized using stainless steel-beads and
a Qiagen-TissueLyser II homogenizer (Qiagen, Hilden, Germany).
The total RNA was isolated using an RNeasy Mini Kit according to
the manufacturer’s instructions (Qiagen). To avoid genomic DNA
contaminations, on-column DNase digestion with an RNase-Free
DNase set (Qiagen) was performed. 
The respective cDNA syntheses were performed using 250 ng total
RNA of each sample and a QuantiTect Reverse Transcription Kit
following the manufacturer’s protocol (Qiagen). 
Real-time PCR. For relative quantification of the HMGB1 and RAGE
transcript levels in the samples the beta-glucuronidase (GUSB) and
hypoxanthine-guanine phosophoribosyltransferase (HPRT) genes
were used as endogenous controls. The real-time PCRs were analysed
according to the delta delta CT (ΔΔCT) method. All the PCR
amplifications were carried out using the Eppendorf Mastercycler ep
realplex real-time PCR System (Eppendorf AG, Hamburg, Germany).
Two μl of each cDNA corresponding to 25 ng of total RNA were
amplified in a total volume of 25 μl using universal PCR Mastermix
(Applied Biosystems, Darmstadt, Germany) with 600 nM of each
primer and 200 nM fluorogenic probe. The sequence data for the PCR
assays used in this study were: HMGB1: forward primer: 5’-
AAGTGAGAGCCAGACGGG-3’, reverse primer: 5’-TCCTTTGCCC
ATGTTTAATTATTTTC-3’, probe: 5’-6-FAM-CTGGGCGACTCTGT
GCCTCGCT-TAMRA-3’. RAGE: forward primer: 5’-GTCTGT
GGGGAGCAGTAGTAGG-3’, reverse primer: 5’-TTCTGTCCGACC
TGTGTTCAGCTT-3’, probe: 5’-6-FAM-AAGCCGCTGGTGCTC
AACTGTA–TAMRA-3’. GUSB: forward primer: 5’-TGGTGCTG
AGGATTGGCA-3’, reverse primer: 5’-CTGCCACATGGACCCC
ATTC-3’, probe: 5’-6-FAM-CGCCCA CTACTATGCCATCGTGTG-
TAMRA-3’. HPRT: forward primer: 5’-CCTTCTGCAGGAG
AACCT-3’, reverse primer: 5’-TCATCACTA ATCACGACGCT-3’,
probe: 5’-6-FAM-CCTCCTGTTCAGGCTG CCGTCA-TAMRA-3’.
The PCR conditions were: 2 min at 50˚C and 10 min at 95˚C,
followed by 45 cycles of 15 sec at 95˚C and 1 min at 60˚C. 
All the samples were measured in triplicate and for each run non-
template controls and non-reverse transcriptase control reactions were
included. A precedent efficiency analysis of all the PCR assays used
in this study was performed by applying the same template and
dilution steps. The PCR reactions of the HMGB1, RAGE, GUSB and
HPRT assays showed comparable efficiencies ensuring an appropriate
relative real-time PCR analysis. 
For the ΔΔCT analysis the calibrator was defined after performing
relative real-time PCR with HMGB1 as the target gene. The sample
within the control group that showed the most stable CT values for the
target and endogenous control was defined as the calibrator. For
analysis of the relative real-time PCR targeting RAGE expression, the
same sample was used as the calibrator to assure comparability between
the analyses of HMGB1 and RAGE relative expression patterns.
Histological and immunohistochemical procedures. All the formalin-
fixed and paraffin-embedded samples were cut (2-4 μm) and stained
with haematoxylin and eosin (HE) by standard histochemical
procedures. Serial sections were dewaxed and antigen retrieval was
performed by treatment with either microwave with citrate-buffer
(Quartett, Berlin, Germany) (HMGB1; 20 min) or demasking solution
G ( Biologo, Kronshagen, Germany) (RAGE; 20 min). The inhibition
of endogenous peroxidase activity was achieved by immersion in 0.5
% H2O2 (v/v) in methanol for 20 min. Non-specific binding was
blocked with inactivated goat or horse serum diluted 1:5 in phosphate-
buffered saline (PBS; pH 7.1). The blocking serum was drained and
replaced by the first antibody rabbit polyclonal to HMGB1 (1:15.000;
Abcam, Cambridge, UK) or goat polyclonal to RAGE (1:1200;
Abcam). After washing, the tissue sections were incubated with a
biotin-conjugated goat-anti rabbit IgG or horse-anti goat IgG (Vector
Laboratories, Burlingame, CA, USA). The avidin-biotin-peroxidase
ANTICANCER RESEARCH 31: 1541-1548 (2011)
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reagent (Vector Laboratories) was used according to the manufacturer’s
instructions including a tyramin amplification technique (26). The
chromogen used was 3,3’-diaminobenzidine-tetrahydrochloride (Sigma
Aldrich, Munich, Germany) 0.05% (w/v) with 0.03% H2O2 (v/v) as
substrate in 0.1 M Tris-buffered saline (Tris-hydroxymethyl-
aminomethane; Merck, Darmstadt, Germany) pH 7.6. The tissue
sections were counterstained with Mayer’s haematoxylin and mounted. 
Statistical analysis. Statistical analysis of the relative real-time PCR
results applying the hypothesis test was performed with the relative
expression software tool (REST) 2008, version 2.0.7 (27). REST
determined the significance of differences in gene expression between
the control and the neoplastic samples taking into account real-time
PCR reaction efficiencies and using randomization techniques. The
statistical analysis was performed separately for HMGB1 and RAGE
within the four analysed tissue groups (liver, lymph node, lung,
spleen) and the two different reference genes (GUSB, HPRT). A p-
value of <0.05 was considered to be statistically significant. 
Results 
HMGB1 and RAGE real-time PCR analysis. Using GUSB as
the endogenous control the median HMGB1 expression in
liver samples was 0.829 (0.412-1.39) and 0.904 (0.216-
1.47); expression in the lung non-neoplastic sample was
1.56 and in the tumour samples the median was 0.727
(0.577-0.995); in the lymph node samples the median was
1.10 (1-1.21) and 1.07 (1.02-1.11) and in the spleen samples
median was 1.388 (0.76-2.07) and 0.96 (0.404-1.8) relative
to the calibrator (lymph node sample), for the non-
neoplastic controls and the tumour tissues, respectively
(Figure 1 A). The median RAGE expression was 0.25 (0.08-
0.51) and 0.53 (0.04-1.41) in the liver samples; expression
in the lung non-neoplastic sample was 30,867 and in the
tumour samples the median was 176.82 (0.161-530); the
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Figure 1. Relative HMGB1/GUSB (A) and HMGB1/HPRT (B) expression. A non neoplastic lymph node sample was set as calibrator. * statistically
significant expression difference in the tumour samples compared to controls. RQ, relative quotient.
median values 0.65 (0.3-1) and 0.31 (0.2-0.4) in the lymph
node samples and 0.38 (0.09-0.67) and 0.29 (0.03-1.75) in
the spleen samples for the non-neoplastc and tumour tissues,
respectively (Figure 2A, 3A). 
When HPRT was used as the endogenous control the
median HMGB1 expression in liver samples was 0.507 (0.22-
0.793) and 0.635 (0.22-1.13); expression in the lung non-
neoplastic sample was 1.65 and in the tumour samples the
median was 0.504 (0.349-0.647); in the lymph node samples
median was 1.96 (0.923-1) and 0.582 (0.47-0.69) and in the
spleen samples was 1.7 (1.6-1.8) and 0.671 (0.33-1.15)
relative to the calibrator (lymph node sample), for the non-
neoplastic controls and the tumour tissues, respectively
(Figure 1 B). The median RAGE expression was 3.31 (0.53-
8.35) and 3.3 (0.32-9.59) in the liver samples; expression in
the lung non-neoplastic sample was 132,000 and in the
tumour samples the median was 638.89 (2.23-1,912); 0.91
(0.83-1) and 0.98 (0.42-1.54) in the lymph node samples and
1.36 (0.34-2.38) and 0.45 (0.13-1.89) in the spleen samples
for the non-neoplastc and tumour tissues, respectively
(Figure 2B, 3B). 
The statistical analysis showed a significant down-
regulation of RAGE within the lung (p=0.000) tumour samples
with both GUSB and HPRT as the endogenous controls.
HMGB1 was significantly down-regulated in the lung tumour
sample (p=0.000) using GUSB and the lymph node (p=0.000)
and spleen (p=0.000) using HPRT compared to the non-
neoplastic tissue.
HMGB1 and RAGE immunhistochemistry. In all the specimens,
the neoplastic cells showed dot-like granular to finely stippled
protein expression of HMGB1 predominantly localised within
the cytoplasm (Figure 4A). The intensity of the cytoplasmic
HMGB1 staining was quite variable within each tumour,
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Figure 2. Relative RAGE/GUSB (A) and RAGE/HPRT (B) expression. A non neoplastic lymph node sample was set as calibrator. RQ, relative quotient.
ranging from negative to strongly immunoreactive neoplastic
cells. Faint nuclear expression was present in individual
neoplastic cells of all the examined tissue samples (Figure 4
A), but the majority of cells had no nuclear expression.
In all non-neoplastic tissue samples, the immunohisto-
chemical staining reaction was restricted to the nucleus
(Figure 5).
In all the tumours, all the neoplastic cells showed dot-
like granular to finely stippled cytoplasmic RAGE immuno-
reactivity with sparing of the nucleus (Figure 5A).
Multifocally, cytoplasmic signals showed a disk-like
formation with a clear central core. The intensity of the
cytoplasmic RAGE staining was quite variable within each
tumour, ranging from negative to strong. In two dogs,
beside the cytoplasmic expression pattern an additional
nuclear signal was detected in some tumour cells. In
autolytic tumour tissues the RAGE expression was
markedly diminished. In the normal tissue, cytoplasmic
staining was present in some cell types (Figure 5 B). In the
lymph nodes, individual immune cells also exhibited a
slight nuclear staining. 
Discussion 
RAGE was significantly down-regulated in the lung tumours
compared to the non-neoplastic lung tissue independent of the
housekeeping control gene while HMGB1 expression was
down-regulated in the lung tumours only when using GUSB
and in the lymph node and spleen tumour samples with HPRT.
Although statistically the HMGB1/GUSB and HMGB1/HPRT
results differed, the analysis indicated a trend towards
decreased expression of HMGB1 in canine DHS. It is
generally recommended to use more than one endogenous
control when performing relative real-time PCRs to gain more
reliable expression results (28). Furthermore, the number of
tissue samples analysed in this study was small for powerful
statistical analysis and further analyses of more samples is
necessary. 
The deregulation of RAGE and HMGB1 expression levels
has been associated with many pathological states and
neoplastic disorders such as pancreatic, prostate and colon
cancer (29). In non small cell lung cancer (NSCLC), the
expression of RAGE has been found to be strongly reduced
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Figure 3. Relative RAGE/GUSB and RAGE/HPRT expression in lung samples. A non neoplastic lymph node sample was set as calibrator. 
*Statistically significant expression difference in the tumour samples compared to controls. RQ, Relative quotient.
(30) and correlated with higher tumour stage dependent of
histological subtype, while the over expression of RAGE
diminished tumour growth, also suggesting that RAGE
down-regulation enhances lung cancer progression (31, 32).
HMGB1 was also reported to be down-regulated in human
NSCLC correlating with the tumour stage (33). Canine DHS
might exhibit similar biological mechanisms in RAGE and
HMGB1 expression as human NSCLC. However, the
different origins of these tumours should be considered.
The present study also showed HMGB1 down-regulation in
the lymph node and splenetic tumour samples compared to the
controls. In contrast, in human and canine Lymphoma the
overexpression of HMGB1 was described (34, 35) suggesting
that different biological mechanism of HMGB1 expression
might appear in the progression of histiocytic disorders in
comparison to haematopoietic neoplasias. No current studies
have reported HMGB1 expression patterns in spleen and
tumours of the spleen.
In breast carcinoma, melanomas and interestingly also in
NSCLC, dendritic cells were also found to be blocked in an
immature or partially mature state (36-38) leading to disease
progression. As HMGB1 and RAGE play a key role in the
maturation of DCs, deregulation could influence the
maturation status of DCs within neoplastic tissues. The down-
regulation of HMGB1 and RAGE in lung and down-regulation
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Figure 4. HMGB1 Immunohistochemistry. A: Canine disseminated
histiocytic sarcoma in the lung. Loosely aggregated, pleomorphic
mononuclear and multinucleated giant cells with cytoplasmic
immunoreactivity of HMGB1 (arrows). Individual cells had nuclear
HMGB1 expression (arrow-head). B: Clinically unaltered canine lung
tissue. Immunohistochemical staining reaction is restricted to the nucleus
of varying cells such as bronchiolar epithelium (arrow-head). Bar=25 μm.
Figure 5. RAGE Immunohistochemistry. A: Canine disseminated
histiocytic sarcoma in the lung. Mononuclear cells exhibited a dot-like
granular or finely-stippled cytoplasmic RAGE expression (arrows). B:
Clinically unaltered canine lung tissue. Immunohistochemical staining
reaction is mostly restricted to the cytoplasm, e.g. bronchiolar
epithelium (arrow head) with individual slight nuclear signal in immune
cells (arrow). Bar=25 μm.
of HMGB1 in lymph node and spleen neoplastic samples,
detected in the present study, could thus have an effect on the
maturation of histiocytes in the affected tissues and the
progression of canine DHS. 
Immunohistochemically cytoplasmic RAGE was detected in
all the tumours and non-neoplastic samples with variable
intensity comparable to the RAGE mRNA expression.
Unexpectedly, a few tumour samples and individual immune
cells in non-neoplastic lymph nodes exhibited slight nuclear
immunoreactivity. Additionally, it seemed that the RAGE-
antigen is sensitive to autolysis with reduced immunoreactivity.
Similarly, high RAGE levels were found in hepatocellular,
colorectal and breast carcinoma and the localisation was always
cytoplasmatic (39).
The intensity of the cytoplasmic HMGB1 immuno-reactivity
was also quite variable within each tumour and again was
comparable to the findings for HMGB1 mRNA expression.
Generally, in normal cells, HMGB1 shuttles actively between the
nucleus and cytoplasm (40). When HMGB1 is underacetylated
as it is in most cells, the protein appears predominantly or solely
in the nucleus as in the non-neoplastic samples in the present
study. Upon activation with lipopolysaccharide (LPS) or
cytokines like extracellular HMGB1, macrophages and
monocytes acetylate HMGB1, leading to the relocalisation and
accumulation of acetylated-HMGB1 in cytoplasmic lysosomes
which upon binding of lysophosphatidylcholine (LPC) secrete
the protein into the extracellular environment (40, 41). DC
maturation follows a similar path (18) and LCs in LCH
correspond to an early activated stage of DC maturation,
combining an immature phenotype with high level cytokine
expression (23). Similar shuttling of HMGB1 between the
nucleus and cytoplasm may occur in canine immune cells and
might explain the cytoplasmatic immunoreactivity of the present
neoplastic histiocytic cells. 
The neoplastic samples in the present study were derived
mostly from Bernese mountain dogs while the non-neoplastic
samples were from dogs of several different breeds. Additionally,
number of the tissue samples was limited, thus any correlation
with age, sex or breed was not possible. More dogs should be
included in further studies to examine the involvement of genes
such as HMGB1 and RAGE in the pathology of DHS. 
Conclusion
The down-regulation of RAGE and HMGB1 in lung, lymph node
and spleen detected in canine DHS compared to control tissue
samples might play a role in the progression of histiocytic
disorders. 
Acknowledgements 
This research was funded by the Gesellschaft zur Förderung
Kynologischer Forschung e.V., Bonn, Germany, and was also in part
supported by the collaboratory research cluster SFB Transregio 37
(Micro- and Nanosystems in Medicine) funded by the German
Research Foundation DFG.
References
1 Fulmer AK and Mauldin GE: Canine histiocytic neoplasia: an
overview. Can Vet J 48(10): 1041-1043, 1046-1050, 2007.
2 Withrow S and Vail DM: Withrow and MacEwen's Small Animal
Clinical Oncology, fourth edition. St. Louis: Saunders Elsevier;
2007.
3 Rosin A, Moore P and Dubielzig R: Malignant histiocytosis in
Bernese Mountain dogs. J Am Vet Med Assoc 188(9): 1041-
1045, 1986.
4 Affolter VK and Moore PF: Localized and disseminated
histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol
39(1): 74-83, 2002.
5 Soller JT, Murua Escobar H, Janssen M, Fork M, Bullerdiek J
and Nolte I: Cytokine genes single nucleotide polymorphism
(SNP) screening analyses in canine malignant histiocytosis.
Anticancer Res 26(5A): 3417-3420, 2006.
6 Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P,
Bourgain C, Parker HG, Vaysse A, Margaritte-Jeannin P, Galibert
F, Ostrander EA and Andre C: Epidemiology, pathology, and
genetics of histiocytic sarcoma in the Bernese mountain dog
breed. J Hered 100(Suppl 1): 19-27, 2009.
7 Nielsen L, Andreasen SN, Andersen SD and Kristensen AT:
Malignant histiocytosis and other causes of death in Bernese
mountain dogs in Denmark. Vet Record 166(7): 199-202,
2010.
8 Ng-Cheng-Hin B, O'Hanlon-Brown C, Alifrangis C and Waxman
J: Langerhans cell histiocytosis: old disease new treatment. Qjm
104(2): 89-96, 2011.
9 Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M,
Bucsky P, Egeler RM, Elinder G, Gadner H, Gresik M, Henter
JI, Imashuku S, Janka-Schaub G, Jaffe R, Ladisch S, Nezelof C
and Pritchard J: Contemporary classification of histiocytic
disorders. The WHO Committee On Histiocytic/Reticulum Cell
Proliferations. Reclassification Working Group of the Histiocyte
Society. Med Pediatr Oncol 29(3): 157-166, 1997.
10 Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S
and Bullerdiek J: Angiogenetic signaling through hypoxia:
HMGB1: an angiogenetic switch molecule. Am J Pathol 166(4):
1259-1263, 2005.
11 Muller S, Ronfani L and Bianchi ME: Regulated expression and
subcellular localization of HMGB1, a chromatin protein with a
cytokine function. J Intern Med 255(3): 332-343, 2004.
12 van Beijnum JR, Buurman WA and Griffioen AW: Convergence
and amplification of toll-like receptor (TLR) and receptor for
advanced glycation end products (RAGE) signaling pathways via
high mobility group B1 (HMGB1). Angiogenesis 11(1): 91-99,
2008.
13 Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC,
Elliston K, Stern D and Shaw A: Cloning and expression of a
cell surface receptor for advanced glycosylation end products of
proteins. J Biol Chem 267(21): 14998-15004, 1992.
14 Murua Escobar H, Soller JT, Sterenczak KA, Sperveslage JD,
Schlueter C, Burchardt B, Eberle N, Fork M, Nimzyk R, Winkler
S, Nolte I and Bullerdiek J: Cloning and characterization of the
canine receptor for advanced glycation end products. Gene 369:
45-52, 2006.
Sterenczak et al: HMGB1 and RAGE in Canine Disseminated Histiocytic Sarcoma
1547
15 Buckley ST and Ehrhardt C: The receptor for advanced glycation
end products (RAGE) and the lung. J Biomed Biotechnol 2010:
917108, 11 pages, 2009.
16 Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ:
HMGB1 and RAGE in inflammation and cancer. Ann Rev
Immunol 28: 367-388, 2010.
17 Han SH, Kim YH and Mook-Jung I: RAGE: The beneficial and
deleterious effects by diverse mechanisms of actions. Mol Cells
31(2): 91-97, 2011.
18 Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M,
Nawroth PP, Arnold B, Bianchi ME, Manfredi AA and Rovere-
Querini P: Release of high mobility group box 1 by dendritic cells
controls T cell activation via the receptor for advanced glycation
end products. J Immunol 174(12): 7506-7515, 2005.
19 Altmann S, Lange S, Pommerencke J, Murua Escobar H,
Bullerdiek J, Nolte I, Freund M and Junghanss C: High Mobility
Group Box 1-Protein expression in canine haematopoietic cells and
influence on canine peripheral blood mononuclear cell proliferative
activity. Vet Immunol Immunopathol 126(3-4): 367-372, 2008.
20 Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA and Rovere-
Querini P: The secretion of HMGB1 is required for the migration
of maturing dendritic cells. J Leukoc Biol 81(1): 84-91, 2007.
21 Yang D, Chen Q, Yang H, Tracey KJ, Bustin M and Oppenheim
JJ: High mobility group box-1 protein induces the migration and
activation of human dendritic cells and acts as an alarmin. J
Leukoc Biol 81(1): 59-66, 2007.
22 Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T,
Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus
A, Bianchi ME, Rovere-Querini P and Del Maschio A: Maturing
dendritic cells depend on RAGE for in vivo homing to lymph
nodes. J Immunol 180(4): 2270-2275, 2008.
23 Laman JD, Leenen PJ, Annels NE, Hogendoorn PC and Egeler
RM: Langerhans-cell histiocytosis 'insight into DC biology'.
Trends Immunol 24(4): 190-196, 2003.
24 Murua Escobar H, Meyer B, Richter A, Becker K, Flohr AM,
Bullerdiek J and Nolte I: Molecular characetrization of the canine
HMGB1. Cytogenet Genome Res 101: 33-38, 2003.
25 Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT,
Eberle N, Nolte I, Bullerdiek J and Murua Escobar H: Cloning,
characterisation, and comparative quantitative expression analyses
of receptor for advanced glycation end products (RAGE) transcript
forms. Gene 434(1-2): 35-42, 2009.
26 von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M
and Georgii A: Tyramine amplification technique in routine
immunohistochemistry. J Histochem Cytochem 45(11): 1455-
1459, 1997.
27 Pfaffl MW, Horgan GW and Dempfle L: Relative expression
software tool (REST) for group-wise comparison and statistical
analysis of relative expression results in real-time PCR. Nucleic
Acids Res 30(9): e36, 10 pages, 2002.
28 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A and Speleman F: Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol 3(7): RESEARCH0034, 12
pages, 2002.
29 Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J,
Rutledge R, Lin B, Amoscato AA, Zeh HJ and Lotze MT: RAGE
(Receptor for Advanced Glycation Endproducts), RAGE ligands,
and their role in cancer and inflammation. J Transl Med 7: 17, 21
pages, 2009.
30 Schraml P, Bendik I and Ludwig CU: Differential messenger RNA
and protein expression of the receptor for advanced glycosylated
end products in normal lung and non-small cell lung carcinoma.
Cancer Res 57(17): 3669-3671, 1997.
31 Bartling B, Hofmann HS, Weigle B, Silber RE and Simm A:
Down-regulation of the receptor for advanced glycation end-
products (RAGE) supports non-small cell lung carcinoma.
Carcinogenesis 26(2): 293-301, 2005.
32 Bartling B, Demling N, Silber RE and Simm A: Proliferative
stimulus of lung fibroblasts on lung cancer cells is impaired by
the receptor for advanced glycation end-products. Am J Respir
Cell Mol Biol 34(1): 83-91, 2006.
33 Shen X, Hong L, Sun H, Shi M and Song Y: The expression of
high-mobility group protein box 1 correlates with the progression
of non-small cell lung cancer. Oncol Rep 22(3): 535-539, 2009.
34 Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J,
Wickenhauser C and Bullerdiek J: Non-Hodgkin lymphoma
expressing high levels of the danger-signalling protein HMGB1.
Leuk Lymphoma 49(6): 1184-1189, 2008.
35 Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S,
Junghanss C, Nolte I, Bullerdiek J, Simon D and Murua Escobar
H: High-mobility group B1 (HMGB1) and receptor for advanced
glycation end-products (RAGE) expression in canine lymphoma.
Anticancer Res 30(12): 5043-5048, 2011.
36 Padgett GA, Madewell BR, Keller ET, Jodar L and Packard M:
Inheritance of histiocytosis in Bernese mountain dogs. J Small
Anim Pract 36(3): 93-98, 1995.
37 Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco
Y and Lebecque S: Dendritic cells infiltrating human non-small
cell lung cancer are blocked at immature stage. J Immunol 178(5):
2763-2769, 2001.
38 Simonetti O, Goteri G, Lucarini G, Rubini C, Stramazzotti D, Lo
Muzio L, Biagini G and Offidani A: In melanoma changes of
immature and mature dendritic cell expression correlate with
tumor thickness:an immunohistochemical study. Int Journal
Immunopathol Pharmacol 20(2): 325-333, 2007.
39 Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression
of HMGB1 protein and its receptor RAGE in human malignant
tumors. Mol Cell Biochem 337(1-2): 251-258, 2010.
40 Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A,
Rubartelli A, Agresti A and Bianchi ME: Monocytic cells
hyperacetylate chromatin protein HMGB1 to redirect it towards
secretion. Embo J 22(20): 5551-5560, 2003.
41 Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi
ME and Rubartelli A: The nuclear protein HMGB1 is secreted by
monocytes via a non-classical, vesicle-mediated secretory
pathway. Embo Rep 3(10): 995-1001, 2002.
Received January 11, 2011
Revised April 13, 2011
Accepted April 14, 2011
ANTICANCER RESEARCH 31: 1541-1548 (2011)
1548
Results? ? ?
? 45
3.3.?? Expression?pattern?of?the?HMGA?family?members?in?canine?lymphoma?
The?expression?of?members?of?the?HMGA?family?was?shown?to?be?re?activated?in?neoplasias?
with?a?correlation?of?the?expression?level?with?the?aggressiveness?and?progression?of?several?
malignant?tumours.?Within?this?thesis,?expression?analyses?of?HMGA1?and?HMGA2?in?canine?
lymphomas? were? performed.? Canine? lymphoma? is? one? of? the? most? common? occurring?
spontaneously?developing?haematopoietic?neoplasia?that?also?acts?as?an?appropriate?model?
for?human?non?Hodgkin´s? lymphoma.?Regarding? the?high? incidence? rate?of? this?neoplasia,?
the?identification?of?biomarkers?would?be?of?great?value.??
?
V.?“Expression?of?the?high?mobility?group?A1?(HMGA1)?and?A2?(HMGA2)?genes?in?canine?
lymphoma:?analysis?of?23?cases?and?comparison?to?control?cases”?
Joetzke?et?al.,?Veterinary?and?Comparative?Oncology,?2010?
Within? this? study,? the?expression? levels?of?HMGA1?and?HMGA2? in?canine? lymphoma?were?
determined?via?relative?quantitative?real?time?PCR.?As?endogenous?control?the?canine?GUSB?
gene?was?used.?The? study? included?23?neoplastic?and? three?non?neoplastic? control? lymph?
node? samples.? The? 23? neoplastic? samples? included? 19? multicentric? and? four? intestinal?
lymphomas? whereas? among? the?multicentric? samples? 15? B?cell? lymphomas,? three? T?cell?
lymphomas? and? one? lymphoma? without? known? origin? were? included.? The? three? non?
neoplastic?control?samples?were?obtained?from?dogs?euthanised?due?to?lymphoma?unrelated?
diseases.? HMGA1? expression? was? significantly? higher? within? the?multicentric? lymphomas?
while?HMGA2?expression?did?not?differ?from?the?control?samples?within?this?group.?HMGA1?
was?expressed?significantly?higher?in?B?cell?lymphomas?when?compared?to?T?cell?lymphomas?
while? HMGA2? was? significantly? higher? in? T?cell? lymphomas? in? contrast? to? the? B?cell?
immunophenotype.?Comparison?of?other?disease?parameters? such?as? clinical? substage?did?
not?display?significant?differences?in?HMGA1?and?HMGA2?expression.?
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Expression of the highmobility group
A1 (HMGA1) and A2 (HMGA2) genes
in canine lymphoma: analysis of 23 cases
and comparison to control cases
A. E. Joetzke1, K. A. Sterenczak1,2, N. Eberle1, S. Wagner1,2, J. T. Soller1,2,
I. Nolte1, J. Bullerdiek1,2, H. Murua Escobar1,2 and D. Simon1
1Small Animal Clinic and Research Cluster of Excellence ‘REBIRTH’, University of Veterinary Medicine
Hannover, Hannover, Germany
2Centre for Human Genetics, University of Bremen, Bremen, Germany
Abstract
Overexpression of high mobility group A (HMGA) genes was described as a prognostic marker in
different human malignancies, but its role in canine haematopoietic malignancies was unknown so
far. The objective of this study was to analyse HMGA1 and HMGA2 gene expression in lymph nodes of
canine lymphoma patients. The expression of HMGA1 and HMGA2 was analysed in lymph node
samples of 23 dogs with lymphoma and three control dogs using relative quantitative real-time
RT-PCR. Relative quantity of HMGA1 was signiﬁcantly higher in dogs with lymphoma compared with
reference samples. HMGA2 expression did not differ between lymphoma and control dogs. With the
exception of immunophenotype, comparison of disease parameters did not display any differences
in HMGA1 and HMGA2 expression. The present ﬁndings indicate a role of HMGA genes in canine
lymphoma. This study represents the basis for future veterinary and comparative studies dealing with
their diagnostic, prognostic and therapeutic values.
Keywords
dogs, gene expression,
HMGA, lymphoma, relative
quantitative real-time
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Introduction
The highmobility group A (HMGA) protein family
consists of three members: HMGA1a, HMGA1b
and HMGA2. These highly conserved,1 small,
chromatin associated non-histone proteins are
encoded for by two different genes (HMGA1
and HMGA2) and regulate gene expression by
inducing genomic DNA conformation changes.
These changes indirectly take effect on transcription
regulation by inﬂuencing the binding of various
transcription factors.2 Although HMGA genes are
abundantly expressed in embryonic cells, their
expression in most human adult healthy tissues
is low or even absent.3
The HMGA proteins are known to play a sig-
niﬁcant role in the pathogenesis of various diseases
including cancer. Re-expression of HMGA1 was
detected in various human malignancies including
thyroid, lung, prostatic and colorectal carcinoma,
as well as leukaemia and lymphoma,4–11 whereas
HMGA2 re-expression was described, for example,
in leukaemia, mammary, non-small cell lung, oral
squamous cell and thyroid carcinoma.12–16 In sev-
eral of these malignancies HMGA overexpression
has been reported to be associated with aggres-
sive biologic behaviour.4,7,9–11,13,15 Furthermore,
HMGA1 and HMGA2 have attracted interest as
potential therapeutic targets and future inﬂuencers
on the choice of therapy.17 Demonstration of
HMGA2 expression in canine prostate carcinoma
tissue provided evidence that HMGA expression
may also play a role inmalignant tumours of dogs.18
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The various similarities in biologic behaviour of
many canine and humanneoplastic diseases suggest
similar mechanisms to be involved in the respective
pathogenic events. Numerous canine malignancies
are considered to be appropriate models for human
oncology: among these, osteosarcoma, mammary
carcinoma, oral melanoma, pulmonary carcinoma
and non-Hodgkin’s lymphoma.19
Lymphoma is one of the most common neoplas-
tic diseases in the dog with an estimated annual
incidence of 24–114 per 100 000 dogs.20,21 Fur-
thermore, it belongs to the most chemoresponsive
malignancies in dogs.19 Therefore, factors involved
in the pathogenesis of canine lymphoma are of great
interest for veterinarians as well as for comparative
oncology. A wide variety of factors, for example,
has been investigated for prognostic relevance,22–27
but there are still strong variations in outcome of
canine lymphoma that cannot be completely pre-
dicted.Molecularmarkers may provide new insight
into the pathogenesis of canine lymphoma and
therefore might help in predicting outcome.
As a result of the reported role of HMGA re-
expression inmalignant tumours and its association
with tumour aggressiveness in humans, the expres-
sion of the corresponding proteins is presumed
to represent a powerful diagnostic and prognostic
molecular marker. Therefore, it was the aim of the
present study to analyse the HMGA1 and HMGA2
gene expression in canine lymphomas and to com-
pare it with ﬁndings in a group of control cases.
Materials andmethods
Patients
Dogs with cytologically or histologically conﬁrmed
lymphoma were included in the analysis. Dogs
that had received chemotherapy prior to sampling
were excluded, whereas those pretreated only with
glucocorticoidswere included. Control lymphnode
samples were acquired from dogs with clinically
unaltered peripheral lymph nodes diagnosed with
diseases other than haematopoietic neoplasia.
Signed owner consent was obtained for every
patient and the study design was reviewed
and approved by the governmental animal care
committee.
Staging and immunophenotyping
Clinical staging in dogs with lymphoma was per-
formed according to the WHO clinical staging
system28 based on physical examination, com-
plete blood count, serum biochemistry, thoracic
and abdominal radiographs and bone marrow
aspiration cytology. Flow cytometry was used to
determine the immunophenotype of multicentric
lymphoma cases as previously described.29
Samples
Enlarged peripheral (multicentric lymphoma) or
abdominal (intestinal lymphoma) lymph nodes
were sampled via ﬁne needle aspiration. Control
samples were obtained from excised peripheral
popliteal or superﬁcial cervical lymph nodes within
20 min following euthanasia. All samples were
immediately frozen in liquid nitrogen and stored at
−80 ◦C until RNA isolation.
RNA isolation and complementary DNA
synthesis for transcript characterization
The samples were homogenized using the iron-
beads QIAshredder homogenizer method (Qiagen,
Hilden, Germany). Following, total RNA was
isolated using the RNeasy Mini Kit according to
the manufacturer’s instructions (Qiagen, Hilden,
Germany). In order to avoid genomic DNA
contaminations, on-column DNase digestion with
the RNase-Free DNase set (Qiagen, Hilden,
Germany) was performed.
The respective complementary DNA (cDNA)
syntheses were performed using 250 ng total RNA
of each sample, the adaptor primer AP2: AAG GAT
CCGTCGACATC(17)T andQuantiscript Reverse
Transcriptase following the manufacturer’s proto-
col (Qiagen, Hilden, Germany) with an integrated
removal of genomic DNA contamination.
Quantitative real-time RT-PCR
For relative quantiﬁcation of the HMGA1 and
HMGA2 transcript levels, reverse transcriptionPCR
(RT-PCR) ampliﬁcations were carried out using
the Applied Biosystems 7300 real-time PCR System
(Applied Biosystems, Darmstadt, Germany). Two
© 2010 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 8, 2, 87–95
HMGA1 and HMGA2 in canine lymphoma 89
Table 1. Sequences of the primers and ﬂuorogenic probes used in the RT-PCR procedures
Forward Reverse Fluorogenic
Gene primer 5′ → 3′ primer 5′ → 3′ probe 5′ → 3′
HMGA1 ACCCAGTGAAGTGCCAACA
CCTAA
CCTCCTTCTCCAGTTT
TTTGGGTCT
6-FAM-AGGGTGCTGCCAA
GACCCGGAAAACTACC A-TAMRA
HMGA2 AGTCCCTCCAAAGC AGCTCA
AAAG
GCCATTTCCTAGGTCT GCCTC 6-FAM-AGAAGCCACTGGAGAAAAACG
GCCA-TAMRA
GUSB TGGTGCTGAGGATTGGCA CTGCCACATGGACCCC ATTC 6-FAM-CGCCCACTACTATGCCATCGT
GTG-TAMRA
GUSB, glucuronidase beta.
microlitres of each cDNA corresponding to 25 ng
of total RNA was ampliﬁed in a total volume of
25 μL using universal PCR Mastermix (Applied
Biosystems, Darmstadt, Germany) with 600 nM
each of the respective forward and reverse primer
(Table 1) and 200 nM of the respective ﬂuorogenic
probe (Table 1). PCR conditions were as follows:
2 min at 50 ◦C and 10 min at 95 ◦C, followed by 45
cycles with 15 s at 95 ◦C and 1 min at 60 ◦C.
For relative quantiﬁcation based on the compari-
son of theHMGA expression with the expression of
a housekeeping gene the canine glucuronidase beta
transcriptwas chosenas endogenous control.30 Two
microlitres of each cDNA corresponding to 25 ng
of total RNA was ampliﬁed with 600 nM of each
primer (Table 1) and 200 nM ﬂuorogenic probe
(Table 1). The PCR was performed under the same
conditions as the PCR reactions of the target genes.
All samples were measured in triplicate and for
each run, non-template controls and no reverse
transcriptase control reactions were included.
Before performing the relative real-time quantiﬁ-
cations, an absolute real-time PCR reaction was
performed with all assays (results not shown),
in order to ensure the comparability between the
endogenous control and the respective target PCR
reactions.All PCRreactions showed similar ampliﬁ-
cation efﬁciencies. To compare the gene expression
levels based on the delta-delta-CT method, the
expression in the control lymph node sample with
the lowest variations between the three measure-
ments of both HMGA1 and HMGA2 was used as a
calibrator (expression level = 1).31
Statistical analysis
Expression levels of HMGA1 and HMGA2 were
evaluated for statistically signiﬁcant differences
between anatomic type (multicentric versus intesti-
nal lymphoma,Mann–Whitney test), immunophe-
notype (B-cell versus T-cell, Mann–Whitney test),
WHO-substage (substage a versus substage b,
Mann–Whitney test) and WHO-stage (clinical
stage 3 versus 4 versus 5, Kruskal–Wallis test and
clinical stage 3 and 4 versus 5, Mann–Whitney
test). A Mann–Whitney test was also used to com-
pare expression levels in lymphomas with those in
control dogs.
A P-value of <0.05 was considered to be
statistically signiﬁcant. Statistical analysis was
performedusing SPSS 15.0 statistics software (SPSS,
Chicago, IL, USA).
Results
Patient population
Twenty-three dogs with lymphoma were included
in the study. Control lymph node samples were
obtained from three dogs that were euthanized
because of a sarcoma of the liver, pneumonia
and a mediastinal sarcoma, respectively. Patient
characteristics are summarized in Table 2.
HMGA1 and HMGA2 expression analyses
Lymph node expression of HMGA1 was measured
in all 23 dogs with lymphoma, whereas HMGA2
expression was determined in 22 of the 23
lymphoma patients. Expression of both genes was
analysed in three control lymph node samples.
HMGA expression in lymphoma samples and
comparison to control
The median expression level of HMGA1 in
lymphoma samples (n = 23) was 6.88 (range
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Table 2. Patient characteristics of the lymphoma-affected
and the control dogs
Lymphoma Control
Patients (n = 23) Dogs (n = 3)
Breeds
Mixed-breed n = 6 n = 1
Rottweiler n = 3
Beagle n = 2
Small Munsterlander n = 2
Jagdterrier n = 2
Pitbull Terrier n = 2
Dachshund n = 1
German Shepherd n = 1 n = 1
White Shepherd n = 1
Hovawart n = 1
Golden Retriever n = 1
Dogo Argentino n = 1
Jack Russel Terrier n = 1
Age (years)
Median 9
Range 4–13 7–12
Body weight (kg)
Median 26.5
Range 8.8–52 6–40
Gender
Female (spayed) n = 9 (n = 4) n = 2 (n = 2)
Male (castrated) n = 14 (n = 7) n = 1 (n = 0)
Anatomic form
Multicentric n = 19 (83%)
Intestinal n = 4 (17%)
WHO-stage
3 n = 3 (13%)
4 n = 5 (22%)
5 n = 15 (65%)
WHO-substage
a n = 7 (30%)
b n = 16 (70%)
Immunophenotype
B n = 15
T n = 3
Not determined n = 5
1.09–12.14),whichwas signiﬁcantlyhigher than the
expression measured in control samples (median
0.95, range 0.94–1.00,P = 0.006).HMGA2 expres-
sion showed no signiﬁcant difference between
lymphoma-affected (n = 22; median 0.32, range
0.03–317.66) and control lymph nodes (median
0.52, range 0.33–1.00, P = 0.738).
HMGA expression in multicentric lymphoma
In a separate evaluation including only the dogs
with multicentric lymphoma (n = 19), HMGA1
was detected with a median relative quantity
of 7.20 (range 1.09–12.14). The median relative
quantity of HMGA2 in these dogs (n = 18) was
0.28 (range 0.03–317.66). The expression levels of
HMGA1 in the multicentric lymphoma cases were
higher than in the control samples (median 0.95,
range 0.94–1.00, P = 0.001, Fig. 1A). Expression
of HMGA2 did not differ signiﬁcantly between
multicentric lymphoma and control samples
(median 0.52, range 0.33–1.00,P = 0.534, Fig. 1B).
HMGA1 and HMGA2 expression levels in the
dogs with multicentric lymphoma did not differ
fromthose indogswith intestinal lymphoma(n = 4
HMGA1: median 4.59, range 1.63–10.04, P =
0.505; HMGA2: median 7.02, range 0.14–138.69,
P = 0.118).
In the dogs withmulticentric lymphoma, clinical
stage and clinical substage were not signiﬁcantly
associated with different HMGA1 (P = 0.340 and
P = 0.482, respectively) and HMGA2 (P = 0.964
and P = 0.126, respectively) expression values.
Comparison of a combined group of dogs in stages
3 and 4 with dogs in stage 5 also did not display
any differences inHMGA1 andHMGA2 expression
(P = 0.940 and P = 0.965, respectively).
Median relative HMGA1 expression level in the
multicentric lymphoma dogs with B-cell subtype
(n = 15) was 7.42 (range 4.79–12.14). This was
signiﬁcantly higher than the respective relative
quantity in the T-cell lymphoma cases (n = 3; 1.09,
1.50 and 1.53, respectively,P = 0.002, Fig. 2A). The
relative quantity of HMGA2 expression was on the
other hand signiﬁcantly higher in the T-cell subtype
(n = 3; 21.98, 93.48 and 317.66, respectively) than
in the B-cell lymphoma dogs (n = 14; median 0.17,
range 0.03–5.33, P = 0.003, Fig. 2B).
Discussion
The present study aimed at the quantiﬁcation of
HMGA1 and HMGA2 expression in canine lym-
phoma and a comparison to control cases. It is
the ﬁrst report of HMGA expression analysis in
canine haematopoietic malignancy. In the present
population of dogs with lymphoma, HMGA1 was
overexpressed when compared with control dogs.
In certain subtypes of human non-Hodgkin’s lym-
phoma an alternative methodical approach using
microarray technology indicated differences in
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Figure 1. Relative quantity of HMGA1 (A) and HMGA2 (B) in dogs with multicentric lymphoma and control dogs.
Boxplots graphs comparing multicentric lymphoma to control lymph nodes. (A) Median relative HMGA1 quantity in
multicentric lymphoma (n = 19): 7.20 (range 1.09–12.14), control samples (n = 3): 0.95 (range 0.94–1.00; P = 0.001);
(B) median relative HMGA2 quantity in multicentric lymphoma (n = 18): 0.28 (range 0.03–317.66), control samples
(n = 3): 0.52 (range 0.33–1.00; P = 0.534).
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Figure 2. Relative quantity of HMGA1 (A) and HMGA2 (B) in multicentric lymphoma with different immunophenotype.
Boxplots graphs comparing B-cell and T-cell lymphoma. (A) Median relative HMGA1 quantity in B-cell lymphoma
(n = 15): 7.42 (range 4.79–12.14), in T-cell lymphoma (n = 3): 1.50 (range 1.09–1.53; P = 0.002); (B) median relative
HMGA2 quantity in B-cell lymphoma (n = 14): 0.17 (range 0.03–5.33), in T-cell lymphoma (n = 3): 93.48 (range
21.98–317.66; P = 0.003).
HMGA1 expression levels as well. The expres-
sion was found to be signiﬁcantly upregulated
in the aggressive phase of follicular lymphoma
compared with the indolent phase.10 Human
mantle cell lymphomas with a high prolifera-
tive index as determined immunohistochemically
via Ki-67 expression showed a 3.3-fold higher
HMGA1 expression than those with a low prolifer-
ative index.11 Increased levels of HMGA1 proteins
were also described in Burkitt’s lymphoma cell
lines with increased c-Myc protein.32 Furthermore,
HMGA1 overexpression has been shown in human
leukaemias both of lymphoid andmyeloid origin.6,8
In addition, ﬁndings in mice emphasize the impor-
tance of HMGA1 in haematopoietic malignancies.
Induction of HMGA1 overexpression in transgenic
mice was found to be associated with the devel-
opment of NK-cell lymphomas.33 Interestingly, the
loss of function of the HMGA1 gene shows signif-
icant pathogenic effects, as well. Heterozygous and
homozygousHMGA1 knock-out mice develop car-
diac hypertrophy combined with haematopoietic
malignancies, for example, B-cell lymphoma and
myeloid granuloerythroblastic leukaemia.34
No signiﬁcant difference in HMGA2 expression
levels between canine lymphomaandcontrol lymph
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node samples was detected in the study population.
In human haematopoietic malignancies, both of
lymphoid and myeloid origin, aberrant expression
and/or chromosomal rearrangements affecting
HMGA2 have been described.35–38 Transgenic
mice carrying a truncated HMGA2 gene develop
NK-cell lymphomas with a high frequency and
thus show an association of HMGA2 expression
with haematopoietic neoplasia, as well.39 Although
increased HMGA2 expression levels seem to play a
role in several human myeloid neoplasias,14,38,40
ﬁndings in lymphoid malignancies are more
heterogeneous. Signiﬁcantly lower expression levels
of HMGA2 were found in the bone marrow
of human acute lymphoblastic leukaemia (ALL)
patients when compared with healthy bone
marrow.35 In contrast, there is a report of HMGA2
locus rearrangement with overexpression of a
HMGA2 mRNA lacking a carboxy-terminal tail
in a case of ALL.37 Another paper showed HMGA2
protein expression inbonemarrowblasts associated
with chromosomal translocation involvingHMGA2
in Richter transformation of a chronic lymphocytic
leukaemia.36
Despite the lack of signiﬁcant differences in
HMGA2 expression between canine lymphoma
and control lymph nodes in the present study,
the HMGA2 expression in canine lymphomas var-
ied widely. This indicates that aberrant HMGA2
expression may play a role in canine lymphoma
but that its overexpression is not a consistent ﬁnd-
ing. The role of these expression differences in the
respective pathogenesis remains to be investigated
in future studies incorporating a larger study popu-
lation. Interestingly,HMGA2 expression levels were
found to be signiﬁcantly higher in T-cell than in
B-cell lymphomas. The T-cell immunophenotype
is observed less frequently in canine lymphoma,
comprising approximately 19–33% of lymphoma
cases.22,24,29 Consistent with these ﬁndings, T-cell
lymphomas accounted for 17% of phenotyped
lymphoma cases in the present study. A higher
proportion of T-cell lymphomas may have resulted
in a signiﬁcant difference in HMGA2 expression
betweenmulticentric lymphomas and control sam-
ples. Expression ofHMGA1 as well was signiﬁcantly
different between T-cell and B-cell lymphomas.
In contrast to HMGA2, HMGA1 was expressed
signiﬁcantly higher in B-cell lymphomas. The
known association of immunophenotype with
prognosis of canine lymphoma22,24,25 in addition
to the proven prognostic signiﬁcance of HMGA
expression in several human malignancies4,7,9,13,15
gives rise to the assumption that HMGA expres-
sion levels and especially the different expression of
HMGA1 andHMGA2may be associated with prog-
nosis in canine lymphoma, as well. Further studies
are needed to verify the present ﬁndings and to
proveanassociationwithprognosis. It is interesting,
that there seems to be a low expression of HMGA1
especially in the subgroup (T-cell lymphomas) with
a signiﬁcantly higher expression of HMGA2. When
reviewing other studies about HMGA expression
in different human tumours concurrent overex-
pression of HMGA1 and HMGA2 is found in
some tumour types7 and overexpression of either
HMGA1 or HMGA2 in others.41,42 In some human
tumour entities, the expression proﬁle of HMGA
seems to be useful as a diagnostic tool to differenti-
ate between histologically similar tumours.41,42 It is
possible, that differential expression ofHMGA1 and
HMGA2 may be attributed to different roles they
play in tissue differentiation and tumour pathogen-
esis. Whether it possesses diagnostic or prognostic
importance in canine tumours and especially in
canine lymphomas may become subject of future
studies.
The present study has some limitations that
need to be considered. Some subgroups within
the study population were relatively small, which
decreases the statistical signiﬁcanceof the results but
reﬂects the epidemiological situation in the canine
lymphoma population. The low number of control
cases must be regarded as a limitation, as well. This
group consisted of euthanized dogs with clinically
unaltered peripheral lymph nodes and without
haematopoietic neoplasia. Other neoplastic or non-
neoplastic diseases were not excluded. It cannot be
ruled out that the HMGA gene expression levels
measured in the apparently unaltered peripheral
lymph nodes of these dogs has been inﬂuenced
by their respective disease or the postmortem
sampling.
In the present study, overexpression of HMGA
genes was demonstrated in dogs with lymphoma.
The ﬁndings indicate that HMGA gene expression
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may possess a role in the pathogenesis of canine
lymphoma. Hence, the results of the present study
may provide the basis for future veterinary and
comparative studies on the diagnostic, prognostic
and therapeutic use of HMGA1 and HMGA2.
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Abstract
Background: Prostate cancer is a frequent finding in man. In dogs, malignant disease of the
prostate is also of clinical relevance, although it is a less common diagnosis. Even though there are
numerous differences in origin and development of the disease, man and dog share many similarities
in the pathological presentation. For this reason, the dog might be a useful animal model for
prostate malignancies in man.
Although prostate cancer is of great importance in veterinary medicine as well as in comparative
medicine, there are only few cell lines available. Thus, it was the aim of the present study to
determine whether the formerly established prostate carcinoma cell line CT1258 is a suitable tool
for in vivo testing, and to distinguish the growth pattern of the induced tumours.
Methods: For characterisation of the in vivo behaviour of the in vitro established canine prostate
carcinoma cell line CT1258, cells were inoculated in 19 NOD.CB17-PrkdcScid/J (in the following:
NOD-Scid) mice, either subcutaneously or intraperitoneally. After sacrifice, the obtained
specimens were examined histologically and compared to the pattern of the original tumour in the
donor.
Cytogenetic investigation was performed.
Results: The cell line CT 1258 not only showed to be highly tumourigenic after subcutaneous as
well as intraperitoneal inoculation, but also mimicked the behaviour of the original tumour.
Conclusion: Tumours induced by inoculation of the cell line CT1258 resemble the situation in
naturally occurring prostate carcinoma in the dog, and thus could be used as in vivo model for future
studies.
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Background
Only few species are known to spontaneously develop
prostatic neoplasia; therefore the search for a suitable ani-
mal model for this disease is difficult. Currently, the dog
is used as in vivo model for prostate malignancies in man,
since it shows a similar metastatic pattern as well as age
dependent development of malignant prostatic lesions [1-
3]. Whereas prostate cancer is a frequent finding in man
and even one of the leading causes of death in the Western
world, it is less common in the dog. The prevalence is only
0. 2%–0. 6% [20]. Since this number is based on necropsy
findings, the true number might be higher [4,5]. Although
the relative number appears to be quite low, it results in
an absolute count of estimated 60,000–180,000 affected
dogs in the USA, 6,000–18,000 dogs in the UK, and
5,300–15,900 dogs in Germany, based on population.
Although there are some reports observing a permissive or
protective effect of androgens [6-10], androgens do not
seem to have an influence on development, growth, or
metastasis in prostate carcinoma in dogs. Other than in
human medicine, the diagnosis is usually made at a very
late state of the disease, since for dogs no screening tests
are available as there are for man [13]. Therefore treat-
ment options for prostate cancer in the dog are limited
and mostly remain to be palliative.
Despite the rather high incidence of prostate carcinoma in
man, there are only three cell lines of human prostate car-
cinoma and their sub lines available. Thus, it is not sur-
prising that there are only occasional reports about cell
lines of canine prostatic carcinoma [11-13]. Hence the
purpose of the present study was to establish an animal
model, using the recently described cell line CT1258,
which has been derived from a spontaneous canine pros-
tate carcinoma [14,15]. Special attention was directed
towards comparison of the clinical behaviour of the
induced tumour in mice to the spontaneous tumour in
the donor, as well as histological comparison. A compari-
son of the Ki67 index was performed in order to be able
to address a potential change in proliferation. The Ki67
Index has been described to be associated with a poor out-
come in human prostate cancer [18].
Methods
Donor
The cell line was derived from a prostatic tumour of a
Briard, 10 years, male intact, which had been presented at
the Small Animal Clinic of the University of Veterinary
Medicine Hanover, Germany. The dog had a two week
history of dyschezia, gain of abdominal girth, polydipsia,
and loss of appetite. Clinical examination revealed an
undulating and strained abdomen. Abdominal radio-
graphs showed a highly reduced perceptibility of detail.
On abdominal ultrasound an enlarged prostate could be
detected, which contained several cysts.
Explorative laparatomy was performed and about 3000
ml abdominal fluid were obtained; the prostate itself was
highly enlarged and several miliary masses were found in
the mesentery. There was no evidence of contact metas-
tases to abdominal organs or distant metastases to the
lung. Biopsies have been taken under general anaesthesia;
the cytological diagnosis of a highly malignant adenocar-
cinoma of the prostate resulted in euthanasia ad tabulam.
Prior to euthanasia, biopsies have been taken for further
histological examination and for cell culture. Histological
staining and immunohistochemical staining as well as
cytogenetic analysis was performed as described below.
Cell line
The cell culture conditions, as well as the characteristics of
the canine prostate carcinoma cell line CT1258 have been
described previously [15].
Animals
This study involved 19 NOD-Scid mice (10 male, 9
female). All animals were bred and maintained in a pro-
tected environment at the Institute of Laboratory Animal
Science of the Hanover Medical School. The mice were fed
autoclaved food and water ad libitum, any manipulation
was performed in a laminar flow hood. The animals were
observed on a daily basis and sacrificed depending on the
clinical condition and the size of detectable tumour,
respectively. The tumours were allowed to grow up to a
diameter of 10 mm. Additional criteria for euthanasia
were ulceration of subcutaneous masses, a reduced level
of activity of the mice, and the loss of appetite. The ani-
mals were humanely sacrificed by cervical dislocation
after inhalation of > 70% carbon dioxide. The study was
approved by the Lower Saxony State Office of Consumer
Security and Food Safety (33-42502-05/950), the ethical
approval was sought from the University of Veterinary
Medicine Hanover.
Inoculation of Cells
The cells were harvested from the culture flasks with 1 ml
of TrypLE Express (Invitrogen, Karlsruhe, Germany) and
incubated at room temperature for 1 minute. L-199
medium (Invitrogen, Karlsruhe, Germany) supplemented
with 20% FCS was added and the cells were centrifuged at
350 g for 15 minutes. The cell pellet was washed twice
with PBS. The cells were resuspended in 200 ?l PBS;
immediately before application the suspension was aspi-
rated into Insulin-Syringes (BD Micro-Fine, BD, Heidel-
berg, Germany) and inoculated either subcutaneously
into the left flank of the animals or intraperitoneally.
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For subcutaneous inoculation, the animals received 1 ×
106 cells. For intraperitoneal application, mice received
either 1 × 105 or 5 × 105 cells. The 19 NOD-Scid mice were
subdivided into two groups: One group consisted of four
female and five male mice, the animals received 1 ×
106cells subcutaneously each. The second group consisted
of five male and five female animals, cells were inoculated
intraperitoneally. Four of them (2 male, 2 female)
received 1 × 105 cells; six animals (3 male, 3 female)
received 5 × 105 cells, respectively.
Necropsy and histological staining
Necropsy was performed immediately after death had
occurred. Lung, liver, spleen, kidneys, gonads, bowel, and
detected masses were removed, fixed in 10% buffered for-
malin, paraffin embedded, sectioned, and stained with
hematoxylin and eosin; immunohistochemical staining
for Ki67 was performed, using the monoclonal antibody
MIB-1 (Dianova, Hamburg, Germany) in a dilution of
1:100. The paraffin sections were pretreated in a micro-
wave oven for 20 minutes in citrate buffer solution, pH 6.
The secondary antibody was a biotinylated goat-?-mouse
antibody, for detection, the Vectastain ABC-Kit (Vector
Laboratories, Burlingame, USA) has been used. The Ki67
Index was determined by detecting the fraction of Ki67
positive stained cells in total 500 cells. This was per-
formed in the original tumour, as well as in the induced
tumours. Intestinal mucosa served as positive control. In
addition, tumour samples of each mouse were obtained
in liquid nitrogen for real time RT-PCR and in Hank's
Medium for further in vitro culturing and Cytogenetic
analysis. In order to address the growth pattern, the origi-
nal canine tumour and the murine tumours have been
classified based upon the presence of glandular, urothe-
lial, squamoid, or sarcomatoid differentiation.
Cytogenetic analysis
For cytogenetic investigation, cells have been processed as
described previously [15]. Tissue was transferred to liquid
nitrogen immediately after dissection and stored at -70°C
until examination.
Statistics
This study was intended to be descriptive rather than sta-
tistically significant. However, a paired student's t-test was
performed. A P-value < 0.05 was considered to be signifi-
cant.
Results
Pathological and histological examination
Original canine tumour
On histological examination the tumour showed to be
consisting of poorly differentiated cells with numerous
signs of malignancy. A strong anisocytosis, numerous cells
with multiple nuclei, anisokaryosis, multiple mitotic fig-
ures, to some extent atypical mitotic figures, and a varying
nucleus: plasma ratio could be detected. The tumour
showed a compact growth with glandular differentiation.
The Ki67 index was 43%.
Subcutaneous tumours
For analysis of duration until sacrifice of the mice, only
those individuals were considered that were sacrificed due
to tumour burden. All female mice and four of five male
mice developed a detectable tumour mass after subcuta-
neous inoculation of 1 × 106 cells of the canine prostate
carcinoma cell line CT1258 (Table 1). One mouse with-
out detectable tumour growth was sacrificed due to bad
clinical condition; necropsy revealed a mass of the thy-
mus, histologically addressed as thymoma. In the remain-
ing mice tumours were allowed to grow up to a size of 5–8
mm, which lasted 20 to 42 days (mean 25.37 days,
median 22 days). Gender distribution showed a mean
value of 28.75, median 26.5 days for female mice, and a
mean and a median of 22 days for the males. None of the
mice showed any signs of metastasis or of invasive growth
pathologically or histologically; except for the mouse that
did not develop any tumour mass, all animals remained
in good clinical and nutritional condition.
Histology revealed a highly heterogeneous population of
cells, numerous mitotic figures, anisokaryosis, anisocyto-
sis, and several cells containing more than one nucleus;
there was a variable nucleus: plasma ratio (Figures 1, 2).
The centre of the obtained masses showed to be highly
necrotic. Glandular differentiation was present. Immuno-
histochemistry revealed a strong positivity for the Ki67-
antigen (Figure 3); the Ki67 index was between 41% and
48%, respectively
Intraperitoneal Tumours
The group was subdivided in two categories: Animals
receiving 1 × 105 cells, consisting of two males and two
females each, and animals receiving 5 × 105 cells, consist-
ing of three males and three females each. The criteria for
sacrification were impairment of the general condition,
worsening of the nutritional condition, and/or reduction
of activity level. Weight gain was not a reliable factor due
to the development of massive peritoneal effusion.
Table 1: Tumour growth after subcutaneous injection of 1 × 106 
cells of CT1258.
Mean No growth Range SD
[days] [No of animals] [days]
Male 22 1 20–24 1.63
Female 28.75 0 20–42 10.05
Total 25.38 1 20–42 7.58
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In all mice receiving 1 × 105 cells tumour growth could be
detected. The mean duration until sacrifice was 28 days. In
one of three females and two of three males inoculated
with 5 × 105 cells tumour growth could be detected, in this
group the mean duration until sacrifice was 26 days
(Table 2). Overall seven out of ten mice intraperitoneally
inoculated with CT1258 developed tumour growth. Of
those animals all but one male, which had received 5 ×
105 cells, had an extended abdomen and proved to have
peritoneal effusion. The male without obvious tumour
growth had developed a thymoma, which was the cause
for the bad clinical condition. Six of these ten mice devel-
oped a mass at the injection site, although at inoculation
a proper amount of time had elapsed until withdrawal of
the needle. Necropsy showed a moderate to high tumour
burden at the peritoneum and no visible signs of metasta-
sis to the lungs (Figure 4). Histological examination of the
obtained masses showed a similar pattern as the subcuta-
neous masses with a glandular differentiation (Figure 5);
staining for Ki67 was strongly positive with a Ki67 index
between 45% and 47%. Isolated populations of tumour
cells could be detected in the lungs, but there was no sign
Diaphragm after i.p. injection of 5 × 105 cells with a high tumour burden; see Figure 5 f r histology; the thoracic aspect of the diaphragm is not affec edFigure 4
Diaphragm after i.p. injection of 5 × 105 cells with a 
high tumour burden; see Figure 5 for histology; the 
thoracic aspect of the diaphragm is not affected.
Subcutaneous mass with multiple mitotic figures and necrotic area; the large p le cells surrounding the hair follicle are partof the s b ceous gland and should not be mistaken as t mour c lls (arrow)Figure 2
Subcutaneous mass with multiple mitotic figures and 
necrotic area; the large pale cells surrounding the 
hair follicle are part of the sebaceous gland and 
should not be mistaken as tumour cells (arrow).
Subcutaneous mass with a high mitotic indexFigure 1
Subcutaneous mass with a high mitotic index. The 
arrow indicates an atypical mitotic figure.
Ki67 staining of subcutaneous mass with a high amount of cells st i i  positively for Ki67F gure 3
Ki67 staining of subcutaneous mass with a high 
amount of cells staining positively for Ki67.
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of vascularisation (Figure 6). In abdominal organs only
peripheral tumour growth could be observed.
Cytogenetic Analysis
The cytogenetic investigation of intraperitoneal and sub-
cutaneous tumours revealed the same markers that have
been shown in analysis of the original tumour and of the
cell line [15]. A hyperdiploid karyotype was present. Cen-
tromeric fusion between chromosomes 1 and 5 (der (1;
5)) and chromosomes 4 and 5 (der (4; 5)) were detected.
A large biarmed marker (mar) was found (Figure 7, 8).
Discussion
Ideally a cell line should not only be immortalized spon-
taneously but also be tumourigenic in experimental ani-
mals. Another claim may be the mimicking of the original
natural behaviour of the tumour in the host. This condi-
tion promotes the predictability of any results obtained
with that very cell line. This is true especially for cell lines
derived from nonhuman tumours if the origin may serve
as a model itself.
This study reveals that the cell line CT1258 is highly
tumourigenic in NOD-Scid mice. Local tumour growth
occurred in 89% of the animals that had received cells
subcutaneously; 86% of the animals that had been inocu-
lated intraperitoneally and that had developed tumour
growth also developed local tumour growth at the injec-
tion site. The latter was not desired, and since it is not
known how many cells remained in the branch canal, the
size of those accidental masses cannot be compared accu-
rately. Focussing on the mice with cells inoculated i.p.,
86% developed peritoneal effusion just as the donor did
and all of them had multiple small nodules within the
serous membranes of the peritoneum rather than one
large mass. The excellent local tumour growth on one
hand and the rapid development of pleural effusion on
the other hand indicates that in studies to come the use of
the cell line might be of a greater value in local adminis-
tration rather than in systemic inoculation. Orthotopic
implantation might be of great value, since this could ena-
ble the assessment of local growth and invasion as well as
potential metastasis. Due to the lack of vascularisation,
the tumour cells found in the lungs of the mice must be
addressed as tumour cell embolism rather than metasta-
sis. Since neither the mice nor the donor had evidence of
lymphogenic or hematogenic metastasis, we conclude
that time for metastasis exceeds the time limitation owed
to local tumour growth. Whether this is due to the rapid
growth rate or due to potentially little disposition of the
cells to degrade extracellular matrix and therefore has a
generally low tendency to metastasise remains unclear.
The absence of bone metastasis is a remarkable fact, which
is contrary to the high incidence of bone metastasis in
Table 2: Tumour growth after intraperitoneal injection of 1 × 105 
and 5 × 105 cells.
Mean No growth Range SD
[days] [No of animals] [days]
Male 26.75 1 24–30 3.2
Female 27.67 2 24–30 3.21
1 × 105 cells 28 0 24–30 2.71
5 × 105cells 26 3 24–30 3.46
Total 27.14 3 24–30 1.12
Diaphragmatic mass (see figure 4 for macroscopic appear-ance)Figure 5
Diaphragmatic mass (see figure 4 for macroscopic 
appearance).
Ki67-staining of tumour cells in the lung; there is no evidence of vascularisation, therefore these cells are tumour mboli rather than metastasisF gu e 6
Ki67-staining of tumour cells in the lung; there is no 
evidence of vascularisation, therefore these cells are 
tumour emboli rather than metastasis.
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canine and human patients [5,19]. Potentially there was
not enough time for bone metastasis to develop due to
rapid local tumour growth, on the other hand, this partic-
ular tumour might have a reduced tendency for skeletal
metastasis. At first glance this reduces the value of the
present tumour model for comparative oncology, but this
interesting feature might be used for further studies
focussing on skeletal metastasis in particular, if the cause
for the absence of metastasis to the skeleton in this other-
wise highly malignant prostate carcinoma is detected. The
tendency to show necrotic areas in the centre might be due
to rapid tumour growth.
The number of cells obviously did not seem not to have a
direct impact on tumour growth, since all mice that had
been inoculated with 1 × 105 cells developed tumours, but
50% of the animals that received 5 × 105 cells did not;
although this is not considered to be statistically signifi-
cant, it suggests that an even lower number of cells might
have been sufficient to induce a tumour. The difference
between male and female animals is not statistically sig-
nificant.
The Ki67 indices in both, the original tumour and the
experimentally induced tumours, were considered to be
high. The difference between the original tumour on one
hand and the subcutaneous and intraperitoneal masses
on the other hand were statistically not significant. In
human medicine a high Ki67 index has shown to be asso-
ciated with a poor prognosis [20]. Considering the histo-
logical characteristics of the described tumour, the high
Ki67 index is not a surprising finding. Comparison of the
Ki67 index of the original tumour to the xenograft
revealed no change in proliferation.
One limiting factor is that two of the nineteen mice in the
study developed thymoma within the course of the study.
This is a frequent finding in older NOD-Scid mice [16,17].
Therefore the animals must not be considered to be
healthy.
Metaphase spread from cells derived from the original canine tumourFigure 7
Metaphase spread from cells derived from the original canine tumour. The arrows indicate the derivative chromo-
somes der (1; 5), der (4; 5) and the marker chromosome mar, which consists of chromosome 1 and chromosome 2 material.
der(4;5)
mar
der(1;5)
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Conclusion
The canine prostate carcinoma cell line CT1258 demon-
strated to be tumourigenic in the NOD-Scid mouse.
Tumours induced in mice resembled the biological behav-
iour of the tumour from which the cell line was originally
derived regarding growth pattern and histological appear-
ance. Therefore we conclude that the use of this animal
model will provide results with a high predictability
towards clinical use in veterinary medicine and due to the
correlation between canine and human prostate carci-
noma in humans as well. The lack of skeletal metastasis is
a potential field for further studies.
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Abstract
Objectives: 
Cell lines represent one of the key tools of cancer research allowing the generation of 
neoplasias in in vivo animal mice models resembling the initial tumors. The MRI based 
characterization of the in vivo development of the induced tumors offers the possibility for the 
detection prior to palpation and allows characterization of the tumor development in early 
stages. Thereby, non invasive and non lethal MRI imaging provides a powerful tool in 
combination with cell contrast MRI agents such as superparamagnetic iron oxide 
nanoparticles (SPIOs) or manganese. Thus, within the present study, direct in vitro manganese 
chloride (MnCl2) and SPIOs cell labelling and 1T MRI based in vitro and 7T MRI based in 
vivo tracing of labelled cancer cells in a model of prostate cancer was established.  
Material and Methods: 
Direct labelling of CT1258 cells was established in vitro with the MRI contrast agents MnCl2 
and SPIOs. After labelling with MnCl2, viability was tested. The in vitro detection of labelled 
cells was performed in an agar phantom in a 1T MRI system. The in vivo detection was based 
on 7T MRI after subcutaneous (sc) injections of labelled cells into NOD-Scid mice (n=20). 
The animals were scanned regularly after sc injections until they were euthanized. The 
respective tumor volumes were analyzed. The obtained tumor masses were analyzed 
histologically.  
Results:
Direct in vitro labelling of CT1258 cells with MnCl2 was established and the labelling 
parameters evaluated revealed no significant metabolic effects on proliferation and cell 
vitality. The in vitro detection-limit of labelled cells using an agar phantom accounted 105 
cells when labelled with both, MnCl2 and SPIOs, while during the in vivo 7T MRI scans, 
lower cell numbers could be detected (103 and 104). MnCl2 labelled cells could be detected 
during a longer time period ranging from 4 days to 16 days after sc injections than SPIOs 
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labelled cells which were detected till 4 days after injection. The MnCl2 labelled CT1258 cells 
were highly tumorigenic within male and female NOD-scid mice and the increment of the 
tumor volume was analyzed in a time dependent manner after sc injection. The number of 
injected cells (104 vs. 103) showed a positive correlation with tumor size and disease 
progression. The tumor development could be detected early and prior to palpation. The 
histological analysis of the obtained tumor masses showed the characteristic morphology of a 
prostate adenocarcinoma. 
Conclusions:
This is a first study reporting direct in vitro MnCl2 labelling and 7T based in vivo MRI tracing 
of cancer cells in a model of prostate cancer. A MnCl2 labelling protocol was established 
without significant effects on cell metabolism. MnCl2 labelled cells could be detected during a 
longer time period than SPIOs labelled cells after injection and MnCl2 labelling was evaluated 
to be more appropriate for in vivo tracing of cancer cells. Labelled CT1258 cells kept their 
highly tumorigenic potential in vivo and the tumor volume development could be detected 
prior to palpation. Thus, MnCl2 labelling of the CT1258 cells did not alter their biological 
activity and morphology.  
Key words: 
in vitro labelling, MnCl2, SPIOs, in vivo 7T MRI, cell tracing, early tumor detection 
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Introduction
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of 
cancer deaths in males worldwide accounting for an incidence rate of 14 % and mortality rate 
of 6 %.1, 2 The estimated rates of new cases and deaths are higher in developed countries than 
in developing countries which is mainly supposed to be reasoned by the lifestyle or wide 
utilization of prostate-specific antigen (PSA) testing that detects clinical important tumors as 
well as slow-growing cancers that otherwise would not be diagnosed.1, 2 Currently, several 
human prostate cancer cell lines established either from primary tissue sources or from clonal 
derivatives of previously established cell lines are available as e.g. the human cell lines DU 
145, LNCaP and PC-33-5 being the most prevalent lines. In general, naturally occurring animal 
models developing prostate cancer are rare. In larger non-human mammalians only the dog is 
known to develop prostatic cancer with considerable numbers. Further, reports of prostate 
carcinoma in primates are rare and none of the cases were detected antemortem6 and in 
rodents the Dunning rat and germfree Wistar rat developed prostate cancer. However, the 
spontaneously occurring neoplasias in dogs represent the most similar animal model. Unlike 
the situation in men, canine prostate cancer is an uncommon neoplasm with a prevalence of 
approximately 0.2 % to 0.6 % based on necropsy studies.7 The prognosis is poor as the 
neoplasm is mostly diagnosed at a late stage of disease and treatment mostly remains 
palliative. Canine prostate cancer shares many characteristics with its human counterpart 
regarding the clinical presentation and pathogenesis. Analogical to men, in dogs, high grade 
prostatic intraepithelial neoplasia (PIN) was described, which is the most likely precursor of 
most human prostate cancers.6-8 The metastatic pattern and increased incidence with age 
reflect further similarities with human prostate cancer.6, 9, 10 However, unlike to prostatic 
adenocarcinomas in humans, canine prostate carcinoma does not appear to respond to 
androgen deprivation11 and most canine prostate cancers do not express androgen receptor 
making it unlikely that these neoplasms arise from prostatic secretory epithelium.12 
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Nevertheless, taken together, the dog displays a suitable model of prostate cancer and 
therapeutical approaches would be of benefit for both humans and dogs. 
Until now five canine cell lines which derived from spontaneously developed primary 
prostate cancer tumors were published. Apart from the cell line CT1258 which was 
established and characterized in our laboratories13, 14 the canine cell lines CPA 1, DPC-I, Ace-
1 and Leo were reported.15-18 Until now, we have characterized the histological type, the 
karyotype and the in vivo behaviour of the CT1258 cell line which was shown to be highly 
tumorigenic when applied in a NOD.CB17-PrkdcSCID/J (in the following NOD-scid) mouse 
model.13, 14 Thereby, the induced tumors mimicked the histopathological and cytogenetical 
behaviour of the original tumor.14  
In this context a key aspect in terms of experimental comparability is the controlled delivery 
of the applied cells to the animals in the study. Further the possibility to monitor the tumor 
development in vivo, without euthanasia of the respective animals offers several advantages. 
Within the present study, the in vivo localization of the cells after injection, the migration 
behaviour and the progression of the tumor growth were monitored in regular time periods via 
7T MRI. In order to enable a visualisation of the injected cells, labelling with known MRI 
contrast agents including manganese chloride (MnCl2) and superparamagnetic iron oxide 
nanoparticles (SPIOs) was performed. MnCl2 is known to act as T1 enhancing agent while 
SPIOs cause signal extinguishments in T2/T2* weighted MRI. Dextran-coated iron oxide 
nanoparticles are widely used as MRI contrast agents with application in the scientific field 
and in the clinic as well due to their biodegradable and biocompatible features.19 The various 
applications include e.g. the tracking of labelled transplanted stem cells in neurological and 
cardiovascular diseases as well as the diagnostic imaging of the liver and spleen for tumor 
detection and staging.19-23 In prostate cancer, labelling of the human cell line PC-3 with lipid-
coated SPIOs was reported24 and the in vitro labelling with microm sized iron oxide 
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nanoparticles (MPIOs) and subsequent in vivo tracing via MRI was performed with the rodent 
prostate cancer cell line TRAMPC1.25  
In contrast to the well characterised iron oxide nanoparticles, the use of MnCl2 as MRI 
contrast agent for cell labelling and non-invasive in vivo cell tracing is rarer. Manganese 
enhanced MRI (MEMRI) has mostly been used in studies of the anatomy and function of the 
central nervous system and the heart which was mostly performed with systemic 
administrations of manganese.26-29 So far in vitro labelling of cells with MnCl2 for MR 
imaging was performed in murine pancreatic beta cells, human lymphocytes, embryonic stem 
cells and bone marrow stromal cells.23, 30-33 The manganese agent Mn (III)-transferrin was 
used for labelling and in vivo detection of murine hepatocytes.34 The use of manganese oxide 
(MnO) for in vitro cell labelling was evaluated in eight human cell lines including a prostate 
adenocarcinoma cell line and labelling with MnO with subsequent MRI based in vivo tracking 
was performed with rat glioma cells.35, 36  
The aim of the present study was the evaluation of appropriate labelling parameters which 
enable MR imaging of the cells with MnCl2 and SPIOs as well, in a CT1258 based in vivo 
model of canine prostate cancer. Labelling of the cells with MnCl2 was found to be more 
suitable for in vivo cell tracing in comparison to SPIOs labelled cells and the cells were 
detectable to a total number of 103 when injected subcutaneously (sc) in the abdominal flank 
of the NOD-scid mice. The manganese labelled CT1258 cells maintained their high 
tumorigenic potential and the tumors mimicked the histopathological and cytgenetical 
behaviour of the original tumor. This is a first study, reporting direct in vitro cell labelling 
with MnCl2 and subsequent MRI based in vivo tracing of prostate cancer cells. Further, the 
tumor development was detected prior to palpation via MRI and the tumor size could be 
analyzed during the progression. Male mice developed higher tumor masses with faster 
progression in correlation with the cell number injected. Regarding differences between male 
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and female animals, no gender-dependence or hormone-status dependence of CT1258 could 
be evaluated possibly due to the small number of animals analyzed. 
 
Materials and Methods
Cell line 
The characteristics, cultivation conditions, and a basic in vivo growth pattern were previously 
described for the canine prostate cell line CT1258.13, 14  
 
In vitro labelling of CT1258 cells with MnCl2
MnCl2·4H2O (Appli-Chem, Darmstadt, Germany) was dissolved in sterile aqua bidest to a 
final volume of 100 ml according to a 1 M MnCl2 concentration. The 1 M MnCl2 solution was 
sterile-filtered and aliquots were pipetted into CT1258 cell culture flasks and mixed with the 
respective volume of culture medium (Medium 199 (Gibco, Karlsruhe, Gemany) 20 % heat-
inactivated fetal calf serum (PAA Laboratories GmbH, Coelbe, Germany), 200 U/ml (U; unit) 
penicillin and 200 ng/ml streptomycin (Biochrom AG, Berlin, Germany)) to a final volume of 
5 ml. Labelling of the cells was performed with the following MnCl2 concentrations: 0.02 M, 
0.025 M, 0.03 M, 0.035 M, 0.04 M, and 0.045 M. Incubation was performed for 1.5 h at 37°C 
and 5% CO2. Cells which were labelled with of 0.035 M were also incubated for 3 h, 4 h, 5 h, 
6 h and 24 h at 37°C and 5% CO2. After incubation the labelling medium was discarded and 
the cell layer washed with PBS and the cells further cultivated over night in culture medium at 
37°C and 5% CO2.  
 
In vitro labelling of CT1258 cells with SPIOs 
The superparamagnetic nanoparticle labelling was performed with Endorem infusion 
suspension (Guerbet S.A., Roissy, France). According to an established protocol 5x106 cells 
were transferred in a culture flask with 5 ml culture medium and 41.15 μl Endorem solution 
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according to 130 pg iron oxide nanoparticles per cell. The cells were incubated over night at 
37°C and 5% CO2.  
 
Cell vitality assay 
0.5 g Trypane-blue (Sigma Aldrich, Munich, Germany) and 0.9 g NaCl (AppliChem, 
Darmstadt, Germany) were filled up to 100 ml with aqua bidest and the solution was sterile-
filtered. Following, 500 μl of a sterile 0.5 % solution of Trypane-blue and PBS were used for 
the cell staining in a cell culture flask. After 10 min incubation at room temperature the 
Trypane-blue solution was discarded, the cell layer washed with PBS and the cells trypsinised 
with 1 ml TrypLE Express (Invitrogen, Karlsruhe, Germany) and the cell number was 
determined.  
 
Cell proliferation assay 
5x104 MnCl2 labelled cells/well were transferred into a 96 well plate (BD Falcon, Heidelberg, 
Germany) and incubated for 24 h in 100 μl culture medium at 37°C and 5 % CO2. As control, 
unlabelled cells were co-incubated. Cell proliferation was evaluated using the Cell 
Proliferation ELISA, BrdU (colorimetric) kit according to the manufacturer’s instructions 
(Roche Diagnostics, Mannheim, Germany). The measurements and data analyses were 
performed with Synergy 2 multi-mode microplate reader and the Gen5TM software (BioTek, 
Bad Friedrichshall, Germany). 
 
Agar phantom construction 
A 1% agar (Invitrogen, Karlsruhe, Germany) gel solution was filled half-full into an empty 
pipette tip box (Greiner Bio-One, Frickenhausen, Germany) and an unskirted 96 well PCR 
plate (Eppendorf, Hamburg, Germany) was embedded onto the agar solution, so that after 
polymerization of the agar gel and removing of the plate, sample wells were formed. The 
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labelled cells were trypsinised, the cell number was determined, aliquoted into 1.5 ml cups 
(Eppendorf, Hamburg, Germany) and finally pelleted. The following cell numbers of either 
MnCl2 or SPIOs labelled cells were used: 7x105, 2.5x105, 105, 5x104, 2.5x104, 104, 5x103, and 
103. As controls 1 μl 1M MnCl2 solution, 1 μl Endorem solution, 105 unlabelled cells and 30 
μl culture medium were used. The cell aliquots and controls were mixed with 30 μl hand 
warm 4% gelatine solution and the gelatine-sample solution was pipetted into the wells of the 
polymerised agar phantom, the air bubbles were removed and the phantom was cooled down 
for 10 min at 4°C. The phantom was covered with 1 % agar gel and air bubbles were 
removed. The phantom was stored at 4 °C until the agar gel polymerised and the plastic box 
was removed prior to MRI scans. 
Animals
This study involved 20 NOD.CB17-Prkdcscid/J mice (6 female, 14 male). Nine animals were 
castrated or ovariohysterectomized (3 female, 6 male) while 11 animals remained intact. All 
animals were bred and maintained in a protected environment at the Institute of Laboratory 
Animal Science of the Hanover Medical School. Mice were fed autoclaved food and water ad
libitum, any manipulation was performed in a laminar flow hood. The animals were observed 
on a daily basis and euthanized depending on the clinical condition and the size of detectable 
tumor, respectively. The tumors were allowed to grow up to a diameter of 10-20 mm. 
Additional criteria for euthanasia were ulceration of subcutaneous masses, reduced activity of 
the mice and the loss of appetite. The animals were humanely euthanized by exsanguination 
after inhalation of >70% CO2. The study was approved by the Lower Saxony State Office of 
Consumer Security and Food Safety (33-42502-05/950). 
 
 
 
 10
Inoculation of cells 
The labelled cells were trypsinised and the cell number was determined. Aliquots of the 
required cell number/animal (either 103 or 104 cells) were transferred into 1.5 ml cups. The 
cells were centrifuged for 10 min at 1,000 rpm and the cell pellet washed twice with sterile 
PBS. The cell pellets were resuspended in 200 μl sterile PBS, aspirated into Insulin-Syringes 
(BD Micro-Fine, BD, Heidelberg, Germany), and injected sc into the abdominal flank of the 
respective animals.  
Altogether 19 animals (6 female, 13 male) were inoculated with 103 (6 female, 8 male) or 104 
(5 male) MnCl2 labelled cells and one male animal was inoculated with 104 SPIOs labelled 
cells.  
 
Autopsy and histological staining 
Animals were autopsied immediately after euthanasia. Brain, heart, kidneys, liver, lung, 
mesenterial lymph nodes, pancreas, salivary gland, spleen, and detected tumor masses were 
removed and fixed in 4% buffered formalin (pH 7.2). After dehydration (Shandon 
Hypercenter, XP), the samples were embedded in paraffin. Sections (4 μm thick) were 
deparaffinised with xylene and hematoxylin and eosin stained. 
 
MRI Scans 
The agar phantom containing MnCl2 and SPIOs labelled cells was scanned with a clinical 1 T 
MRI system (Siemens Magnetom Expert, Erlangen, Germany) and data was analyzed with 
dicomPACS version 5.2 (Oehm and Rehbein, Rostock, Germany). T1 weighted MRI scanning 
parameters were as follows: pulse repetition time (TR) = 330 ms, echo time (TE) = 12 ms, flip 
angle (FA) = 90°, slice thickness (ST) = 3 mm. T2* weighted MRI scanning parameters were: 
TR = 800 ms, TE = 26 ms, FA = 20°, ST = 2 mm.  
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In vivo MR Imaging was performed on a 7T Bruker Pharmascan 70/16 (Bruker Biospin, 
Ettlingen, Germany) under Paravision 5.0 equipped with a 6 cm Volume Resonator. 
Anaesthesia of the animals was maintained during the MRI scans with a concentration of 1- 2 
% isoflurane and the body temperature was held at approximately 37 °C using a temperature 
control unit (Small Animal Instruments, Stony Brook, NY, USA). The animals were divided 
into two groups. The first group consisted of two male animals receiving 104 cells which were 
labelled with MnCl2 or SPIOs. The respective cells were injected sc into to the left abdominal 
flanks of both animals. The scan parameters were as follows: Fast Spin Echo (FSE) T1: TR = 
1300 ms, TE = 9.5 ms, ST = 1 mm; FSE T2: TR = 2500 ms, TE= 36 ms, FA = 180°; (Turbo) 
Rapid Acquisition with Relaxation Enhancement (RARE) T2: TR = 2500 ms, TE = (eff) 36 
ms, FA = 180°, ST = 1 mm; T2*: Multi Gradient Echo (MGE) TR = 2000 ms, TE = 9 ms, 
FA= 30°, ST= 1 mm. The second group consisted of 18 animals (6 female, 12 male) which 
received either 103 or 104 MnCl2 labelled cells. The cells were injected sc into the right 
abdominal flanks of the animals. The scan parameters were as follows: RARE T1: TR = 1300 
ms, TE = 9 ms, ST = 1 mm; (Turbo) RARE T2: TR = 2500 ms, TE = (eff) 36 ms, FA = 180°, 
ST = 1 mm. 
 
MRI data analysis 
Analysis of the MRI image data was performed with the ITK-SNAP 2.1.4-rc1 software37 
which was downloaded from http://www.itksnap.org/. The analyses of tumor sizes were 
performed by manual segmentation in three orthogonal planes at once and for every tumor, 
the size in [mm3] was determined threefold. The mean value was claimed as tumor size.  
 
Results
Cultivation and labelling of CT1258 cells with MnCl2 and SPIOs, cell vitality and cell 
proliferation assays 
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Cell vitality tests were performed 24 h after the respective labelling reactions. Labelling for 
1.5 h with 0.02 M to 0.04 M MnCl2 revealed the percentages of living cells ranging from 91.7 
% to 23 % (tab. 1). The control cell culture flask with unlabelled CT1258 cells revealed 95 % 
of living cells (tab 1). Cells labelled with 0.035 M MnCl2 for different time periods ranging 
from 1.5 h to over night revealed the vitality percentages ranging from 89% to 37% 24 h after 
the respective labelling reactions (tab 2). Control unlabelled CT1258 cells revealed 98 % of 
living cells (tab 2). 
Cell proliferation levels measured after cell labelling with 0.035 M MnCl2 for 1.5 h and 
subsequent incubation for 24 h in culture medium revealed the mean value 0.09413 for the 
labelled cells and mean value of 0.1128 for the untreated control cells showing no noticeable 
difference. The mean value was calculated from 16 measured values of each the labelled cells 
and control cells.  
 
MRI scans 
Agar phantom 1T MRI scans 
In T1 weighted MRI a strong signal enhancement for the MnCl2 positive control (1 M MnCl2 
solution) was detected. The MnCl2 labelled cells were visible to a detection limit of 105 
cells/well (figure 1 A). In T2* weighted MRI the MnCl2 labelled cells were indistinguishable 
to the applied control cells and the culture medium (figure 1 B). 
Cells labelled with SPIOs were indistinguishable to the control cells and the culture medium 
in T1 weighted MRI scan (figure 2 A). The T2* weighted MRI scan detected a strong signal 
extinction for the SPIOs positive control which was the Endorem solution. The SPIOs 
labelled cells could be detected to a limit of 105 cells due (figure 2B).  
In vivo 7T MRI scans 
In a first group two male animals were scanned which were inoculated with 104 cells. The 
injected cells were labelled with either SPIOs or MnCl2. The measurements were performed 
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on the first day then 4 days, 9 days, 15 days and 28 days after inoculation. Figure 3 displays 
the FSE T1 (3 A) and FSE T2 (3 B) weighted in vivo MRI scans of the animal which received 
104 MnCl2 labelled cells at the day of injection (day 1). Figure 4 displays FSE T1 (4 A), FSE 
T2 (4 B) and FISP T2* (4 C) weighted in vivo MRI scans of the animal which was inoculated 
with 104 SPIOs labelled cells at the day of injection (day 1). Figure 5 displays the in vivo MRI 
scans of both animals at the days 1 (5 A and E), 4 (5 B and F), 9 (5 C and G) and 28 (5 D and 
H) after injection.  
The MnCl2 labelled cells were detectable due to a signal enhancement at day 1, 4 and 9 after 
injection in T1 weighted MRI (figure 5 A, B and C). The cells were not detectable in T2 and 
T2* weighted MRI (data not shown). In the subsequent MRI scans (day 15, day 28) the cells 
could not be detected. At day 28 a tumor mass at the left flank was observed (5 D).  
SPIOs labelled cells could be detected at the days 1 and 4 after the injection in T2 weighted 
MRI due to a signal extinguishment (5 E and F). In the subsequent MRI measurements (9 
days, 15 days and 28 days after injection) the labelled cells could not be detected as shown in 
figure 5 at day 9 after injection (figure 5 G). This animal did not develop a tumor mass at the 
site of injection (5 H).  
The subsequent in vivo MRI scans of the second animal group (n=18) were performed with 
mice which were inoculated with either 103 or 104 MnCl2 labelled cells. This second group of 
animals was divided into two subgroups. In the first group, we scanned eight animals (4 
castrated male mice, 4 intact male mice) on the days 1, 4, 8, 10, 15, 17, 22, 24 and 43 after 
inoculation. Figure 6 A shows a T1 weighted MRI scan of a male animal 24 days after 
injection (day 24) that developed a tumor at the site of injection. At day 43, three animals 
were left which were scanned. In the second subgroup (3 ovariohysterectomized female mice, 
3 intact female mice, 2 castrated male mice, 2 intact male mice) the MRI scans were 
performed on the following days after injection: 2, 10, 16, 23, 25, 39, 47, 53, 60, 67 whereas 
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the scans from day 47 up to day 67 were performed in two remaining animals which showed 
at this time still good health conditions.  
In the first subgroup, at day 1 after injection, in all animals (n=8) the labelled cells could be 
detected due to strong signal enhancement in T1 weighted MRI. At the days 4, 8 the number 
of the animals in which cells could be detected decreased and on day 10 two remaining 
animals showed slight signal enhancements indicating the location of the injected cells. 
Tumors could be detected starting with day 17 after injection and were observable prior to 
palpation. In all eight animals, tumors could be detected prior to palpation in T1 and T2 
weighted MRI scans.  
In the second subgroup (n=10) on day 2 after injection in nine animals the cells could be 
detected due to signal enhancement. At days 10 and 16 the number of animals decreased to 
remaining two animals at day 16 in which slight signal enhancements could be detected 
implicating the presence of MnCl2 labelled cells. From day 23 up, tumors were detected which 
developed subcutaneously in the abdominal flanks of the animals whereas five from ten 
animals developed tumors within this subgroup. The tumors could be detected in T1 and T2 
weighted MRI and were measurable prior to palpation.  
 
Analysis of the tumor volumes 
Tumor volumes were analyzed of the animals which were part of the second group of the in 
vivo MRI scans. In 13 of total 18 animals, subcutaneous tumors developed at the site of 
injection. Subdivision of the animals into groups regarding the gender and cell number 
injected, we detected in all male animals (n = 4) which received 104 cells tumors at the site of 
injection (100%). Injection of 103 cells led in 4 female (66%) and 5 male (62.5%) animals to 
tumor growth from a total of 6 female and 8 male animals. The increment of the tumor 
volume in [mm3/day after injection] was analyzed for each gender and cell number injected 
separately and is represented in graphs 7 and 8. The values for each animal are shown in the 
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supplementary tables 1, 2, and 3. The animals were numbered from 1 to 13. Graph 7 A and 
supplementary table 1 show the increment of tumor growth of mice 1 to 4. The male mice 
were inoculated with 104 cells, mice 1 and 2 were intact, and mice 3 and 4 were castrated. At 
day 17 the tumor volumes varied from 1.03 mm3 to 5.26 mm3 and at day 24 which was the 
volumes ranged from 39.74 mm3 to 276.16 mm3. In mouse 4 in both abdominal flanks tumors 
developed due to an incorrect injection.  
Graph 7 B and supplementary table 2 display the increment of tumor growth analysed in the 
male mice 5 to 9 which received sc injections of 103 cells. Mice 5, 6 and 7 were intact and 
mice 8 and 9 were castrated. Within this animal group, firstly in animal 8 at day 17 a tumor 
was detected with a size of 8.165 mm3 while the remaining animals 5, 6, 7, and 9 developed 
tumors which could be detected at day 22 and the sizes ranged from 0.53 mm3 to 11.27 mm3 
The MRI scans were performed till day 66 in animal 7 while the majority of the animals was 
scanned for the last time at day 43 showing tumor sizes ranging from 699.19 mm3 to 1,928.83 
mm3.  
Graph 8 and supplementary value table 3 display the tumor growth in the female mice 10 to 
13 which received 103 cells. Mice 11 and 12 were intact and mice 12 and 13 were 
ovariohysterectomized. At day 24 in three animals out of four, tumors were detected with a 
size ranging from 5.16 mm3 to 19.48 mm3. At day 47 animal 11 remained which developed a 
tumor with a volume of 3.6 mm3 while the majority of the animals were scanned at day 39 for 
the last time and the tumor sizes analyzed ranged from 1.18 mm3 to 420.45 mm3.  
 
Autopsies and histological analyses
Histological analyses of the extracted organs and tumor masses were performed in the animals 
1 to 13. The tumor diameters varied form 10 till 20 mm and all of the tumors were located 
subcutaneously and were non-adhesive to the surrounding tissue. Some of them developed 
ulceration that was a criterion for euthanasia. Except for animal 5, the animals showed no 
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signs of metastasis or of invasive growth. Histological analysis of the tumors showed 
pleomorphic cells with a high mitotic index (figure 6 C and D). The centres of the obtained 
tumors were highly necrotic (figure 6 C). Most of the tumors infiltrated into the subcutaneous 
and fat tissue (figure 6 D) and some tumors developed an incomplete fibrous capsule partly 
demarcating the tumor from the surrounding tissue.  
Discussion
A considerable disadvantage of the use of manganese for in vitro cell labelling is its cellular 
toxicity and thus a dose as low as possible but still high enough to produce a robust MRI 
contrast was necessary.27 Different concentrations of MnCl2 and time periods for cell labelling 
were tested. Incubation of approximately 1x107 cells with 0.035 M MnCl2 and a time period 
not exceeding 1.5 h was evaluated to be suitable for cell labelling without significant toxic 
effects as no significant difference between the vitality and cell proliferation of labelled and 
unlabeled control cells was measured. Concentrations of MnCl2 and incubation times 
exceeding these parameters led to significant toxic effects in the cell metabolism showing low 
vitality levels. The labelling parameters reported for human lymphocytes, embryonic stem 
cells and bone marrow stromal cells differed as those of the recent study. The concentrations 
of the labelling MnCl2 solutions were lower (ranging from 0.1-0.5 mM), the incubations did 
not exceed 30-60 min and - despite of the lymphocytes with a cell number of approximately 
24x106 - the cell numbers were 3x106.23, 31-33 These labelling reactions were uniformly 
performed in 0.9% sodium chloride solutions, whereas the labelling reactions within the 
present study were performed in culture medium. This might have enabled the higher 
concentrations of MnCl2 for labelling without toxic effects. During the respective labelling 
reactions, the cells remained in a buffered medium system and were supplied with nutrients, 
ensuring their viability.  
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MRI scans of the agar phantom revealed the same cell number detection limit accounting 
1x105 cells/well for both labelling reagents, MnCl2 and SPIOs, respectively. In the literature 
lower numbers of SPIO labelled cells were detected in contrast to the present study (as 
reviewed for example in20, 38). Regarding direct MnCl2 cell labelling and in vitro detection, the 
cell numbers applied by other groups were higher than those within the present study 
accounting mostly more than 1x106 cells and the magnetic fields of the MRI systems used, 
were higher than 1T.23, 31-34, 36 However, within those studies, the limit of labelled cells for 
MRI detection was not tested but the manganese concentration or the relaxation properties in 
contrast to our study, with variable cell numbers labelled with the same manganese 
concentration. Nevertheless, our study could show that cell numbers lower than those already 
reported were sufficient for MRI detection in an agar phantom.  
Within the MRI scans of the first animal group (two animals inoculated with each 104 cells) 
the manganese labelled cells were longer detectable than the SPIOs labelled cells. The MnCl2 
labelled cells were locatable due to a positive hyperintense signal until nine days after 
injection in T1 weighted MRI. The cells were not detectable in T2 and T2* weighted MRI 
scans and thus false positive interpretation about the position of the cells within the animal 
could be excluded. SPIOs labelled cells could be detected till four days after the injection in 
T2 and T2* weighted MRI due to a signal extinguishment. In the following days no exact 
distinction of the cells and the surrounding could be made. Generally, SPIOs generate a loss 
of signal on MRI and depending on the localization it is difficult to distinguish the signal 
voids caused by SPIOs from other sources of hypointense MRI signal such as motion 
artifacts, susceptibility artifacts, bleeding/hemosiderin, calcification, water-fat interfaces, or 
air.23, 35, 36 As we injected the cells sc in the abdominal flank of the animals, signal voids 
caused by SPIOs but also by water-fat interfaces or blood for example could not be 
distinguished from each other. Thus, we decided to use manganese as labelling agent for the 
subsequent in vivo MRI scans in the second group of animals. Moreover, as manganese is 
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transported actively through Ca2+ channels into biologically active cells, MRI enables 
correlation between cellular viability and a T1-weighted positive signal.23 Thus the 
assessment of information about the localization and survival of transplanted cells like for 
example in injured myocardium was possible.31-33 Accordingly, within the present study, we 
were able to determine the vitality and localization of the injected CT1258 cells coincidently. 
SPIO labelling in contrast, does not provide any biologic information of the labelled cells, as 
it is also up taken non-specifically by macrophages of the residual SPIOs particles in the 
surrounding tissue from dead SPIO-labelled cells.23, 33 After multiple cell division and death 
of manganese labelled cells, Mn2+ diffuses passively out of these cells resulting in reduced 
T1-shortening effect and loss of contrast effect.23, 36 This was also observed during our present 
study, as we could detect a decrease of signal intensity following by a signal loss after nine 
days within the respective animal of the first group. In the second group of altogether 18 
animals, the results were comparable. MRI scans performed directly after injection showed 
despite of one animal, strong positive T1-weighted signal at the site of injection. During the 
following two weeks, the number of animals in which manganese labelled cells could be 
detected decreased drastically and in only two remaining animals, slight signal enhancements 
after 10 to 16 days could be detected. In a study by Chung et al.23 MnCl2 labelled human 
embryonic stem cells (hESC) injected in murine hind limb were detected till four to five days 
after injection. These scans were performed in a 3T clinical scanner whereas our scans were 
performed in a 7T system which might have led to the detection of manganese after two 
weeks in two remaining animals. Nevertheless, in most of the animals the MnCl2 labelled 
cells were detected during the first five days after injection comparable to the findings 
reported.23 Regarding the cell number injected (103 and 104) no significant correlation 
between cell number and signal intensity was observed. Within a total of 18 animals which 
were part of the second group of animals, in 13 animals tumors developed which mimicked 
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the natural behaviour of the original tumor showing that the MnCl2 labelling performed did 
not altered the biological activity and characteristics of CT1258 cells.  
Depending on the cell number injected, in 100% of the male mice which received 104 cells 
tumors developed, in contrast to animals inoculated with 103 cells, there 66% of the female 
and 62.5% of the male mice developed subcutaneous tumor masses indicating a cell dose 
dependent impact on tumor development. In the first in vivo study of CT1258 cells 
inoculation of 106 CT1258 cells led to tumor development in 100% of the female and 75% in 
the male mice14 showing higher percentages for the female mice than in the present study. 
However, the higher cell numbers injected within this study compared to the present should 
be considered. Additionally no dose dependence could be observed and it was suggested that 
even lower numbers than 105 could be sufficient for tumor development.14 In the present 
study, we could show that 104 and 103 cells were sufficient to induce tumor growth whereby 
the higher cell number showed a higher incidence rate and faster tumor progression.  
Within the first study by Fork et al. the tumor development was analyzed via palpation 
whereby the tumors were allowed to grow to a size ranging from 5 to 8 mm which lasted 20 to 
24 days in the male and 20 to 42 days in the female mice after sc injection of 106 cells.14 In 
the present study, due to the use of 7T MRI, the tumors could be detected prior to palpation 
and in some cases earlier than 20 days after injection although lower cell numbers were 
applied.  
Furthermore, the comparison of the tumors in the male animals showed a correlation between 
cell number injected and the tumor size and disease progression. Animals of both sexes which 
received 103 cells developed tumors after comparable time periods ranging from 17 to 25 days 
following injections. A significant gender-dependent and hormone-status dependent effect on 
tumor size and progression was not determined. The canine prostate cancer cell lines Ace-1, 
and Leo did not expressed the androgen receptor17, 18 suggesting that testosterone is not 
essential factor for growth and survival of the carcinoma cells. Furthermore, there was no 
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difference in the growth, invasion, and metastasis of the ACE-1 cells in female nude mice to 
male mice.17 The growth of canine cell line DPC-1 was independent of androgen stimulation 
and in the canine cell line CPA-1 either androgens or estrogens modified the growth.15, 16 
Thus, the determination of a possible existing hormone dependency of the CT1258 cell line 
would need a separate study with focus on a statistical required number of animals. 
Comparable to the findings made by Fork et al.14 none of the animals of the present study 
developed metastases which might have been caused by the fast tumor progression leading to 
euthanasia of the animal after a relative short time period. Additionally there seems to be a 
low disposition of CT1258 to metastasise. The CT1258 cell line was established from a 
prostate carcinoma of a 10 year old dog and despite of several small metastases in the 
mesentery no signs of abnormalities were found in the heart, lung, testicles and lymph nodes 
after euthanasia.13  
The histological analysis of the tumor masses showed cells with a characteristic appearance 
and morphology of a prostate adenocarcinoma, comparable to the findings which were 
reported during establishment of the cell line.13, 14  
In conclusion, cells of the canine cell line CT1258 were successfully labelled with MnCl2 and 
SPIOs and could be detected in vitro and in vivo via MRI. This is a first study reporting 
MnCl2 labelling and in vivo tracing of prostate cancer cells. In 7T MRI in vivo scans, cells 
labelled with MnCl2 could be detected during a longer time period after injection than SPIOs 
labelled cells. The MnCl2 labelled CT1258 cells were highly tumorigenic in male and female 
NOD-scid mice and showed a correlation of number of injected cells (104 vs. 103) with tumor 
size and disease progression within the animals. Histological analyses of the obtained tumors 
showed the same characteristics of the original tumor. CT1258 cells represent a valuable in
vivo model for canine prostate cancer. A CT1258 based therapeutic strategy would be of 
benefit for both species humans and dogs due to their similarities in disease presentation and 
progression.  
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Figure legends 
Figure 1: 
1T MRI scan of MnCl2 labelled CT1258 cells in a 1 % agar phantom.  
The following numbers of MnCl2 labelled cells were applied: 7x105, 2.5x105, 105, 5x104, 
2.5x104, 104, 5x103, and 103. As controls 1x105 unlabelled cells, the culture medium, and 1 M 
MnCl2 solution were used. A: T1 weighted MRI scan. Wells loaded with the control 1 M 
MnCl2 solution showed a strong signal enhancement. The labelled cells were detected to a 
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limit of 105 cells. Wells loaded with lower cell numbers did not differ to the control 
unlabelled cells and culture medium. B: T2* weighted MRI scan. Wells loaded with labelled 
cells, the controls with unlabelled cells and the culture medium showed comparable signals.  
 
Figure 2: 
1T MRI scan of SPIOs labelled CT1258 cells in a 1 % agar phantom.  
The following numbers of SPIOs labelled cells were applied: 7x105, 2.5x105, 105, 5x104, 
2.5x104, 104, 5x103, and 1x103. As controls 1x105 unlabelled cells, the culture medium, and 
the Endorem solution were used. A: T1 weighted MRI scan. Wells loaded with labelled cells, 
the controls with un-labelled cells and the culture medium showed comparable signals. B: 
T2* weighted MRI scan. Wells loaded with the Endorem solution showed strong signal 
extinction. The labelled cells were detected to a limit of 105cells. Wells loaded with lower cell 
numbers did not differ to the control unlabelled cells and culture medium. 
 
Figure 3: 
7T MRI scans of a male NOD-scid mouse after subcutaneous injection of 104 CT1258 
cells labelled with MnCl2  
The MRI scans were performed at the same day after injection (day 1). A: FSE T1 weighted 
MRI Scan. B: FSE T2 weighted MRI scan. Arrows: localization of the injected MnCl2 
labelled cells in T1 (A) and T2 (B) weighted MRI. In T1 weighted MRI (A) the MnCl2 
labelled cells were detected due to a strong signal enhancement. 
 
Figure 4: 
7T MRI scans of a male NOD-scid mouse after subcutaneous injection of 104 CT1258 
cells labelled with SPIOs  
The MRI scans were performed at the same day after injection (day 1).  
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A: FSE T1 weighted MRI Scan. B: FSE T2 weighted MRI scan. C: FISP T2* weighted MRI 
scan. Arrows: localization of the injected SPIOs labelled cells in T1 (A), T2 (B) and T2* (C) 
weighted MRI. In T2 (B) and T2* (C) weighted MRI the SPIOs labelled cells were detected 
due to a strong signal extinguishment. 
 
Figure 5 
Longitudinal in vivo 7T MRI scans of two male NOD-scid mice after subcutaneous 
injection of 104 CT1258 cells labelled with either MnCl2 or SPIOs at the day 1, 4, 9 and 
28 after injection.
A-D: in vivo MRI scans of the animal which received MnCl2 labelled cells. A: FSE T1 
weighted MRI scan at the day of injection (day 1). B: FSE T1 weighted MRI scan at day 4 
after injection. C: FSE T1 weighted MRI scan at day 9 after injection. D: FSE T1 weighted 
MRI scan at day 28 after injection. The MnCl2 labelled cells were not detectable and a tumor 
mass developed at the site of injection.  
E-H: in vivo MRI scans of the animal which received SPIOs labelled cells. E: FSE T2 
weighted MRI scan at the day of injection (day 1). F: Turbo RARE T2 weighted MRI scan at 
day 4 after injection. G: Turbo RARE T2 weighted MRI scan at day 9 after injection. The 
cells were not detected and there were no signs of tumor development. H: FSE T1 weighted 
MRI scan at day 28 after injection.  
Arrows: localization of labelled cells. 
Figure 6 
T1 weighted MRI scan, three dimensional reconstruction and histological analyses of a 
tumor induced by injection of MnCl2 labelled CT1258 cells into a male NOD-scid mouse 
A: RARE T1 weighted in vivo MRI scan 24 days after sc injection of the labelled cells. On the 
right abdominal flank, a tumor mass developed. No signs of metastasis were detected. B: 
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Three dimensional graphical analyse of the tumor structure 24 days after injection of the 
labelled cells. C and D: Histological analysis of the obtained tumor mass. The obtained tumor 
showed the characteristic appearance and morphology of a prostate adenocarcinoma. The 
analysis displayed pleomorpic cells with a high mitotic index. The centre of the obtained 
tumor was highly necrotic and the tumor infiltrated into the subcutaneous and fat tissue. The 
tumor developed an incomplete fibrous capsule partly demarcating the tumor from the 
surrounding tissue and ulceration.  
 
Figure 7 
Analysis of the increment of tumor volume detected via 7T in vivo MRI in a CT1258 
based in vivo model of prostate cancer 
A: 104 labelled cells were injected sc into four male NOD-scid mice. The animals were 
numbered from 1 to 4, animals 1 and 2 were intact and animals 3 and 4 were castrated. B: 103 
labelled cells were injected sc into five male NOD-scid mice. The animals were numbered 
from 5 to 9, animal 5, 6 and 7 were intact and the animals 8 and 9 were castrated.  
White bars: Tumor volumes of the intact animals. Black bars: Tumor volumes of the castrated 
animals. The animal number is written in brackets following to the day of MRI scan after sc 
injection.  
 
Figure 8 
Analysis of the increment of tumor volume detected via 7T in vivo MRI in a CT1258 
based in vivo model of prostate cancer 
103 labelled cells were injected sc into four female NOD-scid mice. The animals were 
numbered from 10 to 13, animal 10 and 11 were intact, and animals 12 and 13 were 
ovariohysterectomized. White bars: Tumor volumes of the intact animals. Black bars: Tumor 
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volumes of the ovariohysterectomized animals. The animal number is written in brackets 
following to the day of MRI scan after sc injection of the CT1258 cells. 
 
Tables
Table 1: 
Trypane-blue based cell vitality test after labelling of CT1258 cells with different 
concentrations of MnCl2 for 1.5 h 
Concentration
of MnCl2 [M] 
Cell vitality [%]
0 (control) 95 
0.02  91.7 
0.025  83 
0.03  91 
0.035  90 
0.04  32 
0.045  23 
 
Table 2: 
Cell vitality test after labelling of CT1258 cells with 0.035 M MnCl2 for different 
incubation times 
CT1258 cells were labelled with 0.035 M MnCl2 for different incubation times at 37°C and 
5% CO2. After labelling the cells were further cultivated over night in culture medium at 37°C 
and 5% CO2. Cell vitality test was performed with Trypane-blue dye.  
Incubation time [h] Cell vitality [%]
0 (control) 98 
1.5 89 
3 86 
4.5 81 
6 80 
Over night 37 
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Supplement
Supplementary Table 1: 
Analysis of tumour volumes detected via 7T in vivo MRI in a CT1258 based in vivo
model of prostate cancer 
The male animals received 104 MnCl2 labelled cells. The tumour volumes are displayed for 
the respective days of MRI measurements after subcutaneous injection. In animal 4 on the left 
and right abdominal flank tumour masses developed due to an incorrect injection of cells.  
? = male animal 
Animal Day 17; 
Tumour volume [mm3]
Day 22; 
Tumour volume [mm3]
Day 24; 
Tumour volume [mm3]
1
(?, intact) 
5.22 124.02 276.13 
2
(?, intact) 
5.26 71.90 148.58 
3
(?, castrated) 
1.61 40.59 66.14 
4
(?, castrated) 
2.12 
1.03 
120.51 
32.70 
39.74 
69.87 
 
Supplementary Table 2: 
Analysis of tumour volumes detected via 7T in vivo MRI in a CT1258 based in vivo
model of prostate cancer 
The male animals received 103 MnCl2 labelled cells. The tumour volumes are displayed for 
the respective days of MRI measurements after subcutaneous injection. 
? = male animal 
Animal Day 17; 
Tumour
volume
[mm3]
Day 22; 
Tumour
volume
[mm3]
Day 24; 
Tumour
volume
[mm3]
Day 25; 
Tumour
volume
[mm3]
Day 39; 
Tumour
volume
[mm3]
Day 43; 
Tumour
volume
[mm3]
Day 53; 
Tumour
volume
[mm3]
Day 59; 
Tumour
volume
[mm3]
Day 66; 
Tumour
volume
[mm3]
5
(?, intact)
 7.26 13.42       
6
(?, intact)
 0.531 11.78   699.19    
7
(?, intact)
   1.37 1.51  2.14 11.43 36.50 
8
(?, 
castrated)
1.65 11.27 24.72   1,928.83    
9
(?, 
castrated)
 8.66 32.42   1,533.26    
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Supplementary Table 3: 
Analysis of tumour volumes detected via 7T in vivo MRI in a CT1258 based in vivo
model of prostate cancer 
The female animals received 103 MnCl2 CT1258 labelled cells. The tumour volumes are 
displayed for the respective days of MRI measurements after subcutaneous injection.  
? = female animal; OHM=Ovariohysterectomized 
Animal Day 23; 
Tumour volume 
[mm3]
Day 25; 
Tumour volume [mm3]
Day 39; 
Tumour volume [mm3]
Day 47; 
Tumour volume [mm3]
10
(?, intact)
5.16 10.76 420.45  
11
(?, intact)
 1.33 1.18 3.60 
12
(?, OHM)
8.73 12.3 271.19  
13
(?, OHM)
19.48 29.75 148.65  
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Tumourvolume after subcutaneous injection of 104 CT1258 cells labelled with 
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Tumourvolume after subcutaneous injection of 103 CT1258 cells labelled with 
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4.?Discussion?
The?receptor?RAGE?and? its? ligand?HMGB1?were?described?to?play?an? important?role?during?
tumour? progression.? The? RAGE/HMGB1? complex? regulates? migration,? motility? and?
invasiveness?of?tumour?cells.?Blocking?of?this?complex?resulted?in?diminished?tumour?growth?
(Taguchi? et? al.,? 2000)? and? displays? a? valuable? target? in? tumour? therapy.? Besides?HMGB1,?
further?members? of? the?HMG? family?were? associated?with?many? tumour? types? including?
HMGA1? and? HMGA2.? HMGA1? and? HMGA2? represent? genes? that? are? highly? expressed? in?
embryonic? tissues?while? their? expression? is? very? low? or? absent? in? adult? tissues.? Their? re?
expression?was?reported? in?many?tumour?types.?Therapies?targeting?the?knock?down?of?the?
expression? levels? are? therefore? of? great? impact? in? cancer? treatment.? In? this? context,?
appropriate?animal?models?of?cancer?are?of?great?value?and?the?dog?represents?a?powerful?
model?as?it?shares?many?similarities?with?humans.?Thus,?within?this?thesis,?the?canine?RAGE?
gene?and?protein?were?characterised?and?expression? studies?of? the?canine?RAGE,?HMGB1,?
HMGA1? and? HMGA2? were? analysed? in? several? tumour? types? as? precondition? for? the?
establishment?of?tumour?therapies?targeting?the?expression?of?these?genes.??
The?analysis?of?the?canine?RAGE?gene?and?protein?structure?showed?high?similarities?to?the?
correspondent? human? structures? indicating? RAGE? to? be? evolutionary? highly? conserved?
between? both? species.? The? genomic? structure? of? the? RAGE? gene? showed? the? same?
exon/intron?organisation?for?both?species.?Moreover,?the?5´UTR?showed?a?100%?similarity?to?
the?human?counterpart?suggesting?similar?mechanisms? in?the?regulation?of?translation?and?
protein?biosynthesis?within?both?species.?The?comparison?of?the?human?(NM_00136)?and?the?
canine?CDS?(NM_001048081)?to?the?corresponding?rodent?CDSs?of?the?rat?(NM_05336)?and?
the?mouse?(NM_007425)?revealed?the?highest?similarity?between?humans?and?dogs?(82.5%)?
followed?by?mice?(75.7%)?and?rats?(71.5%).?The?comparison?of?the?protein?structures?of?the?
abovementioned? species? to? the? human? RAGE? protein? (BAA89369)? revealed? the? highest?
similarity?index?accounting?77.6%?for?the?canine?protein?(AAX38183),?followed?by?73.5%?for?
the? murine? (AAH61182),? and? 72.8%? for? the? rodent? (AAA42027)? protein? pendants.?
Summarising,? the? canine?RAGE? shares?higher? similarities? in?genomic?and?protein? structure?
with? the? human? correspondents? than? the? common? rodent? animals? used? in? research.?
Interestingly,? within? the? ligand? binding? V?domain,? the?motif? of? the? HMGB1? protein? was?
shown?to?be?identical?in?humans?and?dogs?as?well?(Huttunen?et?al.,?2002a;?Murua?Escobar?et?
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al.,?2003).? Thus,? therapeutic? approaches? targeting? the?HMGB1/RAGE? complex? in?dogs? are?
likely?to?be?suitable?tools?in?terms?of?transferability?to?human?therapies.??
The?analysis?of?RAGE?transcript?isoforms?resulted?in?the?characterisation?of?24?canine?and?4?
human? previously? not? described? splicing? variants.? Remarkably,? the? insertion? of? intron? 1,?
among?other? insertions?and?deletions,?was? found? in?all?samples?analysed?with?exclusion?of?
non? neoplastic? testis? tissue.? Additionally,? varying? presence? of? the? respective? transcript?
variants?were?analysed? in?the?different?samples?that?were?part?of?the?study.?These?findings?
were? comparable? to? the? findings? reported? in?humans? showing?different? range?of? variants?
depending?on? the?sample?source? (Hudson?et?al.,?2008).?The?characterised? transcripts?were?
roughly?classified?into?two?main?groups.?The?first?group?contained?transcripts?that?coded?for?
the?wild?type?full?length?RAGE?and?a?putative?soluble?protein,?while?the?second?group?coded?
for?mutated?protein? isoforms? lacking?the?ability?to?bind?RAGE? ligands.?The?second?group?of?
isoforms?included?isoforms?with?insertion?of?intron?1?and?other?additional?modifications.?The?
sole?insertion?of?intron?1?would?lead?to?a?putative?membrane?bound?protein?isoform,?which?
is?not?able?to?bind? ligands?due?to?a?missing?part?of?the?V?domain.?Further?modifications?by?
insertions?or?deletions?of?other?exons?and? introns?or?parts?of?them?would? lead?to?proteins?
with? absent? or? defective? domains? leading? to? membrane? bound? or? non?sense? protein?
isoforms.?Taken?together,?the?modifications?characterised? indicate?truncated?RAGE?protein?
variants? acting? as? competitive? inhibitors? of? the? receptor? either? by? ligand? binding? (soluble?
RAGE)?or?displacing?the?full?length?receptor? in?the?membrane?(intron?1?containing?variants)?
or?mutated?non?sense?proteins.??
Interestingly,?two?transcript?isoforms,?which?were?found?in?the?canine?samples,?resembled?to?
the?human? isoforms?RAGE_v2?and?RAGE?_v3? (Hudson?et?al.,?2008).? In?canine?histiocytoma,?
malignant? lymphoma,? mastocytoma,? the? cell? lines? CT1258? and? ZMTH3? transcripts? with?
insertion? of? intron? 1? resembling? the? structure? of? the? human? variant? RAGE_v2? (formerly?
known?as?nt?RAGE,?N?RAGE,?N?truncated?RAGE)?were?detected,?while?the?canine?transcript?
corresponding?to?human?RAGE_v3?(formerly?known?as??8?RAGE)?was?found?in?non?neoplastic?
testis?tissue.?Thus,?similar?mechanisms? in?RAGE?splicing?can?be?assumed?due?to?resembling?
structures?of?transcript?variants?in?humans?and?dogs.?Bioinformatic?analyses?by?Hudson?et?al.?
(2008)?revealed?that?the?variants?RAGE_v2?and?RAGE_v3?represent?targets?of?the?nonsense?
mediated? decay? (NMD)? machinery? for? mRNA? degradation? inhibiting? the? expression? on?
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protein?level?(Khajavi?et?al.,?2006;?Hudson?et?al.,?2008).?Thus,?further?studies?will?be?needed?
to?analyse?if?the?splicing?forms?characterised?are?also?expressed?on?protein?level.?During?the?
performed? study,? Northern? Blots? using? commercially? available? human? RAGE? antibodies?
showed?unspecific?results?and?at?the?time?of?the?study,?no?specific?antibodies?for?the?canine?
RAGE?protein?or?protein?variants?were?available.?
Within? this? thesis,? real?time? expression? analyses? allowing? the? absolute? quantification? of?
“unsuspicious”? transcripts? and? “intron? 1”? transcripts?were? performed.? Thereby? “intron? 1”?
transcripts?contain?the?insertion?of?intron?1?while?“unsuspicious”?transcripts?do?not?show?this?
modification?between? the? first? two?exons.?Thus,? the?absolute? real?time?PCR?quantification?
displayed? a? sum? of? several? transcript? isoforms? that?were? characterised? by? one? of? these?
structures,? independently? from? further?downstream?modifications.?The?expression? level?of?
both?variants?was?shown?to?depend?on?the?sample?source?but?not?on?the?pathological?origin?
(non? neoplastic? vs.? neoplastic? tissues).? This? study? firstly? described? canine? RAGE? splicing?
variants? and? their? expression? pattern? in? healthy? and? non? neoplastic? tissues? and? further?
analyses? including? additional? real?time? PCR? analyses? allowing? a? differentiation? between?
distinct? isoforms?would?be?of? interest.?Similar?to?human?RAGE,?splicing?of?the?canine?RAGE?
gene?was? found? to? be? very? complex? and? the?mechanisms? are? still? not?well? understood.?
During?the?last?years,?the?number?of?studies?increased?measuring?the?circulating?RAGE?levels?
in? human? pathological? states? and? cancer? and? deregulations?were? associated?with? disease?
severity?and?progression?(Geroldi?et?al.,?2006).?Until?now,?reports?of?measurements?of?canine?
soluble? RAGE? serum? levels? in? pathological? states? are?missing? probably? due? to? a?missing?
specific?ELISA?assay?for?canine?soluble?RAGE?and?RAGE.?
In? humans? the? HMGB1/RAGE? complex? was? already? described? to? influence? invasiveness,?
growth?and?motility?of? tumour?cells? (Taguchi?et?al.,?2000)?and?expression?deregulations?of?
both?genes?were?described?in?many?cancers?(Sparvero?et?al.,?2009).?While?the?canine?HMGB1?
was?already?characterised?by?our?group?(Murua?Escobar?et?al.,?2003),?the?characterisation?of?
the? canine? RAGE? enabled? expression? analyses? of? the? HMGB1/RAGE? complex? in? canine?
neoplasias?for?the?first?time.?In?contrast?to?now,?during?the?first?years?of?this?thesis,?real?time?
PCR? assays? specific? for? canine? genes?were? not? commercially? available? and? therefore?we?
designed? specific? real?time?PCR?assays? in?order? to?perform?expression?analyses.?Regarding?
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HMGB1?and?RAGE,?we?studied?their?expression?in?neoplasias?including?canine?lymphoma?and?
canine?DHS?representing?neoplasias?of?haematopoietic?and?DC?origin.??
In?human?haematopoietic?tumours?such?as?non?Hodgkin’s?lymphoma?high?HMGB1?and?VEGF?
levels?were?described? indicating? increased?angiogenesis?and?the?VEGF? level?correlated?with?
overall?survival?and?event?free?survival?of?the?affected?patients?(Ribatti?et?al.,?1996;?Salven?et?
al.,?1997;?Bertolini?et?al.,?1999;?Salven?et?al.,?2000;?Molica?et?al.,?2002;?Meyer?et?al.,?2008).?In?
canine? lymphoma,?high?VEGF?expression?was? also?detected? indicating? similar?mechanisms?
and? the? involvement?of?pro?angiogenic? factors? in? canine? lymphoma?progression? similar? to?
those? in?human?non?Hodgkin’s? lymphoma? (Wolfesberger?et? al.,? 2007;?Meyer?et? al.,? 2010;?
Zizzo?et?al.,?2010).?Consistent?with?the?findings? in?human?non?Hodgkin’s? lymphoma?(Meyer?
et?al.,?2008),?we?could?detect?a?significant?HMGB1?over?expression? in?canine? lymphoma.? In?
contrast? to? HMGB1,? RAGE? remained? stable? without? significant? difference? in? expression?
between? the? neoplastic? lymphoma? and? control? samples.? Thus,? the? results? of? our? study?
strongly? support? that? similar? HMGB1?related? mechanisms? exist? in? canine? and? human?
lymphoma?progression.?Moreover,?in?canine?lymphoma?HMGB1?serum?levels?were?detected?
showing? elevated? initial? serum? levels? than? sequential? serum? levels? during/after?
chemotherapy.? Thus? the? initial? serum?HMGB1? level? and? its?modulation? during? treatment?
were? suggested? to? probably? possess? prognostic? value? (Meyer? et? al.,? 2010).? The? RAGE?
expression?determined?in?this?study?indicated?that,?in?terms?of?lymphoma,?the?expression?of?
the? receptor? stayed? stable? at? a? low? level? and?was? not? involved? in? the? increased?HMGB1?
mediated?signalling?during?disease?progression.?Similar?to?our?results,?in?a?study?using?tissue?
microarray? slides,? a? borderline? positive? staining? for? RAGE? was? detected? in? lymphoma?
tumours? indicating? low? levels? of? RAGE? in? the? tumour? slides? analysed,? but? that? was? not?
discussed?further?in?detail?by?the?authors?(Hsieh?et?al.,?2003).??
Summarising,? the?results?of?our?study? indicated? that?HMGB1?induced?effects?are?mediated?
by?the?over?expression?of?HMGB1?itself,?and?HMGB1?depending?induced?signalling?pathways?
might? include? further?HMGB1? receptors? such? as? TLR?2? and? TLR?4.? The? TLRs? 2? and? 4? also?
participate? in? the? complex? signalling? pathways? induced? by? HMGB1? and? thus? should? be?
considered?regarding?lymphoma?development?and?progression.?Moreover,?the?expression?or?
up?regulation?of?TLRs?was?found?in?many?tumour?cell?lines?and?tumours?and?was?associated?
with? tumour?progression? (Yu? and?Chen,? 2008).?Additionally,? a?polymorphism? in? the? TLR?2?
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gene?was? associated?with? increased? risk? of? follicular? lymphoma? and? a? decreased? risk? of?
chronic? lymphocytic? leukaemia? while? polymorphism? in? the? TLR?4? gene? was? positively?
associated? with?mucosa?associated? lymphoid? tissue? lymphoma? and? Hodgkin’s? lymphoma?
(Nieters?et?al.,?2006).?Concluding,? the?present? study? showed? that?an?up?regulated?HMGB1?
signalling? in? lymphoma?was?not?mediated?by?RAGE,?but?possibly?by?TLR?2?and? ?4?receptors?
and?the?extensive?interactions?of?all?factors.??
The?second?type?of?neoplasia,?which?was?analysed?for?HMGB1?and?RAGE?expression?within?
this? thesis?was?DHS.? In?human? LCH,?DCs?were?described? to? remain? arrested? in? a?partially?
activated? immature? stage? with? an? abnormal? proliferation? leading? to? accumulation? and?
disease?progression?(Laman?et?al.,?2003).?As?RAGE?and?HMGB1?were?shown?to?be?required?
for? the?maturation? and?migration?of?DCs,? they? are? crucial? for? the? role? of?DCs? in? immune?
responses? (Dumitriu?et?al.,?2007;?Yang?et?al.,?2007;?Manfredi?et?al.,?2008).?Deregulation?of?
the?expression?of?both?genes?consequently?could?have?major?effect?on? the?progression?of?
histiocytic?disorders.?Within? this? thesis,?we?analysed? tumour? samples?of? tissues?which?are?
mainly?affected?by?DHS?including?lymph?node,?liver,?lung,?and?spleen?(Rosin?et?al.,?1986).?The?
results? showed? a? down?regulation? of? HMGB1? and? RAGE? in? lung? and? down?regulation? of?
HMGB1?in?lymph?node?and?spleen.??
In?contrast?to?our?findings? in?DHS,?the?over?expression?of?HMGB1?and/or?RAGE? is?a?finding?
that?is?reported?more?frequently?in?human?neoplasias.?Nevertheless,?in?human?non?small?cell?
lung? cancer? (NSCLC)? strongly? reduced? expression? of? RAGE? on? transcriptional? and? protein?
level?was? reported? (Schraml?et?al.,?1997).?Moreover,?RAGE?down?regulation?was? found? to?
correlate? with? higher? tumour? stages? independently? from? the? histological? subtype,? to?
enhance? lung?cancer?progression,?and?to?be?a?critical?step? in?tissue?reorganisation?and?the?
formation? of? lung? tumours? (Bartling? et? al.,? 2005;? Bartling? et? al.,? 2006).? Interestingly,? in?
human?NSCLC?HMGB1?down?regulation?was?also?reported?on?mRNA?and?protein?levels?with?
a?positive?correlation?with? the? tumour? stage? (Shen?et?al.,?2009).? In? lung?cancer,? low?RAGE?
levels?as?well?as?decreased?levels?of?sRAGE?were?reported?indicating?that?serum?sRAGE?levels?
decrease? during? lung? cancer? progression? and? reflect? decreased? RAGE? expression? in? lung?
tumour? tissue? (Jing? et? al.,? 2010a;? Jing? et? al.,? 2010b).? These? findings? indicate? similar?
mechanisms?in?lung?biology?of?humans?and?dogs.?Nevertheless,?it?should?be?considered?that?
the?origins?of?these?tumours?differ?from?DHS.?
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In?LCH,?breast?carcinoma,?melanomas?and?in?NSCLC,?DCs?were?described?to?be?blocked?in?an?
immature?or?partial?mature? status? (Padgett?et?al.,?1995;? Laman?et?al.,?2003;?Perrot?et?al.,?
2007;? Simonetti? et? al.,? 2007)? leading? to? disease? progression.? The? herein? detected? down?
regulation?of?HMGB1?and?RAGE? in? lung?and?down?regulation?of?HMGB1? in? lymph?node?and?
spleen?neoplastic?samples?could?thus?have?an?effect?on?the?maturation?of?histiocytes?in?the?
affected?tissues?and?the?progression?of?canine?DHS.?However,?higher?number?of?cases?should?
be? analysed? and? additional? tumour?marker? genes?would? be? necessary? for? further? studies?
within?this?neoplasia.?
Immunohistochemistry? in? neoplastic? DHS? showed? a? positive? nuclear? staining? for? HMGB1?
within? the? control? sections? and? a? cytoplasmic? staining? within? the? neoplastic? sections.?
Generally,?HMGB1? shuttles?actively?between? the?nucleus?and? cytoplasm.?When?HMGB1? is?
underacetylated,? like? in?most?cells,?the?protein?appears?predominantly?or?solely?nuclear?as?
observed? in? the?non?neolastic? tissue? samples? in?our? study.?Upon? activation,?macrophages?
and?monocytes? acetylate?HMGB1? leading? to? relocalisation?of?HMGB1? to? the? cytoplasm? in?
secretory? lysosomes?which?cannot?return? into?the?nucleus?(Gardella?et?al.,?2002;?Bonaldi?et?
al.,? 2003).? Similarly,? in? immature? dendritic? cells,?HMGB1?was? found? to? be? located? in? the?
nucleus?while,? upon?maturation,?HMGB1? left? the? nucleus? and? remained? in? cytoplasmatic?
vesicles?(Dumitriu?et?al.,?2005c).?LCs?in?LCH?were?described?to?correspond?to?early?activated?
stage? of? DC? maturation,? combining? an? immature? phenotype? with? high? level? cytokine?
expression?(Laman?et?al.,?2003).?Taken?together,?our?immunohistochemical?results?indicated?
similar?mechanisms?of?shuttling?of?HMGB1?between?the?nucleus?and?cytoplasm?as?described?
in?human?macrophages,?monocytes?and?dendritic?cells?in?both?non?neoplastic?and?neoplastic?
states.??
In?addition? to?HMGB1,? further?members?of?the?HMG? family? including?HMGA1?and?HMGA2?
were?analysed? in? terms?of?canine?cancer.?At? that? time,? the?cDNA?structures?of?both?genes?
were? analysed? within? our? group.? The? characterisation? of? the? canine? HMGA1? gene? was?
published?(Murua?Escobar?et?al.,?2004;?Murua?Escobar?et?al.,?2005;?Beuing?et?al.,?2008)?and?
the? HMGA2? CDS? sequence? was? submitted? to? the? National? Center? for? Biotechnology?
Information? (NCBI)?Nucleotide? database? (Accession? number? (Acc.?No.)?NM_001003387.1).?
Generally,?HMGA?proteins?are?well?known? to?play?a?significant? role? in? the?pathogenesis?of?
various?diseases? including?cancer.?A?HMGA1? re?expression?was?detected? in?various?human?
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malignancies? including? colorectal,? lung,? pancreatic,? prostatic,? thyroid,? uterine? cervical?
carcinoma,? leukaemia,? and? lymphoma? (Bussemakers? et? al.,? 1991;? Bandiera? et? al.,? 1998;?
Chiappetta?et?al.,?1998;?Abe?et?al.,?1999;?Abe?et?al.,?2000;?Pierantoni?et?al.,?2003a;?Ek?et?al.,?
2004;?Xu?et?al.,?2004;?Diana?et?al.,?2005;?Glas?et?al.,?2005;?Frasca?et?al.,?2006;?Sarhadi?et?al.,?
2006).? A? HMGA2? re?expression? was? described? e.g.? in? mammary? carcinoma,? leukaemia,?
NSCLC,?OSCC,?pancreatic?carcinoma,?and?thyroid?carcinoma?(Rogalla?et?al.,?1996;?Rogalla?et?
al.,?1997;?Rommel?et?al.,?1997;?Abe?et?al.,?2003;?Miyazawa?et?al.,?2004;?Meyer?et?al.,?2007b;?
Belge?et?al.,?2008).?The?over?expression?of?HMGA?has?been?reported?to?be?associated?with?
an?aggressive?behaviour? in?several?of?these?malignancies?(Bussemakers?et?al.,?1991;?Rogalla?
et?al.,?1997;?Abe?et?al.,?1999;?Ek?et?al.,?2004;?Miyazawa?et?al.,?2004;?Glas?et?al.,?2005;?Sarhadi?
et? al.,? 2006).? In? dogs,? aside? from? the? data? presented? here,? HMGA2? over?expression?was?
reported?in?prostate?carcinoma?tissue?(Winkler?et?al.,?2007a).??
In?canine?B??and?T?cell? lymphoma,?HMGA1?was? found?to?be?over?expressed,?while?HMGA2?
expression?did?not?differ?to?expression?in?the?non?neoplastic?control?samples.?Similar?to?our?
findings,? in?human?follicular?and?mantle?cell? lymphoma,?analyses?using?microarrays?showed?
an? up?regulation? of? HMGA1? (Ek? et? al.,? 2004;? Glas? et? al.,? 2005).? Further,? in? follicular?
lymphoma,?HMGA1?was?differentially?expressed?in?the?indolent?and?aggressive?phase?of?the?
disease? showing? a? significant? up?regulation? in? the? aggressive? phase? (Glas? et? al.,? 2005).?
Furthermore,? in?human?Burkitt´s? lymphoma?cell? lines,?the?HMGA1?protein?was?reported?to?
be? significantly?elevated?and? in?human? leukaemia?of? lymphoid?and?myeloid?origin?HMGA1?
was? shown? to? be? over?expressed? (Wood? et? al.,? 2000;? Pierantoni? et? al.,? 2003a;? Xu? et? al.,?
2004).?Knock?out?of?HMGA1?in?embryonic?stem?(ES)?cells?drastically?impaired?differentiation?
of?multilineage?haematopoietic?progenitors.?HMGA1? ?/??ES?cells?showed? reduced?ability? to?
generate?T?cell?precursors?and?preferentially?generated?B?lymphocyte?precursors?(Battista?et?
al.,? 2003).? Transgenic? mice? over?expressing? HMGA1? developed? mixed? growth?
hormone/prolactin? cell? pituitary? adenomas? and? natural? killer? (NK?)?T/NK? cell? lymphomas?
(Fedele? et? al.,? 2005)? while? heterozygous? and? homozygous? HMGA1? knock?out?mice? have?
developed?cardiac?hypertrophy?combined?with?haematopoietic?malignancies?including?B?cell?
lymphoma?and?myeloid?granuloerythroblastic?leukaemia?(Fedele?et?al.,?2006).??
Regarding?HMGA2? in?human?haematopoietic?neoplasias?of? lymphoid?and?myeloid?origin?as?
well,? aberrant? expression? and/or? chromosomal? rearrangements? have? been? reported?
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(Kottickal?et?al.,?1998;?Santulli?et?al.,?2000;?Pierantoni?et?al.,?2003b;?Odero?et?al.,?2005;?Patel?
et?al.,?2005).?Transgenic?mice?carrying?a?truncated?HMGA2?construct?developed?NK?T/NK?cell?
lymphomas? starting? from? 12? months? of? age? and? thus? show? an? association? of? HMGA2?
expression? with? haematopoietic? neoplasias? as? well? (Baldassarre? et? al.,? 2001).? Further,?
increased? expression? of? HMGA2?was? reported? in? several? human?myeloid? neoplastic? and?
preneoplastic?disorders? including?human? chronic?myeloid? leukaemia? (CML),?acute?myeloid?
leukaemia?(AML),?myelofibrosis?with?myeloid?neoplasm?and? in?CD34+?haematopoietic?stem?
cells?(Rommel?et?al.,?1997;?Andrieux?et?al.,?2006;?Meyer?et?al.,?2007a).??
In? the? last? part? of? this? thesis,? a? cell? line? based? in? vivo? model? of? prostate? cancer? was?
established.?Cell? lines? represent?a?powerful? tool? in?cancer? research?as? injections?of?cancer?
cells?lead?to?the?generation?of?neoplasias?in?laboratory?animals?resembling?the?initial?tumour.?
The?canine?prostate?cell?line?CT1258?derived?from?a?prostatic?tumour?of?a?10?year?old?Briard?
and? the? in? vivo? behaviour? was? found? to? be? highly? tumourigenic? whereby? the? tumours?
mimicked?the?histopathological?and?cytogenetical?behaviour?of?the?original?tumour?(Winkler?
et?al.,?2005;?Fork?et?al.,?2008).?Apart?from?CT1258,?four?canine?prostate?cell?lines?have?been?
reported?until?now,? i.e.?CPA?1,?DPC?1,?Ace?1,?and?Leo?(Eaton?and?Pierrepoint,?1988;?Anidjar?
et?al.,?2001;?LeRoy?et?al.,?2006;?Thudi?et?al.,?2011).?Within?this?thesis,?we?could?establish?a?
MRI?based?tracing?of?CT1258?cells?after?injections?into?NOD?scid?mice.?The?usage?of?contrast?
MRI?agents?including?SPIOs?and?MnCl2?allowed?the?study?of?the?migration?of?CT1258?within?
the?animals.?Further,?due? to? the?highly? sensitive?method,?we?could?detect? tumour?masses?
prior?to?palpation?and?could?study?their?progression?in?vivo?during?the?time?period?between?
injection?and?euthanasia.??
During?the?performed?work,?we?found? labelling?with?MnCl2?to?be?more?appropriate.?MnCl2?
labelled?cells?could?be?detected?during?a?longer?time?period?after?injection?and?in?contrast?to?
SPIOs? which? cause? signal? extinguishments? in? T2/T2*? weighted?MRI,? bright? signals? in? T1?
weighted?MRI? caused? by?Mn2+? were? detected.? Thus,? false? positive? interpretation? of? the?
location? of? the? cells? could? be? excluded.? Generally,? SPIOs? generate? a? loss? of? signal? and?
depending? on? the? localisation? of? SPIOs? labelled? cells? within? the? animal,? it? is? difficult? to?
distinguish? these? signal? voids? from? other? sources? of? hypointense?MRI? signals.? Such? signal?
voids? could? also? be? generated? by? motion? artefacts,? susceptibility? artefacts,?
bleeding/hemosiderin,?calcification,?water?fat? interfaces,?or?air?(Na?et?al.,?2007;?Gilad?et?al.,?
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2008;?Chung?et?al.,?2009).?Within?our?study,?we? injected?cells? into? the?abdominal? flanks?of?
the? respective? animals? and? the? signal? voids? detected? could? also? have? been? be? caused? by?
water?fat?interfaces?or?blood?for?example.?
Mn2+?is?transported?actively?through?Ca2+?channels?into?biologically?active?cells?and?thus?MRI?
enables?the?correlation?between?cellular?viability?and?a?positive?signal?(Chung?et?al.,?2009).?
Thus,?the?assessment?of?information?about?the?localisation?and?survival?of?transplanted?cells?
like? in? injured?myocardium,?for?example,?was?possible?(Aoki?et?al.,?2006;?Yamada?and?Yang,?
2008;? Yamada? et? al.,? 2009).?Accordingly,?within? our? stuy?we?were? able? to? determine? the?
localisation?of?the?cells?and?their?vitality.?SPIOs?labelled?cells,?in?contrast,?do?not?provide?any?
biologic? information? of? the? cells,? as? SPIOs? could? be? also? be? taken? up? non?specifically? by?
macrophages?after?death?of?the?labelled?cells?(Chung?et?al.,?2009;?Yamada?et?al.,?2009).??
Regarding? the? tumourigenic? potential? of? CT1258,? the? progression? of? tumour? growth?was?
dependent? on? the? cell? number? injected.? However,? possible? gender?? and? hormone? status?
dependent?difference? in? the? tumour?size?and?progression?could?not?be?analysed,?probably?
due?to?the?small?animal?number?analysed.?Regarding?the? further?canine?prostate?cell? lines,?
Ace?1?and?Leo?did?not?express?the?androgen?receptor?(LeRoy?et?al.,?2006;?Thudi?et?al.,?2011)?
suggesting? that? testosterone? is? not? an? essential? factor? for? growth? and? survival? of? the?
carcinoma? cells.? Furthermore,? in? female? and?male?mice? there? was? no? difference? in? the?
growth,? invasion,?and?metastasis?of?the?ACE?1?cells? (LeRoy?et?al.,?2006).?Cell?growth?of?the?
canine?cell?line?DPC?1?was?independent?from?androgen?stimulation?and?either?androgens?or?
oestrogens?modified?the?growth? in?the?canine?cell? line?CPA?1?(Eaton?and?Pierrepoint,?1988;?
Anidjar? et? al.,? 2001).? Thus,? the? determination?of? an? existing? hormone? dependency? of? the?
CT1258?cell?line?needs?further?analyses?including?higher?animal?numbers.??
In? summary,? the? characterisation? of? the? canine? RAGE? gene? and? protein,? the? expression?
analyses? of? RAGE,? HMGB1,? HMGA1? and? HMGA2? in? several? canine? neoplasias? including?
lymphoma?and?DHS? indicated?similar?tumour?mechanisms? in?dogs?and?humans.?The?results?
gained? during? this? thesis,? strongly? support? the? role? of? the? dog? as? a? valuable? “model”? for?
human?neoplasias.?Thus,?therapeutical?approaches?based?on?blocking?of?the?HMGB1/RAGE?
complex? or? knock?down? of?HMGA2? expression?would? be? of? great? interest? for? the? dog? as?
patient?and?coincidently?as?“model”?organism?for?human?medicine.?
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5.?Summary?
The? leading? cause? of? death? in? economic? strong? countries? is? cancer?while,? in? developing?
countries,? cancer? ranks? on? the? second? position? of? caused? deaths.? The? global? burden? of?
cancer? is?expected?to? increase?continuously?as?result?of?the?growing?age?of?the?population?
and? the? adoption? of? cancer?favouring? lifestyle.? Thus,? the? clinical? and? scientific? research?
aiming? at? the? causes? of? cancer,? the? mechanisms? of? carcinogenesis,? and? the? disease?
progression? for? the? establishment? of? cancer? therapies? are? of? major? interest? in? human?
medicine.?During?the? last?decades,?a? large?number?of? in?vivo?and? in?vitro?models?of?human?
cancer? were? established.? Thereby,? therapeutic? approaches? in? veterinary? patients? have?
attracted? considerable? interest? in? research? and? human?medicine.?A? significant? number? of?
malignancies,?which?were?found? in?veterinary?patients,?resemble?their?human?counterparts?
in?many?ways.?Thus,?therapeutical?approaches?would?be?beneficial? for?both,?the?veterinary?
patient? and,? by? providing? data? as? “animal?model”,? coincidently? for? humans.? In? terms? of?
cancer,?especially?the?dog?attracted?scientific?interest?as?neoplasias?seen?in?dogs?share?many?
characteristics?with? their? human? counterparts,?which? are?missing? in? the? commonly? used?
rodent? models.? Some? of? these? similarities? include? the? presentation,? the? histology,? the?
biological? behavior,? the? tumour? genetics,? and? the? response? to? conventional? therapies?
between?human?and?canine?neoplasias.?Several?canine?cancer? types?were?hypothesised?as?
appropriate?models?for?human?counterparts? including?malignant?non?Hodgkin’s? lymphoma,?
lung?carcinomas,?mammary?carcinomas,?and?oral?melanomas.??
The?aim?of? the?herein?presented?thesis?was?the?analysis?of?the?molecular?structure?and/or?
expression? pattern? of? cancer? associated? genes? and? proteins? in? canine? neoplasias.? The?
analysed? genes? included? the? receptor? RAGE? and?members? of? the? HMG? family? including?
HMGA1,?HMGA2,?and?HMGB1.?The?canine?RAGE?gene?was?characterised?on?DNA?and?protein?
level?while? its?splicing?variants?were?characterised?on?cDNA? level.?The?results?showed?high?
similarities? between? the? canine? and? human? genomic? and? protein? structure? and? splicing?
mechanisms? indicating? RAGE? to? be? highly? evolutionary? conserved? between? both? species.?
Further,?expression?analyses?of?RAGE?and?its?ligand?HMGB1?in?malignant?lymphoma?and?DHS?
showed? similarities? in? the?mechanisms? involved? in? human? and? canine? angiogenesis? and?
dendritic? cell? biology? in? those? neoplasias? as?well.? Additionally,? the? expression? pattern? of?
HMGA1?and?HMGA2?in?canine?lymphoma?revealed?similarities?in?expression?deregulation?as?
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reported? in? human? haematopoietic? neoplasias.? Further,? a? valuable? cell? line? based? in? vivo?
model?of?prostate?cancer?was?established?representing?a?powerful?tool?in?cancer?research?as?
the? cell? line?was? found? to?be?highly? tumourigenic?and?mimicked? the?characteristics?of? the?
original?tumour.?
The?results?gained?during?this?thesis?clearly?show?that?therapies?targeting?the?RAGE/HMGB1?
complex? or? HMGA? expression? can? be? of? great? value? for? the? establishment? of? novel?
therapeutic? strategies? targeting?canine?neoplasias.?Due? to? the? similarities? that?were? found?
between? humans? and? dogs? in? cancer,? in? terms? of? transferability,? established? therapies? in?
dogs?would?be?suitable?as?preclinical?approaches?in?human?neoplasias.??
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6.?Zusammenfassung?
In?wirtschaftlich?hoch?entwickelten?Ländern? ist?Krebs?die?häufigste?Todesursache?wogegen?
Krebs? in? Entwicklungsländern? an? zweiter? Stelle? der? Todesursachen? steht.? Das? weltweite?
Auftreten? von? Krebserkrankungen?wird? laut? Schätzungen?weiterhin? kontinuierlich? steigen?
aufgrund? der? immer? älter? werdenden? Bevölkerung? und? der? Übernahme? von? Krebs?
fördernden?Lebensgewohnheiten.?Daher? ist?die?klinische?und?wissenschaftliche?Erforschung?
von? Krebsursachen,? den? Mechanismen? der? Karzinogenese? und? der? Progression? von?
Tumorerkrankungen? von? hohem? Interesse? in? der? Humanmedizin.? Innerhalb? der? letzten?
Jahrzehnte? wurde? eine? Vielzahl? von? in? vivo? und? in? vitro? Modellen? innerhalb? der?
Krebsforschung?entwickelt.?Dabei?haben?therapeutische?Ansätze,?die?in?der?Veterinärmedizin?
entwickelt? wurden,? immer?mehr? Interesse? auch? in? der? Humanmedizin? erweckt,? da? viele?
Erkrankungen?von?veterinärmedizinischen?Patienten?hohe?Ähnlichkeiten?mit?Krankheiten?des?
Menschen? aufweisen.? Hierbei?würden? veterinärmedizinische? Therapieansätze? in? zweierlei?
Hinsicht? von?Vorteil? sein.? Zum? einen? für?den? veterinärmedizinischen?Patienten? selbst?und?
zum? anderen? als?Modell? für?die?Humanmedizin,? aufgrund?der?hohen?Übertragbarkeit? von?
biologischen?Mechanismen?zwischen?Mensch?und?Tier.? In?Hinsicht?auf?Tumorerkrankungen?
hat? insbesondere? der? Hund? immer? mehr? wissenschaftliches? Interesse? erregt,? da? canine?
Tumore?viele?Ähnlichkeiten?mit?Neoplasien?des?Menschen?aufweisen,?die? in?den?allgemein?
verwendeten?Nagetiermodellen? fehlen.?Diese?Ähnlichkeiten? beinhalten? beispielsweise? das?
Auftreten? der? Erkrankung,? die? histologischen? Merkmale,? das? biologische? Verhalten,? die?
Tumorgenetik? und? das? Anschlagen? von? konventionellen? Therapien.? So? wurden? mehrere?
Tumorerkrankungen? des? Hundes? als? Modell? für? die? menschlichen? Erkrankungen?
hypothesiert,? darunter? das? Non?Hodgkin?Lymphom,? Karzinome? der? Mamma,?
Lungenkarzinome?und?orale?Melanome.??
Das? Ziel? dieser? Promotionsarbeit?war? die?Analyse? der?molekularen? Struktur? und/oder? des?
Expressionsmusters?von?tumor?assoziierten?Genen? in?caninen?Neoplasien.?Es?wurden?dabei?
der?Rezeptor?RAGE?und?Mitglieder?der?HMG?Familie?analysiert.?Hierbei?wurde?die?Expression?
von?HMGA1,?HMGA2? and?HMGB1? untersucht.? Innerhalb? dieser? Arbeit?wurde? sowohl? das?
canine? RAGE?Gen? auf?DNA? und? Proteinebene? charakterisiert,? als? auch? auch? seine? Spleiß?
Varianten?auf?cDNA?Ebene.?Die?Ergebnisse?wiesen?hohe?Ähnlichkeiten?zwischen?den?caninen?
und? humanen? RAGE? Gen? auf? genomischer?? und? Protein?Ebene? sowie? innerhalb? der?
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Spleißvarianten? auf.? Diese? hohen? Übereinstimmungen?weisen? darauf? hin,? dass? RAGE? ein?
stark?konserviertes?Gen?innerhalb?beider?Spezies?ist.?Die?Expressionsanalysen?von?RAGE?und?
HMGB1? im? Lymphom? und? im? disseminierten? histiozytärem? Sarkom? zeigten? weitere?
Übereinstimmungen?zwischen?Mensch?und?Hund.?Hierbei?konnten?ähnliche?Mechanismen,?
die? mit? der? Angiogense? und? der? Biologie? von? dendritischen? Zellen? zusammenhängen,?
zwischen?Mensch?und?Hund? innerhalb?der?untersuchten?Neoplasien?analysiert?werden.?Des?
Weiteren?konnten?ähnliche?Expressionsderegulationen?von?HMGA1?und?HMGA2? in?caninen?
Lymphomen? gefunden? werden,? die? bereits? in? menschlichen? hämatopoetischen?
Erkrankungen?beschrieben?wurden.?Schließlich?wurde?ein?auf?einer?Zelllinie?basierendes? in?
vivo? Modell? für? das? canine? Prostatakarzinom? etabliert.? Die? Zelllinie? zeigte? ein? hohes?
tumorigenes?in?vivo?Verhalten?und?wies?dieselben?Charakteristika?wie?der?Originaltumor?auf.??
Die?Ergebnisse?die? innerhalb?dieser?Arbeit?erzielt?wurden?zeigen,?dass?Therapieansätze,?die?
auf?den?RAGE/HMGB1?Komplex?oder?auf?die?HMGA?Expression?in?caninen?Tumoren?abzielen,?
von? großem? Nutzen? für? die? Entwicklung? von? neuen? Therapieansätzen? in? der?
Veterinärmedizin? sein? könnten.? Aufgrund? der? hohen? Ähnlichkeiten,? die? zwischen? den?
menschlichen? und? caninen? Tumorerkrankungen? bestehen,? könnten? etablierte?
veterinärmedizinische?Therapien?auf?vorklinische?Studien? in?der?Humanmedizin?transferiert?
werden.??
?
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